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Part1 
CIS to MS

Chapter 1
General introduction
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Preface
Multiple sclerosis (MS) is a chronic, disabling disease of the central nervous system (CNS), 
with an age of onset between 20-40 years. It was first identified as a distinct disease by Jean-
Martin Charcot in the second half of the 19th century. Charcot named the disease la sclerose 
en plaques based on the sclerotic plaques that were seen on pathologic examination [1].
To date, over 150 years later, the exact etiology of MS is still not exactly known. The disease 
is thought to manifest itself in genetically susceptible individuals, after exposure to certain 
environmental factors, resulting in a pathology characterized by inflammation, axonal loss 
and demyelination. In recent years, evidence has been accumulating that not only myeli-
nated brain tissue, but also gray matter is affected by the disease. 
In 85% of MS patients, the disease starts with a subacute episode of symptoms resulting 
from inflammation of the optic nerve, spinal cord, cerebrum, cerebellum or brain stem, 
called clinically isolated syndrome or CIS. When a patient has experienced a CIS, there is a 
30-70% chance that he or she will eventually be diagnosed with MS [2]. When this happens 
and these patients experience a second clinical attack,  they enter the relapsing-remitting 
phase of the disease. In the majority of patients this is followed in later years by a second-
ary progressive phase, characterized by a slow progression of disability but lacking evident 
relapses (figure 1). Because of the presence of multiple brain lesions visible on the MRI 
scans of most CIS patients at the time of first symptoms, it is thought that an asymptomatic 
preclinical phase precedes the first clinical symptoms. In 10-15% of MS patients the disease 
is progressive from onset; this is called primary progressive MS (PPMS). This thesis will focus 
on the relapsing-remitting form of MS; the factors that are predictive of a next attack.
 
Figure 1. Clinical course of multiple sclerosis as it observed in the majority of patients: a first attack (clinically iso-
lated syndrome or CIS) is followed by a second attack defining clinically definite MS (CDMS). The relapsing-remitting 
disease course is followed in later years by a secondary progressive phase.  
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Prognostic factors in MS
MS is a complex disease characterized by a large heterogeneity in radiological and patho-
logical findings but also in clinical disease course and treatment response [3-5].
Prognostic factors are needed to 1. reliably counsel patients about their prognosis, 2. dif-
ferentiate between CIS/MS and other causes of the symptoms, 3. be able to start the appro-
priate treatment at the right moment in the right patient, and 4. gain more insight into the 
pathogenesis of MS (and 5. to try to prevent MS in some cases, knowing that the incidence 
of MS is increasing [6], probably caused by a, so far unknown, environmental factor).  
This thesis focuses on predictive factors in patients with CIS and relapsing-remitting MS 
(RRMS). In this introduction, an overview of the known prognostic factors is given, including 
clinical and bedside factors as well as genetics and body fluid biomarkers. First, an  overview 
of risk factors for MS in the general population is given. Second, predictive factors for the 
next attack are described for patients with CIS and RRMS. For patients with CIS, the next 
attack is disease-defining, leading to the diagnosis of clinically definite MS (CDMS). In pa-
tients with RRMS, there is some controversy regarding the importance of relapses. Because 
the progressive phase of the disease (see figure 1) causes most of the long-term disability 
in MS patients, and this is independent of the location, severity and recovery of previous 
relapses [7], some people feel that relapses do not matter in relation to long-term disability. 
However, it is also known that relapses are associated with residual neurological deficit in 
40-50% of cases [8], and that relapses early in the disease course (year 1 and 2) do seem 
to affect later disability [9]. Furthermore, relapses have physical, emotional and financial 
consequences, and may lead to hospitalization and time away from work and home [10]. 
Especially in early disease, relapses are the main cause of disability in MS patients. Because 
relapses are also the main target for all current MS therapies, it is an important topic in MS 
research. Because progressive MS was not investigated in the research described in this 
thesis, these MS subtypes are not discussed here.
The risk for MS
Around the world, over 2.5 million people suffer from MS [11]. The disease incidence and 
prevalence are distributed unevenly over the world: a high prevalence is found in Western 
Europe and North America, and the lowest prevalence in Asia, the Middle East and Africa 
[6]. The risk for MS is determined by both genetic and environmental factors. 
Biological factors
Genetics and ethnicity
Arguments for the influence of genetic factors on the risk for MS include the increased risk 
for MS in family members of patients (figure 2), the regional differences in MS prevalence, 
and the difference in MS prevalence between ethnic groups; MS is very rare in Samis, Turk-
men, Uzbeks, Kazakhs, Kirgizis, native Siberians, North and South Amerindians, Canadian 
Hutterites, Chinese, Japanese, African blacks and New Zealand Maoris, and there is a high 
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risk for MS among Sardinians, Parsis and Palestinians [12]. More than 150 susceptibility loci 
for MS have been described. These loci, all associated with relatively small risks, lie mostly 
in genes with functions in immunity. The greatest effect on individual MS risk is exerted by 
variation in the major histocompatibility complex (MHC), especially the HLA-DRB1*15:01 
allele [13-15]. 
Gender
MS is more common in women than in men, and this sex ratio (female: male exceeding 
3.2:1) [16] seems to be increasing. Worldwide, the incidence of MS has been increasing over 
the last decades, particularly in women [6]. The increasing female: male ratio makes it likely 
that there is in fact a true increase in incidence, explained by a changing environmental 
exposure, particularly in women. Although there are some obvious candidates, for example 
smoking or use of contraceptives, the real culprits have not been identified yet.
Figure 2. Recurrence risks for multiple sclerosis. Age-adjusted recurrence risks for different relatives of probands 
with multiple sclerosis, and degree of genetic sharing between relative and proband. Pooled data from population-
based surveys. Based on: Compston and Coles, Multiple Sclerosis, Lancet 2008 [4].
Vitamin D and UV light
MS prevalence has repeatedly been reported to have a latitudinal gradient; being more 
prevalent in temperate areas further away from the equator [17-19]. This latitudinal gradi-
ent is one of the reasons for sunlight or vitamin D to be regarded as an environmental factor 
for MS risk; one of the strongest epidemiological arguments being the fact that migrants 
from the United Kingdom to the south of Australia have a significantly higher MS risk than 
those who migrated to the north of Australia [20]. However, recent evidence suggests that 
the latitudinal gradient might be decreasing[21] or might not have existed at all in some are-
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as [6]. Nevertheless, there are also many studies that found an inverse association between 
MS prevalence and solar radiation [22, 23] and MS prevalence and serum vitamin D levels 
[24]. Furthermore, there is biological plausibility for a role of vitamin D in MS, as vitamin D 
has immunological properties, and vitamin D related genes have been associated with MS 
risk [14, 25]. UV-light could also act as an immune modulator separately from vitamin D [26, 
27]. 
Taken together this suggests that there is indeed an association between latitude and MS 
risk, possibly attributable to UV-light and vitamin D, but that the latitudinal gradient has 
been leveled out on the northern hemisphere. This is possibly due to differences in sun-
bathing behavior between northern and southern Europeans, to higher dietary intake of 
vitamin D in northern countries, or to migration of many people from around the equator to 
more prosperous northern countries. Perhaps genetic factors also play a role here [6, 28]. A 
recent meta-analysis confirmed the association between latitude and MS prevalence [28].  
Infections and Epstein-Barr virus (EBV)
The ‘hygiene hypothesis’ is based on the theory that exposure to infections in early child-
hood is protective against autoimmunity, possibly because this exposure is needed for the 
immune system to develop normally [29]. According to this hypothesis, when exposure to 
early childhood infections is reduced (due to increased standards of hygiene, vaccinations 
and widespread use of antibiotics), risk of MS or other autoimmune diseases increases with 
increasing age at infection. This hypothesis is attractive because it may partly explain several 
epidemiological features of MS, such as the latitudinal gradient [30]. However, one aspect 
that is not explained by the hygiene hypothesis is the association of MS with the Epstein-
Barr virus (EBV). Nearly all MS patients are seropositive for anti-EBV antibodies, and people 
who are seronegative have practically no risk of developing MS. It appears that EBV infection 
is a prerequisite for the development of MS [31]. Especially after EBV-induced infectious 
mononucleosis, the risk of MS is increased, even more so if infectious mononucleosis oc-
curs after the age of 15 [32]. It should be noted however, that in matched controls of MS 
patients, EBV seropositivity is also very common (90-95%), so most EBV infected people do 
not develop MS [31]. 
Hormonal factors (parity, use of contraceptives)
Because of the increasing female/male ratio in MS epidemiology, sex hormones are sus-
pected to influence MS risk. Several studies have studied different aspects of this, but no 
consistent associations were found. An Australian study showed that the number of preg-
nancies was inversely associated with the risk of a first demyelinating event. The effect of 
the number of family pregnancies was only seen in the mothers, not in the fathers, arguing 
for a role of biological/hormonal factors in the mother and against postnatal environmental 
factors that could also affect the fathers [33]. However, a previous study found no associa-
tion of parity with MS incidence, and also failed to show an association of oral contracep-
tives use and MS risk [34]. Other studies on the use of contraceptives and MS risk have also 
shown conflicting results [35, 36].
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Biomarkers
In 2012, a group from Germany identified the ATP-sensitive inward rectifying potassium 
channel KIR4.1 as target of IgG antibodies in multiple sclerosis. Serum levels of antibodies 
to KIR4.1 were higher in MS patients than controls [37]. The same group also found higher 
levels of KIR4.1 titers in children with demyelinating disease [38]. However, these findings 
could not be replicated by others [39, 40]. These discrepancies are possibly at least in part 
due to technical issues, but further research on this topic is needed. 
Clinical factors
Lifestyle factors (smoking, obesity, alcohol, stress)
One of the best-studied environmental factors associated with the development of MS is 
smoking, with a consistent increased risk for MS in smokers compared to never-smokers 
across the different studies [41-44]. A Swedish study comparing the risk for MS in never-
smokers who had been exposed to passive smoking to never-smokers without exposure, 
found that passive smoking was also associated with an increased MS risk. The use of to-
bacco in the form of moist snuff is not associated with an increased risk, making it plausible 
that the negative effect of smoking results from some sort of irritation in the lungs, and not 
nicotine exposure [41, 45]. 
Recently, a case-control study from Sweden showed that alcohol consumption was associ-
ated with a decreased risk for MS, in a dose-dependent fashion. Furthermore, the use of 
alcohol appeared to reduce the negative effect of smoking [46]. 
A number of studies from different countries reported an association of obesity during 
childhood and adolescence with increased MS risk, particularly in girls [47-50]. Although 
some of these studies are based on self-reported data, the outcome is fairly consistent. The 
inverse association of obesity with vitamin D levels may play a role in the effect of obesity 
on MS risk. Possibly, the obesity epidemic partly explains the increasing incidence of MS. 
It has been suggested that the occurrence of stressful life events increases MS risk [51]. 
However, a recent large cohort study from Denmark could not provide any evidence for the 
association between major life events and subsequent MS risk [52].
In conclusion, the epidemiology of MS is determined by multiple factors, both genetic and 
environmental. Furthermore, several of the known environmental risk factors (e.g. smoking, 
obesity, EBV) have been shown to interact with HLA genotype to influence MS risk [53-55]. 
A genetic predisposition in combination with EBV infection seems to be essential to get the 
disease. Furthermore, vitamin D and sunlight are important contributors to MS risk. The in-
creasing incidence of MS particularly in women argues for other, thus far unknown, environ-
mental factors to be important. Lifestyle factors such as obesity probably play a role here. 
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The risk for attacks
When a patient has experienced a first demyelinating event or CIS, there is a 30-70% chance 
that he or she will eventually be diagnosed with MS [2]. Although the second attack, defin-
ing clinically definite MS (CDMS), comes within the first 5 years for  the majority of patients, 
there is a large variability in time to second attack, and in some patients, the disease will 
always remain monophasic. 
Also after the diagnosis MS has been made, the course of the disease is highly heterogene-
ous. About 10% of patients will have a benign disease course, defined as ‘disease in which 
the patient remains fully functional in all neurologic systems’[56]. In the long term, after 20 
years, 50% of patients will be wheelchair dependent (DSS score of 7). Factors with a negative 
association with long-term prognosis in RRMS patients are male sex, older age at onset, a 
higher relapse rate early in the disease course, greater disability in the first 5 years, the in-
volvement of more systems (especially ataxia, bowel and bladder symptoms, and cognitive 
impairment), and incomplete recovery from an attack[57].
Apart from factors associated with the long term prognosis and disability, some factors have 
been identified that are associated with the development of relapses in the short run. The 
below overview describes these factors, both for CIS patients and RRMS patients. Where 
possible, the data on CIS patients are based on outcome data from untreated CIS patients 
from natural history studies or the placebo arms of treatment studies (the North American 
Optic Neuritis Treatment Trial (ONTT)[58], the Controlled High Risk Subjects Avonex Multi-
ple Sclerosis Prevention Study (CHAMPS)[59], the Rebif Flexible Dosing in early MS study 
(REFLEX)[60], the Early Treatment of Multiple Sclerosis Study (ETOMS)[61], the Betaferon/
Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment study (BENEFIT)[61]. 
Where no prospective data from untreated patients are available, the best available evi-
dence from the literature is used. 
 
Biological factors
Genetics and ethnicity
The association of ethnicity with a diagnosis of CDMS in CIS patients was investigated in the 
ONTT and CHAMPS studies. No significant association was found, but there was a trend for 
a higher risk in white patients compared to black or non-white patients [58, 59], although 
both studies included only a small number of non-white patients. In contrast, in an older 
study [63], a significantly higher risk for an early second attack was found in non-white 
patients. 
Similarly, there seems to be no association with conversion to CDMS of a positive family his-
tory for MS, although also here the number of included patients with positive family history 
was low [58, 59].  
In a study performed with data from 2215 patients with CIS or MS and 2 validations sets, 
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weighted genetic risk scores of CIS and MS patients had similar distributions, suggesting that 
genetic susceptibility for MS and CIS is comparable. The weighted genetic risk score was not 
associated with time to conversion to CDMS  [64]. 
Thus, the genetic susceptibility for CIS and MS appears to be the same. Genetics and ethnic 
background seem to co-determine an individual’s risk to develop a CIS, but not the subse-
quent risk to have a second, disease-defining attack. Larger studies are needed to clarify 
this. 
The association between known MS-risk-associated SNPs and relapses was investigated in a 
recent prospective study from Australia [65]. HLA-DRB1*15:01 was not associated with the 
occurrence of relapse, but five SNPs tagging other genes were. Although these results did 
not remain significant after correction for multiple testing, there was a clear allele dose-re-
sponse effect for two of these SNPs tagging EVI5 and MAPK1, suggesting a true association 
but a lack of power. No association with disability progression was found. Other studies on 
the association of genetics with clinical disease course have not identified significant asso-
ciations besides an earlier age of onset associated with HLA-DRB1*15:01 [66, 67]. This topic 
is currently being studied more extensively in international collaborations. 
Age
The influence of age on the risk of conversion to CDMS is not completely clear. Some, but 
not all, studies found a higher risk for conversion in younger age groups [59, 62, 63]. In RRMS 
patients, age is an important risk factor for entering the secondary progressive phase of the 
disease, and older age is associated with a lower relapse risk [7, 68]. 
Gender
The risk of having a first demyelinating event is higher for women than for men. However, 
the effect of gender on a subsequent diagnosis of CDMS is less clear. In many studies, men 
and women have an equal risk for CDMS, and only few studies found a higher risk in women 
[58, 69]. A meta-analysis including studies with a total of 4732 patients indeed found a high 
risk for CIS in females compared to males (RR 2.12), but only a moderately increased risk for 
CDMS in female CIS patients, which was not significant (RR 1.20)[70]. Not only do women 
have a higher risk for MS, it was also recently shown in a large international study including 
over 80.000 patient years of relapse-onset MS, that female patients have a higher relapse 
rate than males throughout the course of the disease [68]. 
Vitamin D
So far, two studies have investigated the association between 25-OH-vitamin D levels and 
conversion to CDMS [71-73]. The first one [71] found increased risk of CDMS only in women 
with low 25-OH-D levels. The second one [72], found significantly increased risks for new le-
sions and increased lesion volumes on MRI for patients with low 25-OH-D levels, but only a 
borderline increased risk for CDMS. The association of vitamin D levels with disease activity 
in patients with relapsing-remitting MS will be described in this thesis.
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Infections and viruses 
As mentioned before, an infection with EBV is probably a prerequisite to develop a CIS, but 
the association of EBV antibody titers with conversion to CDMS in CIS patients is less clear. 
One study in 147 patients with a mean follow-up of 7 years found an association of higher 
Epstein-Barr Virus-Encoded Nuclear Antigen 1 (EBNA1) IgG titers with risk for McDonald MS 
according to the 2001 revised criteria, but not with risk for clinically definite MS [74]; the 
association with McDonald MS was only statistically significant in the univariate analysis. In 
this study, anti EBNA1 titers were also associated with increased disability. Others reported 
a higher conversion risk in patients with anti-CMV IgG positivity, but not anti-EBV positivity 
[75]. 
In RRMS, it has been hypothesized that EBV-reactivation is associated with relapse risk. How-
ever, studies evaluating serological and viral load markers of EBV reactivation and clinical 
disease course have shown not shown convincing evidence for such an association [76-78]. 
Apart from EBV infections previously in life, patients with CIS often report symptoms of a 
viral infection in the days or weeks before onset of CIS (29% in the ONTT study)[58]. The 
predictive value of these viral symptoms is not clear. In the ONTT study, patients with viral 
symptoms preceding CIS had a higher conversion risk, but this was only true for patients 
with monofocal optic neuritis without T2 lesions on  brain MRI [58]. In contrast, in a cohort 
of Australian pediatric patients, preceding infection was protective against a subsequent 
diagnosis of MS [79]. In patients with RRMS, strong evidence suggests that relapses can be 
triggered by infections [80-82], possibly through induction of secretion of pro-inflammatory 
cytokines by infectious agents or immune activation by interaction of the host immune sys-
tem with viral superantigens. However, the association of infections with the appearance of 
new MRI lesions has not been as consistent. Some of the clinical worsening associated with 
infection may also be due to pseudorelapses [83]. 
Although some case-reports suggest an increased risk of relapse following vaccination, evi-
dence is scarce and the few larger studies do not support an association of vaccination and 
relapse risk [84, 85]. 
Hormonal factors (parity, contraception, assisted reproduction technology)
There is no information on parity, the use of contraceptives or assisted reproduction tech-
nology in CIS patients regarding the risk of a subsequent diagnosis of MS. However, there 
is much evidence that  hormonal factors are associated with relapse risk. For example, it is 
now well-known that the relapse rate decreases during pregnancy, particularly during the 
third trimester, with a decrease in relapse rate of around 70% [86, 87]. After delivery, the 
relapse risk increases again. It is not fully known what causes this increased postpartum 
relapse risk. Assisted reproduction technology is also associated with increased disease ac-
tivity in the following 3 months, especially when the procedure did not result in pregnancy 
and gonadotrophin-releasing hormone [88]. There is inconclusive evidence on the use of 
oral contraceptives and clinical disease course [89].  
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Biomarkers 
Biomarkers are defined by the Biomarkers Definitions Working Group as ‘a characteristic 
that is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes or pharmacological responses to a therapeutic intervention’ [90]. 
Comabella and Montalban have recently reviewed biomarkers currently available for MS 
[3]. ‘Validated’ biomarkers (that is, replicated in relatively large cohorts of patients and the 
potential to become clinically useful) for CDMS in CIS patients are shown in Table 1, and 
biomarkers associated with relapses in RRMS patients are shown in Table 2.
Biomarker Body fluid Comment  
Free kappa light 
chains 
CSF and 
serum 
Plasma cells produce excess kappa and lambda light chains, 
which are secreted as free light chains and can be detected in CSF 
and serum. KFLC are raised in CSF from patients with MS and 
their presence might support disease diagnosis [91-93] but they 
do not seem superior to OCB [94] 
IgM oligoclonal 
bands 
CSF IgM antibodies play a part in the inflammatory response in 
patients with MS and are associated with an increased risk for 
conversion to CDMS [95, 96] 
Measles, rubella 
and varicella 
zoster reaction 
CSF Corresponds with a polyspecific, intrathecal B-cell response 
characterised by antibody production to neurotropic viruses 
(measles, rubella, and varicella zoster). Measles, rubella, and 
varicella zoster reaction has been associated with an increased 
risk for conversion to MS [97, 98] 
Chitinase3like1 CSF Glycoside hydrolase that is secreted mainly by activated 
macrophages. Concentrations are increased in patients with 
clinically isolated syndromes who later convert to clinically 
definite MS compared with patients who remain with clinically 
isolated syndromes. The same group of investigators validated 
the findings in an independent cohort of patients with clinically 
isolated syndromes [99] 
 
Table 1. Potential biomarkers associated with CDMS in CIS patients (based on: Comabella and Montalban, Body 
fluid biomarkers in multiple sclerosis, Lancet Neurology, 2014 [3])
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Table 2. Biomarkers associated with relapses (based on: Comabella and Montalban, Body fluid biomarkers in mul-
tiple sclerosis, Lancet Neurology, 2014 [3])
Biomarker Body fluid Comment  
IgM oligoclonal 
bands 
CSF IgM OCB are associated with an aggressive disease course, more 
relapses and higher T2 lesion load [100,101] 
Nitric oxide 
metabolites 
CSF, serum, 
plasma, 
urine 
Oxidative stress plays a part in MS disease. Concentrations of NO 
and its metabolites (nitrates and nitrites) increase during acute 
exacerbations and are associated with radiological inflammatory 
activity and disability progression [102, 103] 
Matrix metallo-
proteinase 9 
(MMP9) 
CSF, serum 
and PBMC 
Matrix metalloproteinases are involved in myelin breakdown, 
release of proinflammatory cytokines, and axonal damage. 
MMP9 concentrations increase in patients with MS during 
relapses and are linked to radiological disease activity[104-107] 
Myelin basic 
protein (MBP) 
CSF During myelin injury, MBP and its fragments are released into 
the CSF. MBP is increased during clinical attacks and associated 
with gadolinium enhancement [108-110] 
Osteopontin 
(OPN) 
Serum, 
plasma, CSF 
Integrin-binding protein with pleiotropic roles, including 
inflammation, cell-mediated immunity, and cell survival. 
Concentrations are increased in patients with RRMS during 
clinical relapses [111-113] 
Chemokine 
ligand 13 
(CXCL13) 
CSF Has a role in B-cell recruitment to the CNS during inflammation. 
Concentrations are increased in patients with active disease 
[114-116] 
Brain-derived 
neurotrophic 
factor (BDNF) 
Serum, 
plasma and 
PBMC 
Neurotrophic factor secreted not only by neurons, but also by 
immune cells with roles in CNS neurogenesis, neuroprotection, 
and neuroregeneration. Concentrations are increased in patients 
during relapses compared with patients with stable clinical 
phases [117-119] 
Complement 
factor H 
Serum Regulates the formation and function of complement factors C3 
and C5. Concentrations are increased in patients with 
progressive forms of MS and patients with relapsing-remitting 
MS in relapse. The same group of researchers did an in-house 
clinical replication of the findings [120] 
B-cell activating 
factor (BAFF) 
CSF and 
PBMC 
Member of the TNF superfamily with a role in B-cell homeostasis. 
Concentrations in CSF are increased in patients with MS 
compared with patients with other neurological disorders, and 
concentrations are higher in patients with secondary progressive 
MS and RRMS during relapses than during remittance [116, 121].  
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Clinical factors
Clinical symptoms at onset
No differences in MS risk are found between different clinical syndromes (e.g. optic neuri-
tis, transverse myelitis, brainstem syndrome)[59, 62]. It was suggested that patients with 
optic neuritis had a more benign disease course[122], but this is only true for optic neuritis 
patients without lesions on brain MRI [58]. A more severe disease course in patients with 
multifocal onset has been mentioned by some [63] but is not confirmed by others [60, 122].
Lifestyle factors (smoking, obesity, alcohol, stress, diet)
Smoking is a risk factor for CIS and MS, and one study has shown that, in CIS patients, it is 
also a risk factor for conversion to CDMS, with a hazard ratio of 1.83 for smokers [123]. Of 
note, in this study, only patients with white matter lesions on MRI and positive oligoclonal 
bands in CSF were included. Nothing is known about alcohol use or obesity and CDMS risk in 
CIS patients. In RRMS patients, smoking has been associated with conversion to secondary 
progressive MS, but the association with relapses is not clear. An important clinical factor 
associated with relapses is stress. The occurrence of stressful life events has been shown to 
be a risk factor for an MS attack in several studies [124, 125]. 
Recently, a study has been published that showed that high salt intake was associated with 
an increased relapse rate [126]. Indeed, it has recently been shown that salt could stimulate 
the development of pro-inflammatory Th17 cells and worsen EAE [127], so there is also 
biological plausibility that increased dietary salt intake might represent an environmental 
risk factor for MS.
MRI
An abnormal brain MRI scan is found in about 60% CIS patients [128] and this is the most 
important predictive factor for CDMS after CIS: the risk for CDMS is 72-82% if the baseline 
scan shows abnormalities compared to 21-24% in patients with a normal MRI [58, 129]. 
Therefore, MRI abnormalities have been included in the diagnostic criteria for MS since 
2001[130], and since the latest revisions in 2010, the diagnosis of MS can be made in some 
patients after only 1 attack if the MRI scan fulfills certain criteria [131]. Typical MS lesions 
are ovoid shaped lesions that are hyperintense on T2, and localized in the following regions 
of the CNS: periventricular, juxtacortical, infratentorial [132], in the spinal cord [133], or the 
corpus callosum [134]. Both the number of lesions and the localization of the lesions have 
predictive value. In addition to T2 lesions, gadolinium enhancement of lesions is associ-
ated with increased risk of conversion to CDMS [59, 62]. Gadolinium enhancing lesions are 
regarded as ‘active’ lesions, and the simultaneous presence of both enhancing and non-en-
hancing lesions can account for dissemination in time according to the most recent diagnos-
tic criteria for MS [131]. Black holes, which are lesions with low signal on T1, are sometimes 
regarded as markers of more severe demyelination and axonal damage, but their predictive 
value has been shown to be low [135]. Emerging  MRI techniques include diffusion tensor 
imaging (DTI), magnetization transfer imaging, MR spectroscopy and functional MR imag-
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ing; these are less often used in clinical practice and their prognostic potential has not been 
convincingly demonstrated yet [136].  
A special situation is the so-called radiologically isolated syndrome (RIS), which defines the 
incidental identification of white matter abnormalities suggestive for MS on MRI, in people 
without typical MS symptoms [137]. People with RIS are at risk to develop CIS or MS; in a 
large study including 451 RIS subjects, 34% had a clinical event within 5 years. Risk factors 
associated with clinical symptoms were younger age, male sex and spinal cord involvement 
[138]. 
Although the correlation between MRI lesion load and clinical manifestations is weak, con-
ventional MRI techniques are frequently used as a surrogate marker for MS disease activity, 
both in clinical practice and in clinical trials. Gadolinium-enhancing lesions and the appear-
ance of new T2 lesions are associated with relapses, whereas brain atrophy and T1 hypoin-
tense lesions (black holes) are associated with disease progression [139-141].  
Evoked potentials
Evoked potentials were included in the revised diagnostic criteria for MS by Poser et al. in 
1983 [142] as paraclinical evidence of an MS lesion. However, their prognostic value, alone 
or in combination with MRI, was found to be modest [143]
OCT
Optical Coherence Tomography (OCT) is an ophthalmologic instrument that measures the 
retinal nerve fiber layer (RNFL) thickness with a method analogous to ultrasound, but using 
near-infrared light instead of sound. The RNFL contains ganglion cell axons that are continu-
ous with the optic nerve and are unmyelinated, which makes them suitable for measuring 
neurodegeneration. It is known that after optic neuritis, RNFL thickness rapidly decreases, 
but also in MS patients that did not suffer from optic neuritis, RNFL thickness has also been 
shown to decrease over time [144, 145]. However, it is not yet known if OCT measures can 
be used to predict conversion to CDMS in CIS patients. 
Cerebrospinal fluid oligoclonal bands
IgG oligoclonal bands (OCBs) in the cerebrospinal fluid are a sign of intrathecal IgG synthesis, 
without corresponding IgG in serum. They likely represent the humoral immune activation 
in the CNS of CIS patients. OCBs in the CSF of CIS patients are a known predictor for CDMS. 
However, they can also be present in other inflammatory diseases such as sarcoidosis or SLE 
[146]. A recent meta-analysis including 2685 CIS patients showed that OCBs were present 
in 69.5% of patients. Of OCB-positive patients, 64.1% later reached CDMS, compared with 
22.6% of OCB-negative patients (OR 9.88, p<0.00001)[147]. In the latest version of the diag-
nostic criteria for MS, CSF OCBs can no longer be used to reduce the MRI requirements for 
dissemination in space [131]. Although several studies have shown that OCBs are predictive 
for CDMS independent of MRI measures [148, 149], the additional diagnostic value of OCBs 
with the latest imaging criteria remains to be confirmed. 
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Scope of this thesis
This thesis focuses on the prediction of the next attack in MS. In patients with a first demyeli-
nating event, CIS, the next attack is disease-defining, diagnosing the patients with clinically 
definite relapsing-remitting MS. In patients with RRMS, we investigated factors that influ-
ence the relapse risk. This is important, because 50% of relapses cause increased sustained 
disability [8].
In the first part of this thesis, prognostic factors in CIS patients are described. First, in chap-
ter 2, the accuracy of the most recent revisions to the McDonald diagnostic criteria for MS 
was assessed by applying these criteria to our cohort of CIS patients. In chapter 3 and 4, 
we aimed to find new prognostic markers, both clinical and biomarkers. In chapter 3, we 
investigated the prevalence and prognostic value of fatigue in CIS patients, because this is 
a well-known feature of MS but little was known about fatigue in CIS patients. In this chap-
ter, we also evaluated vitamin D-levels in CIS patients. In chapter 4, proteomics analysis 
of cerebrospinal fluid of CIS patients and controls was performed, to look for biomarkers 
that could differentiate CIS patients from controls and differentiate monophasic CIS patients 
from future MS patients. In chapter 5, various predictors are integrated into a predictive 
model for the diagnosis of clinically definite MS in CIS patients. 
The second part of this thesis investigates prognostic factors in patients with relapsing-re-
mitting MS. There was accumulating evidence for a role of vitamin D in MS, but little was 
known about its association with clinical disease course in MS patients. Therfore, in chapter 
6, serum vitamin D levels were measured at regular time intervals in patients with RRMS to 
investigate their association with relapse risk. In chapter 7, vitamin D levels are measured 
during pregnancy in MS patients and healthy women, and the association of pregnancy vi-
tamin D levels and the risk for a postpartum relapse is investigated. In chapter 8, a possible 
association of vitamin A levels and relapse rate is investigated. Chapter 9 discusses osteo-
pontin plasma levels and their association with relapse risk. 
The main findings of this thesis and an interpretation of the results are discussed in chapter 
10.
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Abstract
Background and purpose 
Recently, the McDonald criteria for the diagnosis of multiple sclerosis (MS) have been re-
vised, with the aims to diagnose earlier and to simplify the use of brain MRI. To validate 
the 2010 revised criteria they were applied to a cohort of patients with clinically isolated 
syndromes (CIS). 
Methods 
In all, 178 CIS patients were followed from onset. Test characteristics were calculated after 
1, 3 and 5 years and compared between the 2005 and 2010 revised criteria. The time to 
diagnosis of the 2005 and 2010 criteria was compared using survival analysis and the log-
rank test. Clinical evidence for dissemination in space and time was the gold standard for 
clinically definite MS (CDMS).
Results 
During follow-up, 76 patients converted to CDMS (mean time to conversion 23.9 months). 
At 1 year, the specificity and accuracy of the 2005 criteria were a little higher than those of 
the 2010 criteria (98.0% and 98.4% vs. 86.3% and 88.5%). However, at 5 years, differences 
completely disappeared (specificity 85.7% and accuracy 93.3% for both criteria). MS diag-
nosis could be made significantly faster with the 2010 criteria (P = 0.007). Using the 2010 
criteria, in 19% of patients the diagnosis could already be made at baseline. 
Conclusions 
By applying the 2010 revised criteria a diagnosis of MS can be made earlier, whilst predic-
tion of disease progression is maintained. This validation brings along great advantages, for 
treatment possibilities as well as patient counselling.
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Introduction
Since the publication of the Poser criteria in 1983 [1], the diagnosis of multiple sclerosis 
(MS) has been based on the demonstration of dissemination in space (DIS) and time (DIT): 
evidence that the disease has affected more than one part of the central nervous system on 
more than one occasion. Patients with MS often present with a first episode of symptoms 
suggestive for demyelination, such as optic neuritis or transverse myelitis. This first episode 
is called clinically isolated syndrome (CIS). MS is a disabling disease that affects especially 
young people in the prime of their lives. Patients with CIS face a very insecure future, not 
knowing whether or not they will go on to develop MS and, if they do, how the disease 
course will be [2]. To be able to advise CIS patients as well as possible, it is very important 
that a diagnosis of MS can be made quickly and accurately. Also, the possibility of starting 
appropriate treatment early may be beneficial for disease outcome in MS [3].
 
For these reasons, several attempts have been made over the years to adjust the criteria in 
such a way that the diagnosis of MS can be made earlier and more easily. Several revisions 
to the diagnostic criteria have been published by the International Panel on the Diagnosis of 
MS. In 2001, the MRI scan was added as an important diagnostic tool that could be used for 
the criterion of DIS [4]. In 2005 [5] and 2010 [6], the criteria were revised again. The revised 
diagnostic criteria of 2005 and 2010 for relapsing-remitting MS are shown in Table 1.
In the latest revisions of 2010, aims were to simplify the use of brain MRI for the diagnosis 
of MS and to  allow for earlier diagnosis in different populations. As can be seen from the 
table, with these criteria the diagnosis of MS can sometimes already be made in patients 
with only a single attack (CIS), after a single baseline brain MRI scan. If these criteria prove 
to work well, this would be a huge progress in the diagnostics of MS. However, the risk of 
false positive diagnoses is not imaginary. For example, in a study by Chard et al. [7] it has 
been shown that 10%-15% of patients that were diagnosed with MS based on the 2005 MRI 
criteria never had a clinical second attack in up to two decades. 
To investigate what the 2010 criteria really add to the existing diagnostics in MS, their ac-
curacy was investigated and compared with the 2005 criteria by applying them to our cohort 
of CIS patients.
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Patients and methods
Patients
Patients were included in the neurology outpatient clinic of the Erasmus MC University Hos-
pital, a tertiary referral center for MS patients. In our center, all patients aged 18–50 years 
with a first episode suggestive for demyelination are followed prospectively if they give in-
formed consent (approved by the Erasmus MC ethics committee). For the present study, all 
patients were included who had experienced a first episode suggestive of demyelination, 
had a baseline MRI scan performed within 3 months of symptom onset and had at least 1 
year of follow-up. All patients were clinically assessed at baseline and thereafter seen regu-
larly for reassessment. Exacerbation was defined as a worsening of existing symptoms or 
the appearance of new symptoms lasting for more than 24 h, after a period of more than 30 
days of improvement or stability, confirmed by neurological examination [8]. A temporary 
neurological deterioration associated with fever was not considered as an exacerbation. 
Clinically definite MS (CDMS) was diagnosed when there was clinical evidence for DIS and 
DIT as described by Poser and colleagues [1]. This was used as the gold standard for the 
diagnosis of multiple sclerosis. At baseline, MRI and laboratory tests were performed to rule 
out alternative diagnoses. This was repeated during follow-up if necessary. Patients with 
alternative diagnoses were not included in the analyses.
Procedures
All brain MRI scans were performed on 1.5 T scanners with a standard head coil (Philips, 
Best, The Netherlands, or General Electric, Milwaukee, WI, USA). Scans typically consisted 
of an axial T1-weighted sequence, an axial spin echo proton-density weighted (PDW) and a 
T2-weighted sequence, and an axial fluid-attenuated inversion recovery (FLAIR) sequence, 
with 2–5 mm images. Post-gadolinium T1- weighted sequences were added by the radiolo-
gist on indication in patients with T2 lesions suggestive of demyelination. Since spinal cord 
scans were not systematically performed, these were not included in the analysis.
Baseline scans were scored for Barkhof-Tintoré criteria and Swanton criteria for DIS, and for 
criteria for DIT according to the 2010 revisions to the McDonald criteria. These criteria are 
described in Table 1.
Statistical methods
The following test characteristics were calculated:
Sensitivity:  
The proportion of patients with the disease who have a positive test result. This was calcu-
lated as true positives/(true positives + false negatives).
Specificity: 
The proportion of patients without the disease who have a negative test result. This was 
calculated as true negatives/(true negatives + false positives).
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Positive predictive value (PPV): 
The proportion of patients who have the disease amongst the patients with positive test 
results. This was calculated as true positives/(true positives + false positives).
Accuracy: 
The proportion of true results of a test. This was calculated as (true positives + true  nega-
tives)/(true positives + false positives + true negatives + false negatives).
Test characteristics for the criteria for DIS of the 2005 and 2010 criteria and for DIT of the 
2010 criteria based on the baseline scan were calculated after 1, 3 and 5 years of follow-up. 
For the calculations regarding MRI criteria for DIT at baseline according to the 2010 criteria, 
only patients for whom post-gadolinium images were available or scans that showed no 
abnormalities were taken into account (n = 114).
 McDonald 2005 McDonald 2010 
DIS a) a) Objective clinical evidence of ≥2 lesions, or 
objective clinical evidence of 1 lesion with 
reasonable historical evidence of a prior attack 
involving a different CNS site  
b) ≥3 of the 4 Barkhof-Tintoré criteria fulfilled: 
- ≥9 T2 hyperintense lesions or 1 gadolinium-
enhancing lesion 
- ≥3 periventricular lesions 
- ≥1 juxtacortical lesion 
- ≥1 infratentorial lesion 
(1 spinal cord lesion can substitute for 1 brain 
lesion and spinal cord lesions can be included in the 
total T2 lesion count))  
c) ≥2 T2 lesions plus positive CSF (isoelectric 
focusing evidence of oligoclonal bands and/or 
elevated IgG index) 
a) Objective clinical evidence of ≥2 lesions, or 
objective clinical evidence of 1 lesion with 
reasonable historical evidence of a prior attack 
involving a different CNS site  
b) ≥1 T2 lesion in at least 2 of 4 MS-typical regions 
of the CNS (Swanton criteria):  
- Periventricular 
- Juxtacortical 
- Infratentorial 
- Spinal cord 
(symptomatic lesions in patients with brainstem or 
spinal cord syndrome are excluded) 
DIT a) ≥2 attacks separated by a period of at least one 
month 
b) 1 gadolinium-enhancing lesion ≥3 months after 
CIS if not at the site corresponding to CIS 
c) A new T2 lesion compared with a previous scan 
obtained ≥30 days after CIS 
a) ≥2 attacks separated by a period of at least one 
month 
b) Simultaneous presence of asymptomatic 
gadolinium-enhancing and non-enhancing 
lesions at any time 
c) A new T2 and/or gadolinium-enhancing lesion 
on follow-up MRI, irrespective of its timing with 
reference to a baseline scan  
 
Table 1. Overview of revisions of the diagnostic criteria for MS and. DIS= dissemination in space; DIT= dissemination 
in time; CNS= central nervous system; CSF= cerebrospinal fluid; CIS= clinically isolated syndrome; MRI= magnetic 
resonance imaging. Based on 2005 revisions to the McDonald criteria [5] and 2010 revisions to the McDonald 
criteria [6].
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Test characteristics of the 2010 diagnostic criteria (DIS + DIT) were calculated after 1, 3 and 5 
years of follow-up and compared with the 2005 criteria. For these calculations, only patients 
who had at least one follow-up scan were included in the analyses (n = 61).
Time to diagnosis with the 2005 and 2010 criteria was analysed using Kaplan–Meier survival 
analyses and compared with a log-rank test. Survival analysis included all patients with a 
follow-up scan and/or a diagnosis of MS according to 2010 criteria. Statistical analyses were 
performed using SPSS version 17.0 for Windows.
Results
Patients
In all, 187 patients from our CIS cohort met the inclusion criteria. Nine patients (4.8%) were 
diagnosed with diseases other than MS (four neuromyelitis optica, two Leber’s hereditary 
optic neuropathy, one chronic relapsing inflammatory optic neuropathy, one vascular, one 
psychogenic); these patients were not included in the analysis, which left 178 patients eli-
gible for analysis (figure 1). Median follow-up time of the patients was 44.5 months (range 
12–174). 
 
Figure 1. Flowcharts of patients in analysis and percentages of patients in the different groups that had clinically 
definite MS during follow up; left for 2005 revised criteria and right for 2010 revised criteria. DIS = dissemination in 
space, DIT = dissemination in time, CDMS = clinically definite MS.
Baseline characteristics of the included patients are shown in Table 2. Seventy-six patients 
(42.7%) had at least one relapse during follow-up leading to the diagnosis of CDMS. Mean 
time to conversion was 23.9 months (median 16.5, range 1–86). Twenty-four patients 
187 CIS patients 
fulfilled
inclusion criteria
9 alternative 
diagnoses
178 patients 
eligible for analysis
DIS based on MRI 
or MRI + CSF
125 (70%)
No DIS
53 (30%)
CDMS
67 (54%)
CDMS
9 (17%)
187 CIS patients 
fulfilled
inclusion criteria
9 alternative 
diagnoses
178 patients 
eligible for analysis
DIS based on MRI
108 (61%)
No DIS
70 (39%)
CDMS
60 (56%)
CDMS
16 (23%)
2005 2010
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(13.5%) received immune-modulating therapy before they had a second clinical attack. Six-
ty-one patients (34.3%) had at least one follow-up MRI scan.
Table 2. Characteristics of patients (n=178). CDMS = clinically definite MS
 
DIS and DIT criteria of baseline scans
When comparing the 2005 and 2010 criteria for DIS, the following could be seen in our 
cohort (see also Fig. 1 and Table 3A). Seventy-two of 178 patients (40.4%) fulfilled the Bark-
hof-Tintoré criteria; 125 patients (70.2%) fulfilled DIS 2005 criteria including cerebrospinal 
fluid (CSF). Sixty-seven (53.6%) of the DIS 2005 positive patients converted to CDMS during 
follow-up. Nine (17.0%) of 53 patients who did not fulfil DIS 2005 criteria converted to CDMS 
during follow-up. The sensitivity of the DIS 2005 criteria was 88.2% (95% CI 80.9–95.4) and 
the specificity was 43.1% (95% CI 33.5–52.8). The PPV for DIS 2005 was 53.6% (95% CI 44.9–
62.3) and the accuracy 62.4% (95% CI 55.2– 69.5).
The Swanton criteria for DIS as used in the 2010 revisions to the McDonald criteria were ful-
filled in 108 (60.7%) of our patients. Sixty (55.6%) of them developed CDMS during follow-
up. Sixteen (22.9%) of 70 patients who did not fulfil the Swanton DIS 2010 criteria converted 
to CDMS. The sensitivity of the Swanton criteria was 79.0% (95% CI 69.8–88.1) and the spec-
ificity was 52.9% (95% CI 43.3–62.6). The PPV and accuracy were 55.6% (95% CI 46.2–64.9) 
and 64.0% (95% CI 57.0–71.1), respectively.
Characteristic N (%)    
Gender 
Male 
Female 
 
52 (29.2%) 
126 (70.8%) 
  
Ethnicity 
Caucasian 
Asian 
Black 
Mediterranean 
 
168 (94.4%) 
1 (0.6%) 
3 (1.7%) 
6 (3.4%) 
  
Clinical syndrome 
Optic neuritis 
Brainstem 
Spinal cord 
Cerebellum 
Cerebral hemispheres 
Other 
 
74 (41.6%) 
27 (15.2%) 
39 (21.9%) 
9 (5.1%) 
20 (11.2%) 
9 (5.1%) 
  
CDMS 76 (42.7%)   
Age at onset (years) mean 32.7  median 33.0  (range 16-54) 
Time to baseline MRI (weeks) mean 4.8  median 4.0  (range 0-13) 
Follow-up time (months) mean 51.7  median 44.5  (range 12-174) 
Time to CDMS (months) mean 23.9  median 16.5  (range 1-86) 
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When examining the 2010 criteria for DIT, it was found that 36 (31.6%) of 114 patients ful-
filled the criteria at baseline. Sixteen (44.4%) of them converted to CDMS during follow-up. 
Twenty-seven (34.6%) of 78 patients who did not fulfil the new DIT criteria converted to 
CDMS. The sensitivity of the DIT  criteria was 37.2% (95% CI 22.8–51.7) and the specificity 
was 71.8% (95% CI 61.4–82.3). Thirty-three (18.5%) patients fulfilled criteria for both DIS 
and DIT 2010 at baseline.
2010 vs. 2005 revised criteria
Of the 61 patients for whom a follow-up scan was available, 43 (70.5%) had the diagnosis 
MS according to the 2005 criteria, with a mean time to diagnosis of 26.1 months (SD 22.4). 
Forty-four (72.1%) patients received the diagnosis MS according to the 2010 criteria, with a 
mean time to diagnosis of 23.6 months (SD 24.0). Thirty-eight of those patients had a sec-
ond clinical attack during follow-up leading to CDMS. Mean time to CDMS was 27.9 months 
(SD 23.9). 
At 1 year of follow-up, 58.8% of patients who were diagnosed with MS according to the 
2010 criteria had had a second clinical attack leading to CDMS. At 3 years, this was 86.4%. 
At 5 years of follow-up, 18 of 30 patients (60.0%) were diagnosed with MS according to the 
2010 criteria. At this time, 16 (53.3%) patients had CDMS; so at 5 years two patients (6.7%) 
who had the MS diagnosis based on 2010 criteria would still never have had a second clini-
cal attack. However, one of these two patients had a second clinical attack at 5 years and 4 
months after CIS. The PPV of the 2010 criteria increases from 58.8% at 1 year to 86.4% at 
3 years and 88.9% at 5 years. The specificity at 1, 3 and 5 years is 86.3%, 87.5% and 85.7%, 
respectively. The specificity (and thus also the number of false positives) of the 2010 criteria 
at 5 years is the same as for the 2005 criteria. The test characteristics are shown in Table 3B.
The survival curves of time to diagnosis with the 2005 and 2010 criteria are depicted in fig-
ure 2; the main difference is the much larger number of diagnoses made at baseline with the 
2010 criteria, with a steep drop at this point. Time to diagnosis between the two methods 
differed significantly (P = 0.007). 
Figure 2. Survival curve of time to diagnosis with both criteria: 2010 criteria allow for earlier diagnosis.
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Table 3A and B. Test characteristics of criteria for DIS and DIT of baseline scans (A) and for 2005 and 2010 criteria 
as a whole (B). For the latter only patients for whom a second scan was available are taken into account. Test 
characteristics are shown at 1, 3 and 5 years of follow-up and total follow-up. PPV = positive predictive value. DIS = 
dissemination in space. DIT = dissemination in time.
Discussion
In this study the performance of the new diagnostic criteria for MS was investigated. The 
criteria for DIS and DIT used in the 2005 and 2010 criteria in our cohort of 178 CIS patients 
were also tested with an average follow-up time of over 4 years. 
Many studies have calculated test characteristics for the  Barkhof-Tintoré criteria [9–18]. 
To be able to better compare DIS criteria in the 2005 and 2010 revisions to the diagnostic 
criteria for MS, the test characteristics for DIS 2005 were calculated including both Barkhof-
Tintoré criteria and CSF analysis. In doing so, a relatively high sensitivity (88.2%) for DIS 2005 
was found compared with other studies, but a lower specificity (43.1%) [9–18]. The DIS 
2010/Swanton criteria showed a somewhat lower sensitivity (79.0%) and a higher specific-
ity (52.9%) compared with DIS 2005. Overall, the DIS criteria of 2005 and 2010 performed 
A  
DIS 2005 
(Barkhof- Tintoré 
+ CSF) 
 
DIS 2010  
(Swanton) 
 
DIT 2010 
Baseline MRI 
B 
2005 DIS + DIT 
(n=61) 
 
2010 DIS + DIT 
(n=61) 
Sensitivity 
1 yr (n=178) 
3 yr (n=110) 
5 yr (n=54) 
Total f-up 
(n=178) 
 
92.3% (82.1-100) 
92.3% (83.9-100) 
84.4% (71.8-97.0) 
88.2% (80.9-95.4) 
 
80.8% (65.6-95.9) 
84.6% (73.3-95.9) 
84.4% (71.8-97.0) 
79.0% (69.8-88.1) 
 
62.5% (38.8-86.2) 
52.4% (31.0-73.7) 
61.5% (35.1-88.0) 
37.2% (22.8-51.7) 
 
 
 
Specificity 
1 yr (n=178) 
3 yr (n=110) 
5 yr (n=54) 
Total f-up 
(n=178) 
 
33.6% (26.1-41.1) 
31.0% (20.2-41.7) 
31.8% (12.4-51.3) 
43.1% (33.5-52.8) 
 
42.8% (34.9-50.6) 
47.9% (36.3-59.5) 
54.6% (33.7-75.4) 
52.9% (43.3-62.6) 
 
73.5% (64.7-82.2) 
76.7% (64.1-89.4) 
90.9% (73.9-100) 
71.8% (61.4-82.3) 
 
98.0% (94.2-100) 
91.7% (80.6-100) 
85.7% (67.4-100) 
78.3% (61.4-95.1) 
 
86.3% (76.8-95.7) 
87.5% (74.3-100) 
85.7% (67.4-100) 
73.9% (56.0-91.9) 
PPV 
1 yr (n=178) 
3 yr (n=110) 
5 yr (n=54) 
Total f-up 
(n=178) 
 
19.2% (12.3-26.1) 
42.4% (31.9-52.9) 
64.3% (49.8-78.8) 
53.6% (44.9-62.3) 
 
19.4% (12.0-26.9) 
47.1% (35.5-58.8) 
73.0% (58.7-87.3) 
55.6% (46.2-64.9) 
 
27.8% (13.2-42.4) 
52.4% (31.0-73.7) 
88.9% (68.4-100) 
50.0% (30.8-69.2) 
 
90.9% (73.9-100) 
90.5% (77.9-100) 
88.9% (74.4-100) 
88.4% (78.8-98.0) 
 
58.8% (35.4-82.2) 
86.4% (72.0-100) 
88.9% (74.4-100) 
86.4% (76.2-96.5) 
Accuracy 
1 yr (n=178) 
3 yr (n=110) 
5 yr (n=54) 
Total f-up 
(n=178) 
 
42.1% (34.9-49.4) 
52.7% (43.4-62.1) 
63.0% (50.1-75.8) 
62.4% (55.2-69.5) 
 
48.3% (41.0-55.7) 
60.9% (51.8-70.0) 
72.2% (60.3-84.2) 
64.0% (57.0-71.1) 
 
71.9% (63.7-80.2) 
68.8% (57.4-80.1) 
75.0% (57.7-92.3) 
58.8% (49.7-67.8) 
 
98.4% (95.2-100) 
95.4% (89.1-100) 
93.3% (84.4-100) 
91.8% (84.9-98.7) 
 
88.5% (80.5-96.5) 
93.0% (85.4-100) 
93.3% (84.4-100) 
90.2% (82.7-97.6) 
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similarly in the prediction of CDMS (accuracy 62.4% and 64.0%). The new criteria for DIT had 
a reasonable specificity (71.8%) but a low sensitivity (37.2%), in our study even somewhat 
lower than in the study by Gomez-Moreno et al. [18]. 
When comparing the 2005 and 2010 criteria taking both DIS and DIT into account, a some-
what lower specificity was found for the 2010 criteria (73.9%) compared with the 2005 
criteria (78.3%), and a similar PPV (86.4% vs. 88.4%). However, it should be noted that the 
PPV for the 2010 criteria strongly increases with follow-up time, whereas it remains sta-
ble for the 2005 criteria (as shown in Table 3): at 1 year,  specificity and PPV of the 2005 
criteria were a little higher than those of the 2010 criteria, but at 5 years differences were 
completely gone. This reflects the fact that in many patients a diagnosis can be made much 
earlier with the 2010 criteria, whilst some of them will have their second clinical attack only 
many years later. So, the longer the follow-up time is, the better the test characteristics for 
the 2010 criteria get. In our cohort, after 5 years only two patients got a diagnosis of MS 
with the new criteria but did not experience a second clinical attack (‘false positives’). One 
of them did have a second clinical attack but after 5 years and 4 months of follow-up, so the 
number of false positives would decrease even further with increasing follow-up time.
 
At 5 years of follow-up, the number of false positives for both diagnostic methods is the 
same, but diagnosis was made significantly faster with the 2010 criteria. For a serious dis-
ease with such a  considerable impact on one’s life as MS, it is of great importance to have 
as few false positives as  possible. However, it is also very valuable to be able to give a pa-
tient some certainty early in a disease process that brings already many uncertainties with 
it. Also, an early diagnosis allows for earlier  treatment, which may be beneficial for disease 
outcome [3], although it might be debatable if this is really an advantage for patients who 
turn out to have a mild disease course. 
Since the introduction of the 2010 revisions, the CSF examination is no longer included in 
the diagnostic criteria for relapsing-remitting MS. However, as is acknowledged, CSF can 
still be important to evaluate alternative diagnoses [6,19]. This was not tested in this study 
because of the low number of patients  with alternative diagnoses in our cohort. Those pa-
tients were excluded from the analyses. 
There are some shortcomings to our study. Not all patients underwent spinal cord MRI and 
not all patients had a follow-up MRI scan performed. For this reason, test characteristics for 
the 2005 and 2010 criteria as a whole were calculated in the subgroup of patients for whom 
a second scan was available. A small number of patients (13.5%) received immune-mod-
ulating therapy before a second attack. These ‘high risk’ patients were not excluded from 
this study because they would probably have provided more  bias if they were excluded 
than now being included. In this cohort, the frequency of diagnoses other than MS was low 
(4.8%). In this situation, specificity (reflecting the proportion of patients without the disease 
that have a negative test result) functions to differentiate between monophasic and pro-
gressive disease, more than between MS and other diagnoses. To be noted, other studies 
testing diagnostic  criteria for MS have also excluded alternative diagnoses [14,15,20]. It re-
mains questionable whether the criteria that work well in such cohorts retain their specific-
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ity when applied to populations in general hospitals. At least for the Swanton criteria for DIS, 
this seems to be the case [21]. Still, it should be emphasized, especially for use in more gen-
eral patient populations, that it is always necessary to rule out alternative diagnoses first.
In a cohort of 178 patients it was shown that the diagnosis of MS could be made easier and 
faster with the 2010 revised criteria compared with the 2005 criteria. One other study ap-
plied the 2010 criteria to a cohort of CIS patients [18] and, although in this study no follow-
up scans were included, it also  confirmed the value of the new criteria. As recent posters at 
the ECTRIMS congress showed (e.g. [22]), the new criteria are starting to be validated glob-
ally. In our cohort, in a substantial number of CIS patients (33; 18.5%) the diagnosis could 
already be made at baseline. Test characteristics of the 2010 and 2005 criteria are similar, 
but because test characteristics of 2010 criteria increase with follow-up time, those criteria 
might perform better when tested in a cohort with an even longer follow-up time. The fact 
that the diagnosis of MS can be made earlier with the 2010 criteria is a great advantage, giv-
ing CIS patients at least a glimpse of certainty after a life-changing event.
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Abstract
Objective
Fatigue is a common, disabling symptom of multiple sclerosis (MS), but little is known about 
fatigue in patients with clinically isolated syndrome (CIS), often the presenting symptom of 
MS. We aimed to  investigate the prevalence and severity of fatigue in patients with CIS, and 
its association with a diagnosis of clinically definite MS (CDMS). 
Methods
127 patients were consecutively included in our ongoing prospective CIS study. At baseline, 
clinical, demographic, laboratory and MRI data were collected, and fatigue severity was as-
sessed using Krupp’s  Fatigue Severity Scale (FSS); fatigue was defined as FSS≥5.0. Fatigue 
scores were compared with scores of 113 healthy controls and with scores from the litera-
ture. The association of fatigue with CDMS was calculated using Cox regression models.
Results
The mean FSS of patients with CIS was 4.3, similar to MS patients, and significantly higher 
than that of healthy individuals (p<0.001). Fatigue prevalence in patients with CIS (46.5%) 
was significantly higher than in controls ( p<0.001). Fifty-two patients (40.9%) reached CDMS 
during follow-up. Fatigue was associated with a diagnosis of CDMS in univariate analysis (HR 
2.6, 95% CI 1.5 to 4.6) and in multivariate analysis correcting for sex, age, neuroanatomical 
localisation of CIS, 25-OH-vitamin D, anxiety, depression, MRI dissemination in space and 
gadolinium enhancement (HR 4.5, 95% CI 1.9 to 10.6).
Conclusions 
Already at the stage of CIS, fatigue is a very common symptom, with a severity similar to 
fatigue in MS patients. This fatigue seems unrelated to the type or severity of the attack. 
Importantly, we found that fatigue was an independent predictor of a subsequent diagnosis 
of MS.
47
ch
ap
te
r 3
Fatigue at time of CIS is an independent predictor of a subsequent diagnosis of MS 
Introduction
Fatigue is a very common and disabling symptom in patients with multiple sclerosis (MS), re-
ported by over 75% of MS patients at some point in the course of the disease [1–3]. Never-
theless, the mechanism of fatigue in MS patients remains poorly understood. The proposed 
causes range from altered cerebral activation or influences and effects of pro-inflammatory 
cytokines to sleep disorders or depression[4]. Even less is known about fatigue among pa-
tients with a clinically isolated syndrome (CIS), often the presenting symptom of MS. 
In this study, we aimed to investigate the prevalence and severity of fatigue in patients with 
CIS, and its association with a diagnosis of clinically definite MS (CDMS).
Low vitamin D has been associated with fatigue in several conditions, such as systemic lupus 
erythematosus (SLE)[5,6] and traumatic brain injury[7], and is considered to be involved in 
the development and disease course of MS[8–10]. Therefore, a second aim of this study 
was to investigate if fatigue was associated with the vitamin D status of patients with CIS. 
To do this, fatigue, 25-OH-D concentrations (the metabolite best reflecting vitamin D status)
[11] and other clinical parameters were measured in our ongoing prospective multicenter 
CIS study.
Methods
Participants
Patients were consecutively included in our ongoing prospective CIS study, the PROUD study 
(Predicting the Outcome of a Demyelinating event). This observational study is a multicenter 
study of our tertiary referral center for MS in collaboration with several regional hospitals. 
Patients with CIS suggestive of MS are included if they give informed consent and fulfil the 
following inclusion criteria: age between 18 and 50 years, inclusion within 6 months after 
symptom onset and no serious comorbidity. At baseline, clinical and demographic data are 
collected, an MRI is performed and fatigue is assessed. For the present investigation, we 
applied the following supplementary inclusion criterion: time between fatigue assessment 
and blood sampling less than 2 months. Patients with alternative diagnoses were excluded 
from the analyses, as well as patients with comorbidity likely to cause fatigue, other than 
depression. All patients were followed prospectively and were seen regularly for clinical re-
assessment. The Ethics Committee of the Erasmus MC University Medical Center Rotterdam 
approved the study protocol and informed consent was obtained from all participants. 
To compare the prevalence and severity of fatigue between patients with CIS and controls, 
we used data from a group of 113 healthy controls included previously in our center[12]. 
These controls were volunteers recruited from hospital personnel, relatives or friends of 
patients visiting the outpatient clinic, and volunteers unfamiliar with the study. They had 
declared themselves to be healthy and not taking any medication that could contribute to 
fatigue. We also compared the fatigue of patients with CIS with healthy controls and MS 
patients from the literature[13,14].
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Definitions
Exacerbation was defined as a worsening of existing symptoms or the appearance of new 
symptoms lasting for more than 24 h, after a period of more than 30 days of improvement 
or stability, confirmed by neurologic examination[15]. A temporary neurological deteriora-
tion associated with fever was not considered as an exacerbation. All patients in this study 
were termed CIS, and also included patients who fulfilled the 2010 McDonald criteria. CDMS 
was diagnosed when there was clinical evidence for dissemination in space and time as de-
scribed by Poser et al.[16].
Instruments and clinical data
Fatigue was assessed using Krupp’s Fatigue Severity Scale (FSS)[17]. This is a self-admin-
istered questionnaire that is widely used and has been validated for use in patients with 
MS[13,14,17]. It has nine items and seven possible responses per item, ranging from 1 
(strong disagreement) to 7 (strong agreement). The mean value of the nine items is the final 
score. Fatigue is defined as an FSS score of ≥5.0 [18–20].
Since fatigue is known to be associated with depression, we also measured depression, 
using the Hospital Anxiety and Depression Scale (HADS). The HADS is a self-administered 
questionnaire consisting of 14 items measuring symptoms of anxiety (7 items) and depres-
sion (7 items)[21,22].
Neuroanatomical localization of CIS was determined at baseline and divided into the follow-
ing groups: optic nerve, spinal cord, brain stem, other and multiregional. 
Measurement of 25-OH-D
Concentrations of 25-OH-D were determined by a radioimmunoassay method (DiaSorin, 
USA) using an extraction method. The inter-assay variation coefficient at a concentration of 
62 and 109 nmol/L is 11.6% and 10.3%, respectively. The intra-assay variation coefficient at 
the levels is 5.7% and 6.6%, respectively.
MRI
All brain MRIs were performed on 1.5 T scanners with a standard head coil (Philips, Best, the 
Netherlands, or General Electric, Milwaukee, Wisconsin, USA). Scans typically consisted of 
an axial T1-weighted sequence, an axial spin echo proton density-weighted and T2-weight-
ed sequence, and an axial fluid-attenuated inversion recovery sequence, with 2–5 mm im-
ages. Post-gadolinium T1-weighted  sequences were added by the radiologist on indication 
in patients with T2 lesions suggestive of demyelination. Scans were scored for dissemination 
in space according to the 2010 McDonald criteria (≥1 lesion in at least two of the following 
areas: periventricular, juxtacortical, infratentorial or spinal cord)[23] and for gadolinium en-
hancement. All brain MRIs were performed within 3 months of symptom onset.
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Statistical analysis
Fatigue was analyzed both as a continuous variable (FSS) and as a dichotomous variable 
(yes/no with FSS 5.0 as a cut-off value). Comparison of continuous variables between groups 
was done using Student t test or ANOVA. Student t test was also used to compare the mean 
FSS of patients with CIS with values from the literature. Dichotomized variables were com-
pared using the χ2 test. To calculate the association of two continuous variables, correlation 
analysis was used. The association of fatigue with the diagnosis of CDMS was analyzed using 
survival analysis with univariate and multivariate Cox regression models. In these analyses, 
25-OH-D levels were divided into two groups (low: <50 nmol/L, and high: >50 nmol/L). Anxi-
ety and depression were included in the model as dichotomous variables. All calculations 
were done using SPSS V.21 for Windows.
Results
Participants
Of the 137 patients in our ongoing CIS study who fulfilled the inclusion criteria, 7 were ex-
cluded from the analyses because of alternative diagnoses and 3 were excluded from the 
analyses because of comorbidity likely to cause fatigue (1 Crohn’s disease, 1 untreated hypo-
thyroidism and 1 panhypopituitarism). This left 127 patients for the analyses: baseline char-
acteristics of patients and 113 healthy controls are depicted in table 1. During follow-up, 52 
patients (40.9%) met the criteria for CDMS, with a mean time to diagnosis of 21.1 months 
(SD 17.0). Blood samples for vitamin D measurement were available for 104 of 127 patients.
Table 1. Baseline characteristics and FSS outcome for CIS patients and healthy controls.
Fatigue
Fifty-nine patients (46.5%) suffered from fatigue, and the mean FSS for patients with CIS was 
4.3 (SD 1.9). In the control group, fatigue was significantly less prevalent (5.3%, p<0.001) 
and less severe (mean FSS 2.9 (SD 1.1), p<0.001). Similarly, in healthy individuals from the 
literature, the mean FSS was 3.00 (SD 2.24)[13] and 3.31 (SD 1.38),[14] which was signifi-
cantly lower than in patients with CIS (both p<0.001). The FSS of our patients with CIS was 
similar to that of the MS patients in the cited studies[13, 14] (mean 4.66, SD 1.64 and mean 
4.81, SD 1.46, both p>0.05). FSS scores did not depend on gender or age.
The mean FSS did not differ significantly between patients with different neuroanatomical 
localizations of CIS. FSS scores did not depend on the time between symptom onset and fill-
ing out of the questionnaires.
 CIS-patients n=127 Controls n=113 
Sex (nr of  females), n(%) 98 (77.2%) 54 (47.8%) 
Age (years) mean (SD) 34.0 (8.8) 54.2 (14.8) 
Follow-up (months) mean (SD) 35.4 (19.3)  
FSS mean (SD) 4.3 (1.9) 2.9 (1.1) 
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Fatigue was not associated with 25-OH-D levels: neither with FSS as a continuous variable, 
nor with fatigue as a dichotomous variable. FSS was not associated with age, nor with MRI 
measures (number of T2 lesions, gadolinium enhancement, and normal versus abnormal 
MRI). FSS correlated with both anxiety (r=0.44, p<0.001) and depression (r=0.51, p<0.001).
In univariate analysis, fatigue was associated with a diagnosis of CDMS both as a continu-
ous variable (HR 1.3, 95% CI 1.1 to 1.6) and as a dichotomous variable (HR 2.6, 95% CI 1.5 
to 4.6). Thirty-two (61.5%) of 52 patients who reached CDMS suffered from fatigue, versus 
27 (36.0%) of 75 patients who did not reach CDMS. Patients suffering from fatigue had a 
shorter time to diagnosis than non-fatigued patients: 32 months in fatigued patients versus 
54.8 months in non-fatigued patients (Log Rank test: p=0.001). The Kaplan-Meier curve of 
time to CDMS for patients with and without fatigue is shown in figure 1.
Figure 1. Kaplan-Meier curves for time to CDMS for patients with and without fatigue (FSS ≥5.0) . Log Rank test: 
p=0.001.
25-OH-D
The mean 25-OH-D concentration of patients with CIS was 67.6 nmol/L (SD 34.4). 25-OH-
D levels showed a seasonal fluctuation with the peak level in July and nadir in January. 
Thirty-one patients (24.4%) had low vitamin D levels(<50 nmol/L). We found no association 
between 25-OH-D levels and a diagnosis of CDMS (HR for the low-level group 1.5, 95% CI 0.8 
to 2.8). Since in a recent study[10] an increased risk for CDMS was found for only the lowest 
10% of 25-OH-D concentrations, we also analyzed the risk of CDMS for 25-OH-D divided into 
10 equal groups, but we did not find an increased risk in the lowest 25-OH-D level group, not 
even when men and women were analyzed separately. 25-OH-D levels were also not associ-
ated with time to CDMS, MRI measures and presence of anxiety or depression.
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Multivariate analysis
In a multivariable model correcting for sex, age, localization of symptoms, vitamin D, anxiety, 
depression, number of T2 lesions and gadolinium enhancement, the association of fatigue 
with CDMS was significant, with an HR for CDMS in fatigued patients of 4.5 (95% CI 1.9 to 
10.6). Also in the multivariable model, low 25-OH-D levels were not associated with CDMS 
(HR 0.9, 95% CI 0.3 to 2.1). In fact, fatigue turned out to be the most significant predictor for 
CMDS in the model. HRs are shown in table 2.
*p for trend 0.22
Table 2. Hazard ratios for clinically definite MS according to the multivariate analysis. Events = a diagnosis of CDMS
Discussion
In this study, we show that fatigue is a common symptom in patients with CIS, with almost 
half of patients (46.5%) suffering from it. The prevalence and the severity of fatigue in pa-
tients with CIS are significantly higher than in healthy persons, and similar to the fatigue in 
MS patients. Importantly, we found that fatigue is associated with a greater risk of CDMS, 
Variable  n Events Hazard ratio (95% CI) P-value 
Age <30 
30-40 
>40 
52 
40 
35 
21 
16 
15 
1 (ref) 
0.8 (0.3-1.9) 
0.4 (0.1-1.2) 
-* 
0.63 
0.09 
Sex Male 
Female 
29 
98 
8 
44 
1 (ref) 
1.3 (0.6-3.1) 
- 
0.52 
DIS criteria McDonald 
2010 
Not fulfilled 
Fulfilled 
45 
70 
12 
34 
1 (ref) 
1.7 (0.7-4.4) 
- 
0.27 
Gadolinium 
enhancement 
No  
Yes 
45 
31 
16 
19 
1 (ref) 
1.8 (0.7-5.0) 
- 
0.22 
Vitamin D <50 
>50 
31 
73 
16 
26 
0.9 (0.3-2.1) 
1 (ref) 
0.75 
- 
Fatigue No 
Yes 
68 
59 
20 
32 
1 (ref) 
4.5 (1.9-10.6) 
- 
0.001 
Anxiety No 
Yes 
79 
45 
31 
20 
1 (ref) 
0.9 (0.4-2.2) 
- 
0.89 
Depression  No 
Yes 
97 
27 
39 
12 
1 (ref) 
1.7 (0.6-5.0) 
- 
0.34 
Symptom localization Optic nerve 
Spinal cord 
Brain stem 
Multiregional 
Other 
42 
35 
12 
22 
15 
14 
13 
6 
11 
8 
1 (ref) 
1.0 (0.3-3.1) 
0.4 (0.1-1.1) 
3.2 (1.1-9.4) 
1.3 (0.4-5.0) 
- 
0.98 
0.25 
0.03 
0.67 
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even independent of MRI measures. The mean time to diagnosis is significantly shorter in 
patients suffering from fatigue than in non-fatigued patients. 
There are several possible explanations for fatigue in patients with CIS. First, it is known 
that fatigue correlates with neurological disability[24], so the fatigue in patients with CIS 
could be related to the attack itself. However, one would expect this fatigue to differ among 
patients with different  neuroanatomical localizations of CIS (e.g., lower FSS in patients with 
optic neuritis) or lesion loads, and to improve along with amelioration of symptoms; we 
did not find any association with neuroanatomical localization, nor with lesion load, nor 
with time from symptom onset. Second, fatigue could be due to the psychological impact 
of getting a possible diagnosis of MS. Indeed, we found an association with anxiety and 
depression, a phenomenon that has been shown previously[25]. Nevertheless, correction 
for anxiety and depression in the multiple regression analysis did not influence the associa-
tion between fatigue and CDMS. Third, fatigue could be related to the second attack, which 
would explain the association with CDMS. However, as the mean time to the second attack 
in patients who reach a diagnosis of CDMS is 21.1 months, this does not seem very likely. We 
favor a fourth explanation: that the fatigue of patients with CIS is the MS-related fatigue pre-
senting itself already at the moment of CIS, independent of the type or severity of CIS. One 
previous study[26] has shown that fatigue sometimes precedes other symptoms in MS and 
another study[27] described fatigue in early MS; however, in both studies, fatigue was not 
studied separately in patients with CIS. Although fatigue is very frequently seen in all sub-
types of MS[28], its pathophysiology is still not well understood. It is likely to be multifacto-
rial, with major roles for inflammatory cytokines associated with the disease combined with 
CNS dysfunction and secondary mechanisms such as sleep disorders or depression[4,28]. 
We did not find associations of fatigue with MRI measures. In this study, we also tested the 
hypothesis that vitamin D is involved in fatigue, but we did not find any evidence for this in 
patients with CIS. Also, we could not confirm the earlier described association between low 
vitamin D concentrations in patients with CIS and risk of CDMS[10,29]. Here, a lack of power 
cannot be ruled out, but the association, if it exists, will be small as the HR is only 1.2. 
Fatigue is a serious disabling symptom of MS, with a negative impact on quality of life. Our 
study is the first to show that already at the stage of CIS fatigue is very common, with a 
severity similar to fatigue in MS patients. This fatigue is unrelated to the type or severity of 
the attack. In addition, we found that fatigue was predictive for definite MS, independent 
of vitamin D and known predictors of a subsequent diagnosis of MS such as the McDonald 
2010 criteria.
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Abstract
Background
There is a substantial need for biomarkers in patients with clinically isolated syndrome (CIS), 
the first presenting symptom of multiple sclerosis (MS), for several reasons. First, biomark-
ers could provide more insight into the pathophysiology of the early events leading to MS, 
which is still largely unknown. Second, the course of the disease after CIS is very heterogene-
ous and not well predictable, so biomarkers could improve patient counselling and enable 
early treatment in the right patients. 
In recent studies we have shown the usefulness of cerebrospinal fluid (CSF) proteomics 
studies for the detection of pathologically relevant proteins for multiple sclerosis (MS). 
Objectives
To compare the proteome of CIS patients and controls to find disease-related proteins. 
To investigate the proteins associated with a first demyelinating attack and with progression 
to clinically definite MS. 
Methods
Proteomics analysis was performed in CSF samples of 47 CIS patients with clinical and MRI 
data collected within 2 months after symptom onset , and 45 controls. CSF samples were 
enzymatically digested and subsequently measured by LC-MS/MS on a LTQ-Orbitrap mass 
spectrometer. The mass spectra were analyzed and differential abundance of the identified 
proteins between groups were investigated.
Results
A total of 3159 peptides were identified, relating to 485 proteins. Only 1 protein was sig-
nificantly more abundant in CSF of CIS patients than in controls: Ig kappa chain C region. 
Thirty-five proteins were lower in CIS patients than controls, most of them with functions in 
nervous system development and function (such as contactin 1, contactin 2 and neuronal 
cell adhesion molecule). These 35 proteins were even lower in patients with the highest MRI 
lesion loads. We observed no significant differences in specific peptide abundance levels 
between patients who did and did not reach a diagnosis of clinically definite MS. 
Conclusions
In conclusion, we found no difference in protein abundance relating to disease progression, 
but we did observe a remarkably lower abundance of neuro-axonal proteins in patients with 
a first demyelinating event. It remains to be determined whether this is a reflection of an MS 
predisposing gray matter disturbance, or rather a result of disease pathology itself. 
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Introduction
Multiple sclerosis (MS) is a common chronic, disabling disease of the central nervous sys-
tem (CNS). Although its pathophysiology is still not completely clear, it seems to result from 
an interplay of genetic susceptibility and environmental exposure[1]. In most MS patients, 
the disease starts with a subacute episode of symptoms (such as optic neuritis, transverse 
myelitis or brainstem syndrome) called clinically isolated syndrome (CIS). However, only 30-
70% of CIS patients will eventually develop MS[2]. In some patients the diagnosis of MS can 
already be made after the first attack, based on the most recent diagnostic criteria[3], but 
in the majority of CIS patients those criteria are not met, and it is hard to predict who will 
develop MS and who will not. The discovery of biomarkers could lead to better predictors 
of disease course in CIS patients, and could also shed new light on the pathophysiologic 
mechanisms of MS. 
In recent studies, we and others have shown the usefulness of cerebrospinal fluid (CSF) pro-
teomics studies for the detection of pathologically relevant proteins for MS[4-8].
In the present study we aimed to identify novel markers for a first demyelinating event and 
further MS disease progression, using advanced mass spectrometry techniques. 
 
Methods
Participants
Patients were included at the neurology outpatient clinic of the Erasmus MC University Hos-
pital, a tertiary referral center for MS patients. In our center, all patients aged 18–50 years 
with a first episode suggestive for demyelination are followed prospectively if they give in-
formed consent (approved by the Erasmus MC ethics committee). For the present study, we 
included patients with CSF samples, clinical and MRI data collected within 2 months after 
symptom onset. 
Clinically definite MS (CDMS) was diagnosed if there was clinical evidence for dissemination 
in space and time as described by Poser and colleagues.[9]
Controls were ‘symptomatic controls’ as defined in [10]; persons who underwent lumbar 
puncture at the outpatient clinic of our hospital for reasons other than neuroinflammatory 
diseases; these were negative neurosyphilis (40.0%), acute headache without neurological 
disease after follow up (e.g. no subarachnoid hemorrhage, no inflammation or idiopathic 
intracranial hypertension, 20.0%) and other (e.g. back pain, muscle pain without neurologi-
cal disease, 40.0%).
Sample preparation, mass spectrometer measurements and analysis
CSF samples were taken from patients and controls and immediately centrifuged for 10 
minutes at 3000 rpm to discard cells and cellular elements. The samples were subsequently 
used for routine CSF diagnostics, which included quantification of total protein concentra-
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tion. The remaining volume of the samples was aliquoted and stored at -80°C, where they 
remained until sample preparation for this study. 
From each CSF sample, 20 μL was added to 20 μL of 0.2% Rapigest (Waters, Milford, MA) in 
50 mM ammonium bicarbonate buffer. After 30 minutes incubation periods with 1,4-dithi-
othreitol (60 °C) and, subsequently, iodoacetamide (37 °C), 4 μL of 0.1 μg/μL gold-grade 
trypsin (Promega, Madison, WI)/3 mM Tris-HCl (pH 8.0) was added to each sample. The 
samples were incubated overnight at 37 °C. To adjust the pH of the digest to pH < 2, trif-
luoroacetic acid (TFA) was added to the mixture prior to the final incubation step at 37°C for 
a duration of 45 minutes to stop the enzymatic digestion reaction.
Mass spectrometry measurements were carried out on a Ultimate 3000 nano LC system 
(Dionex, Germering, Germany) online coupled to a hybrid linear ion trap/Orbitrap mass 
spectrometer (LTQ Orbitrap XL; Thermo Fisher Scientific, Germany). Five µL digest (i.e. 2  µL 
CSF) were loaded on to a C18 trap column (C18 PepMap, 300 µm ID ×5 mm, 5 µm particle 
size, 100 Å pore size; Dionex, The Netherlands) and desalted for 10 minutes using a flow 
rate of 20 µL/min 0.1% TFA. Then the trap column was switched online with the analytical 
column (PepMap C18, 75 µm ID ×150 mm, 3 µm particle and 100 Å pore size; Dionex, The 
Netherlands) and peptides were eluted with following binary gradient: 0%–25% solvent B in 
120 minutes and 25%–50% solvent B in further 60 minutes, where solvent A consist of 2% 
acetonitrile and 0.1% formic in water and solvent B consists of 80% acetonitrile and 0.08% 
formic acid in water. Column flow rate was set to 300 nL/min. For mass spectrometry detec-
tion a data dependent acquisition method was used: high resolution survey scan from 400–
1800 Th. was performed in the Orbitrap (value of target of automatic gain control AGC 106, 
resolution 30,000 at 400 m/z; lock mass was set to 445.120025 u (protonated (Si(CH3)2O)6). 
Based on this survey scan the 5 most intensive ions were consecutively isolated (AGC target 
set to 104 ions) and fragmented by collision-activated dissociation (CAD) applying 35% nor-
malized collision energy in the linear ion trap. After precursors were selected for MS/MS, 
they were excluded for further MS/MS spectra for 3 minutes. 
The raw data was pre-processed using the Progenesis LC-mass spectrometry software pack-
age (version 4.0, Nonlinear Dynamics, Newcastle-upon-Tyne, United Kingdom). Peptides 
were identified and assigned to proteins by exporting features, for which MS/MS spectra 
were recorded, using the Bioworks software package (version 3.2; Thermo Fisher Scientific, 
Germany; peak picking by Extract_msn, default settings). The resulting .mgf file was sub-
mitted to Mascot (version 2, Matrix Science, London, United Kingdom) for identification 
to interrogate the UniProt-database (release 2013_07; taxonomy: Homo sapiens, contain-
ing 20265 sequences). Only ions with charge states between +2 and +8 were considered 
and only proteins with at least two unique peptides (Mascot ions sore > 25, (i.e. a peptide 
probability cut off value of 0.01)) assigned to them were accepted as true identifications. 
Modifications: carbamidomethylation of cysteine was set as fixed and oxidation of methio-
nine as variable modification, allowing a maximum of 2 missed cleavages. Mass tolerance 
for precursor ions was set to 10 ppm and for fragment ions at 0.5 Da. The Mascot search 
results were imported back into the Progenesis software to link the identified peptides to 
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the detected abundances of these peptides. The peptide abundances were normalized to 
the total ion current to compensate for experimental variations using an algorithm available 
in the analysis software. Subsequently the data were exported in Excel format. 
All CSF samples were tested for blood contamination by checking for the presence of the 
blood-specific proteins hemoglobin and apolipoprotein B-100; none were found to be con-
taminated. 
The reproducibility of the measurement procedure was tested by measuring a single CSF 
digest multiple times over the course of the experiment. This sample was measured after 
every six CSF samples and analysis of these runs showed no significant changes in machine 
function over the course of the study.
Statistical analysis
The raw abundances of all identified peptides were compared between the groups of sam-
ples by performing a non-paired 2-tailed t-test on all individual peptides. Proteins of which 
50% or more of the peptides had a low p-value in this t-test (p<0.05), and 25% of the pep-
tides of the protein had a very low p-value (p<0.01) were deemed to be significantly dif-
ferentially abundant between the two groups. An additional condition for proteins to be 
deemed significant was that 75% or more of the peptides must be altered in the same direc-
tion between the groups.
The following clinical variables were used in the analyses: conversion to CDMS (dichoto-
mous), sex (dichotomous), age (dichotomous; older or younger than median, i.e. 33 years), 
optic neuritis vs. other symptom localization, and positive CSF defined as the presence of 
oligoclonal bands and/or IgG-index ≥ 0.68 (dichotomous). The following MRI parameters 
were used: normal MRI vs. abnormal MRI (defined as ≥ 1 T2 hyperintense lesion), gadolini-
um enhancement (dichotomous), fulfilling of criteria for dissemination in space according to 
2010 McDonald criteria (dichotomous), and the number of T2 hyperintense lesions (in three 
groups: 0 lesions, 1-9 lesions, >9 lesions). 
Protein function and network analysis
We searched for the functions of the identified proteins in online databases (www.uniprot.
org) and previous reports using Pubmed. Identified proteins were uploaded in the Ingenuity 
Pathways Analysis service (Ingenuity Systems, Redwood City, CA, USA) for network analysis 
of their biological context. 
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Table 1. Baseline characteristics of patients and controls as mean (SD) unless otherwise specified.
Results
Participants
Fifty-four patients and 45 controls with other neurological diseases fulfilled the inclusion cri-
teria. Seven CIS samples were not measurable and therefore excluded from the analysis (2: 
very low signal and 5: bad retention time alignment in the analysis software). This left 47 pa-
tients and 45 controls for the analysis. During a mean follow-up time of more than 4 years, 
twenty-one CIS patients reached a diagnosis of clinically definite MS, with a mean time to 
diagnosis of 31.4 months (SD 26.3). No significant differences were observed between pa-
tients and controls in terms of age, total protein and albumin concentrations. Among the 
patients were more females than among controls. Characteristics of patients and controls 
are shown in Table 1. 
Protein identification
The Mascot database search against the human subset of the Uniprot database resulted in 
the identification of 3159 peptides that related to 485 proteins. 
CIS versus controls
Using stringent statistical criteria, we found 36 proteins significantly different between pa-
tients and controls. Only 1 protein was significantly more abundant in the CSF of CIS patients 
than in controls: Ig kappa chain C region. Thirty-five proteins were significantly less abun-
dant in CIS. Most identified proteins that were lower in CIS than controls have functions in 
the development and maintenance of the nervous system. Uploading of the differentially 
Variable Patients n=47 Controls n=45 P 
Sex, nr of females (%) 34 (72.3%) 20 (44.4%) 0.006 
Age (years) 34.8 (8.9) 32.6 (9.4) 0.26 
Protein concentration (g/l) 0.40 (0.16) 0.34 (0.15) 0.09 
Albumin concentration (g/l) 0.22 (0.11) 0.20 (0.10) 0.39 
CIS type 
- Optic neuritis  
- Transverse myelitis 
- Brainstem 
- Cerebral 
- Cerebellar 
 
17 (36.2%) 
13 (27.7%) 
13 (27.7%) 
2 (4.3%) 
2 (4.3%) 
  
CDMS 21 (44.7%)   
Time between CIS and LP (weeks) 3.7 (2.7)   
Time to CDMS (months) 31.4 (26.3) range 1-103   
Follow-up (months) 49.1 (36.6) Range 0-141   
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abundant proteins in the Ingenuity Pathway analysis software showed 21 of the differen-
tially abundant proteins in a network relating to nervous system development and func-
tion, 8 proteins in a network relating to cell-to-cell signaling and interaction, and 6 proteins 
in a network relating to cell morphology, cell death and survival. The identified proteins 
that were differentially abundant in CSF of CIS patients and controls are shown in table 2. 
Comparing these identified proteins between patients with the highest MRI T2 lesion load 
(>9 lesions) and patients without any MRI abnormalities, we found the majority lower in 
the group with the highest lesion load, although this did not reach significance. This is also 
shown in table 2. 
CIS patients: MS or no MS
There were no significant differences in peptide abundance between patients who did and 
did not reach a diagnosis of clinically definite MS during follow up. Next we questioned 
whether the CSF peptide abundances from ‘fast converters’, i.e. patients who reached 
CDMS within two years, were different from the monophasic CIS group, but this was not 
the case. We observed no differentially abundant proteins related to gender, nor between 
patients with normal versus abnormal MRI, nor between patients with and without gado-
linium enhancement. 
When comparing patients with and without positive CSF (defined as the presence of oligo-
clonal bands or IgG index ≥ 0.68), we found, unsurprisingly, peptides relating to multiple im-
munoglobulin proteins: Ig kappa chain V-I region, Ig kappa chain C region, Ig gamma-1 chain 
C region, Ig kappa chain V-III region, and Ig kappa chain V-II region.
When looking at type of CIS, we found that only 2 proteins were significantly more abundant 
in patients with brainstem symptoms compared to patients with optic neuritis: these were 
pleiotrophin (PTN) and extracellular superoxide dismutase [Cu-Zn] (SOD3); the latter was 
also on the list of differentially abundant proteins in patients and controls (table 2). 
 
Discussion
We performed Orbitrap-based high-resolution proteomics analysis of CSF in, to our knowl-
edge, the largest set of CIS patients so far. We found several proteins that were clearly dif-
ferentially abundant in CIS patients and controls. Interestingly, these were for the main part 
markers related to gray matter development and function that we found to be less abundant 
in CIS. 
Consisted with our findings, some of the identified proteins have been implicated in MS 
before. For example, contactin 2, which is a neuronal membrane protein expressed at the 
juxtaparanodal region,  and contactin 1, which is thought to be involved in the formation of 
axon connections, have been found to be differentially abundant in CIS patients and controls 
by others[11, 12]. Contactin-2 directed autoimmunity is identified in multiple sclerosis pa-
tients and immunity directed against its rat homologue TAG-1 mediates gray matter pathol-
ogy in animal models[13].
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The finding that many gray matter related proteins and no myelin products were differen-
tially abundant at this early stage of demyelinating disease feeds the hypothesis that gray 
matter pathology is not secondary to demyelination but might be the primary characteristic 
of the disease pathology. This is in line with recent work by Dhaunchak et al. in pediatric 
patients [14] and Schutzer et al.[12] who showed in a smaller cohort of 9 CIS patients, 12 re-
lapsing-remitting MS patients and 6 controls that several gray matter related proteins were 
quantitatively different at the time of CIS. It is also congruent with natural history studies 
of MS showing that disease progression, which is probably caused by neurodegeneration, 
starts early and progresses at similar pace among all disease subtypes of MS, independent 
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Protein Genetic 
name 
Fold 
change 
Function MRI 0 lesions vs. 
>9 lesions 
Pathway: Nervous system development and function 
Receptor-type tyrosine-protein 
phosphatase N2  
PTPRN2 0.579 Implicated in 
development of nervous 
system. Involved in lipid 
signaling, cell signaling 
and membrane trafficking 
Lower in >9 lesions 
Neurotrimin  NTM 0.723 Neural cell adhesion 
molecule. Mediates 
effects on neurite 
outgrowth 
No difference 
Neuroendocrine protein 7B2  SCG5 0.655 Chaperone for PCSK2/PC2, 
which is involved in 
maturation of 
neuroendocrine peptides 
Lower in >9 lesions 
Superoxide dismutase [Cu-Zn]  SOD1 0.905 Destroys radicals Lower in >9 lesions 
Neurosecretory protein VGF  VGF 0.710 Involved in regulation of 
cell-cell interactions and 
synaptogenesis during 
nervous system 
maturation. Antimicrobial. 
Lower in >9 lesions 
Major prion protein  PRNP 0.692 Involved in neuronal 
development and synaptic 
plasticity 
Lower in >9 lesions 
Metalloproteinase inhibitor 2  TIMP2 0.715 Metastasis suppressor, 
inhibits proliferation of 
endothelial cells. 
Important in tissue 
homeostasis 
Lower in >9 lesions 
Extracellular superoxide 
dismutase [Cu-Zn]  
SOD3 0.737 Scavenges radicals Higher in >9 lesions 
Neurocan core protein  NCAN 0.796 May  modulate neuronal 
adhesion and neurite 
growth during 
development 
No difference 
Neuronal growth regulator 1  NEGR1 0.832 Involved in cell adhesion. 
May function as trans-
neural growth-promoting 
factor in regenerative 
axon sprouting. 
 
Amyloid-like protein 1  APLP1 0.665 Involved in post-synaptic 
function, regulation of 
neurite outgrowth and 
synaptic maturation 
Lower in >9 lesions 
Cartilage acidic protein 1  CRTAC1 0.764 Unknown Lower in >9 lesions 
Contactin-2  CNTN2 0.825 Cell adhesion molecule. 
Contributes to the 
organization of axonal 
domains at nodes of 
ranvier by maintaining 
VGKC at the 
juxtaparanodal region.  
 
Contactin-1  CNTN1 0.756 Cell adhesion molecule. 
May be involved in 
formation of axon 
connections in the 
developing nervous 
system 
No difference 
Cadherin-2  CDH2 0.745 Calcium-dependent cell-
adhesion molecule. 
Neuronal recognition, 
regulation of dendritic 
spine density. 
No difference 
Neuronal cell adhesion molecule  NRCAM 0.829 Involved in neuron-
neuron adhesion. 
Promotes directional 
signaling during axonal 
cone growth 
Lower in >9 lesions 
Cell adhesion molecule 3  CADM3 0.749 Involved in cell-cell 
adhesion 
Lower in >9 lesions 
Cadherin-13  CDH13 0.910 May act as negative 
regulator of neural cell 
growth. Cell migration, 
phenotypic changes. 
Lower in >9 lesions 
Calsyntenin-1  CLSTN1 0.794 Regulates calcium 
concentration, 
intracellular transport  
Lower in >9 lesions 
Collagen alpha-1(I) chain  COL1A1 0.790 Component of collagen Higher in >9 lesions 
Pathway: Cell-to-cell signaling and interaction 
Ig kappa chain C region  IGKC 2.050 Antigen binding, immune 
response 
Higher in >9 
lesions 
Trans-Golgi network integral 
membrane protein 2  
TGOLN2 0.616 Involved in regulating 
membrane traffic to and 
from trans-Golgi network 
Lower in >9 lesions  
Calsyntenin-3  CLSTN3 0.631 May modulate calcium-
mediated postsynaptic 
signals 
Lower in >9 lesions 
CD59 glycoprotein  CD59 0.664 Inhibitor of complement 
action 
No difference 
Table 2. Differentially abundant proteins in CIS-patients and controls
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Protein Genetic 
name 
Fold 
change 
Function MRI 0 lesions vs. 
>9 lesions 
Pathway: Nervous system development and function 
Receptor-type tyrosine-protein 
phosphatase N2  
PTPRN2 0.579 Implicated in 
development of nervous 
system. Involved in lipid 
signaling, cell signaling 
and membrane trafficking 
Lower in >9 lesions 
Neurotrimin  NTM 0.723 Neural cell adhesion 
molecule. Mediates 
effects on neurite 
outgrowth 
No difference 
Neuroendocrine protein 7B2  SCG5 0.655 Chaperone for PCSK2/PC2, 
which is involved in 
maturation of 
neuroendocrine peptides 
Lower in >9 lesions 
Superoxide dismutase [Cu-Zn]  SOD1 0.905 Destroys radicals Lower in >9 lesions 
Neurosecretory protein VGF  VGF 0.710 Involved in regulation of 
cell-cell interactions and 
synaptogenesis during 
nervous system 
maturation. Antimicrobial. 
Lower in >9 lesions 
Major prion protein  PRNP 0.692 Involved in neuronal 
development and synaptic 
plasticity 
Lower in >9 lesions 
Metalloproteinase inhibitor 2  TIMP2 0.715 Metastasis suppressor, 
inhibits proliferation of 
endothelial cells. 
Important in tissue 
homeostasis 
Lower in >9 lesions 
Extracellular superoxide 
dismutase [Cu-Zn]  
SOD3 0.737 Scavenges radicals Higher in >9 lesions 
Neurocan core protein  NCAN 0.796 May  modulate neuronal 
adhesion and neurite 
growth during 
development 
No difference 
Neuronal growth regulator 1  NEGR1 0.832 Involved in cell adhesion. 
May function as trans-
neural growth-promoting 
factor in regenerative 
axon sprouting. 
 
Amyloid-like protein 1  APLP1 0.665 Involved in post-synaptic 
function, regulation of 
neurite outgrowth and 
synaptic maturation 
Lower in >9 lesions 
Cartilage acidic protein 1  CRTAC1 0.764 Unknown Lower in >9 lesions 
Contactin-2  CNTN2 0.825 Cell adhesion molecule. 
Contributes to the 
organization of axonal 
domains at nodes of 
ranvier by maintaining 
VGKC at the 
juxtaparanodal region.  
 
Contactin-1  CNTN1 0.756 Cell adhesion molecule. 
May be involved in 
formation of axon 
connections in the 
developing nervous 
system 
No difference 
Cadherin-2  CDH2 0.745 Calcium-dependent cell-
adhesion molecule. 
Neuronal recognition, 
regulation of dendritic 
spine density. 
No difference 
Neuronal cell adhesion molecule  NRCAM 0.829 Involved in neuron-
neuron adhesion. 
Promotes directional 
signaling during axonal 
cone growth 
Lower in >9 lesions 
Cell adhesion molecule 3  CADM3 0.749 Involved in cell-cell 
adhesion 
Lower in >9 lesions 
Cadherin-13  CDH13 0.910 May act as negative 
regulator of neural cell 
growth. Cell migration, 
phenotypic changes. 
Lower in >9 lesions 
Calsyntenin-1  CLSTN1 0.794 Regulates calcium 
concentration, 
intracellular transport  
Lower in >9 lesions 
Collagen alpha-1(I) chain  COL1A1 0.790 Component of collagen Higher in >9 lesions 
Pathway: Cell-to-cell signaling and interaction 
Ig kappa chain C region  IGKC 2.050 Antigen binding, immune 
response 
Higher in >9 
lesions 
Trans-Golgi network integral 
membrane protein 2  
TGOLN2 0.616 Involved in regulating 
membrane traffic to and 
from trans-Golgi network 
Lower in >9 lesions  
Calsyntenin-3  CLSTN3 0.631 May modulate calcium-
mediated postsynaptic 
signals 
Lower in >9 lesions 
CD59 glycoprotein  CD59 0.664 Inhibitor of complement 
action 
No difference 
Table 2. Differentially abundant proteins in CIS-patients and controls - continued
65
ch
ap
te
r 4
Decreased neuro-axonal proteins in CSF at first demyelinating event 
Transmembrane protein 132A  TMEM132A 0.581 Involved in embryonic and 
postnatal development of 
the brain, resistance to 
cell death 
No difference 
Seizure 6-like protein  SEZ6L 0.759 May contribute to 
specialized endoplasmic 
reticulum functions in 
neurons 
Lower in >9 lesions 
Tyrosine-protein phosphatase 
non-receptor type substrate 1  
SIRPA 0.739 Supports adhesion of 
cerebellar neurons, 
neurite outgrowth and 
glial cell attachment. 
Mediates phagocytosis, 
mast cell activation and 
dendritic cell activation. 
Lower in >9 lesions 
Proline-rich transmembrane 
protein 3  
PRRT3 0.780 Unknown No difference 
Pathway: Cell morphology, cell death and survival 
Ribonuclease pancreatic  RNASE1 0.670 Catalyzes RNA cleavage Lower in >9 lesions 
Extracellular matrix protein 1  ECM1 0.739 Stimulates proliferation of 
endothelial cells, 
promotes angiogenesis. 
May be involved in CNS 
repair 
Lower in >9 lesions 
Seizure 6-like protein 2  SEZ6L2 0.756 May contribute to 
specialized endoplasmic 
reticulum functions in 
neurons 
Lower in >9 lesions 
Testican-1  SPOCK1 0.708 Involved in cell-cell and 
cell-matrix interactions 
No difference 
Seizure protein 6 homolog  SEZ6 0.824 Involved in cell-cell 
recognition, neuronal 
membrane signaling, 
development of 
appropriate excitatory 
synaptic connectivity, 
dendrite outgrowth. 
Lower in >9 lesions 
Glucosidase 2 subunit beta  PRKCSH 0.700 Subunit of enzyme in 
endoplasmic reticulum 
No difference 
Pathway: Other 
VPS10 domain-containing 
receptor SorCS3  
SORCS3 0.580 Neuropeptide receptor 
activity 
Lower in >9 lesions 
Protocadherin Fat 2  FAT2 0.868 Involved in migration of 
epidermal cells, cerebellar 
development 
Higher in >9 lesions 
 Table 2. Differentially abundant proteins in CIS-patients and controls - continued
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of the duration, amount and severity of previous relapses[15]. Furthermore, MRI studies 
show that gray matter lesions and atrophy can already be observed in CIS patients[16, 17].
 
A remarkable finding of our study is, that all differentially abundant proteins between CIS 
patients and controls except immunoglobulin, were less abundant in CIS patients. This is 
of note, because if these gray matter proteins in CSF would simply result from leakage or 
release as a consequence of tissue injury caused by the disease process, one would expect 
them to be more abundant in CIS patients than in controls. The relatively stringent crite-
ria used here for the level of significance, the amount of molecules involved in the same 
physiological system, all different in the same direction (decreased) leaves little room for a 
false positive finding. Theoretically, the control group might have had disproportionally high 
levels of gray matter proteins for some reason. However, as the control group consisted of 
patients who did not have overt CNS disease, this seems unlikely. It should be acknowledged 
that the controls were not fully sex-matched. However, as no differences were observed 
between males and females it is highly unlikely that this has affected our results.
So, why are these molecules lower in patients already early after the first manifestation of 
the disease? Overall there are two possibilities: the lower abundance of proteins involved in 
the integrity of the CNS may either precede or even predispose for a first demyelinating at-
tack, or alternatively be the consequence of the attack and subsequent smoldering chronic 
disease process.
It will be impossible to study whether lower abundance of these proteins really precedes 
the first attack, but in this light it is tempting to hypothesize that a disturbed neuro-axonal 
physiology, reflected by a lower abundance of functionally relevant proteins, predisposes 
for a first demyelinating event. Such a phenomenon would fit at least partially an “inside-
out model” for MS pathogenesis. This would be consistent with reports from others who 
have described  a lower abundance of proteins in patients compared to controls, not only 
in demyelinating disease [11, 12, 14], but also in other more clearly neurodegenerative dis-
eases such as Alzheimer’s, Huntington’s and Parkinson’s disease[18, 19]. In a recent study 
by Mapstone et al.[20] in Alzheimer patients, a depletion of several proteins was found in 
the serum of patients in the very early stage of the disease. The authors hypothesized that 
this revealed the breakdown of neural cell membranes in those individuals destined to phe-
noconvert from cognitive intactness to Alzheimer’s disease. In a similar manner, in early MS 
it can be hypothesized that a dysfunction in CNS gray matter physiology can be observed as 
a depletion of proteins essential for normal development and function in the CSF in those 
destined to undergo a first demyelinating event. The fact that recently discovered new MS-
related genes also included several gray-matter related genes might add to the credibility of 
this hypothesis[21]. 
The alternative option for lower abundance of proteins at first attack may be that the dis-
ease process, which has already started, directly leads to lower levels. The inflammatory 
neuropathological process may have a dampening effect on the production of certain pro-
teins that are important in the physiologic maintenance of the CNS. This would rather fit 
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an “outside-in” model for the axonal and neuronal pathology of the disease. The active 
inflammatory process may also consume these proteins, for example by a higher rate of 
elimination of proteins from the CSF by macrophages. An argument in favor of this alterna-
tive explanation is the fact that most identified proteins were even lower in patients with 
the highest MRI T2 lesion load. Considering MRI T2 lesions as a measure for inflammation, 
the protein abundances seem to decrease with increasing inflammation.  
 
We did not find any markers that could discriminate between monophasic CIS and patients 
who convert to relapsing-remitting MS, not even when only the fast converters were taken 
into account. Some other studies did show differences between monophasic CIS and RRMS-
CIS patients [12, 22, 23], although differences between CIS and healthy controls seem to be 
more pronounced than between RRMS and CIS patients [12]. Which factors determine if a 
patient remains monophasic or goes on to develop MS remains to be elucidated.
In conclusion, we found no difference in protein abundance relating to disease progression, 
but we did observe a remarkably lower abundance of neuro-axonal proteins in patients with 
a first demyelinating event. It remains to be determined whether this is a reflection of an MS 
predisposing gray matter disturbance, or rather a result of disease pathology itself. 
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Abstract
Background
Clinically isolated syndrome (CIS) is often the first manifestation of multiple sclerosis (MS). 
However, not all patients with CIS will go on to develop multiple sclerosis (MS). 
Objective
To develop a simple and reliable prediction model for MS in patients with CIS.
Methods
CIS patients were included with age 18-50 years, inclusion within 6 months after symptom 
onset and no serious comorbidity. Clinical, demographic, MRI, serum and CSF parameters 
were collected at baseline. The outcome measure was clinically definite MS (CDMS) as de-
fined by Poser and colleagues. A multivariable Cox regression model was created after uni-
variate screening of candidate predictors. A simple scoring system was then constructed 
giving equal weight to all predictors. Model performance was quantified according to the c 
statistic indicating discriminative ability, with internal validation using bootstrapping tech-
niques.
Results
Of 431 patients in the analysis, 109 fulfilled the criteria for CDMS within 2 years. The follow-
ing 5 variables were found to be the main predictors of CDMS: DIS+DIT2010 (the baseline 
scan fulfills criteria for dissemination in time and place according to the 2010 revised Mc-
Donald criteria), corpus callosum lesion, cerebrospinal fluid oligoclonal bands, fatigue and 
abnormal MRI. The final model had a reasonable discriminative ability with a c statistic of 
0.71. Three risk groups were created: low risk (0-1 risk factor present), intermediate risk (2-3 
risk factors) and high risk (4-5 risk factors). The 5-year risk for CDMS in the low-risk group 
was 19% versus 56% in the intermediate-risk group and 93% in the high-risk group. 
Discussion
With the proposed clinical prediction model, 3 risk groups can be distinguished, with 5-year 
risks for clinically definite MS ranging from less than 20% in the low-risk group to more than 
90% in the high-risk group. If further validated, the proposed simple tool can assist to inform 
CIS patients and to support decision making regarding the early start of immunomodulatory 
treatment. 
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Introduction
Clinically isolated syndrome (CIS) is a subacute manifestation of symptoms that is often the 
first manifestation of multiple sclerosis (MS). However, not all patients with CIS will go on to 
develop MS: after 20 years, about 63% will have experienced a second attack, defining clini-
cally definite MS (CDMS)[1]. The uncertainty about whether or not a CIS patient will develop 
MS is problematic both for the wellbeing of the patient[2, 3] and for the possibility to start 
immunomodulatory medication early in the course of the disease[4]. Therefore, worldwide 
efforts are being made to find predictors for the course of the disease after CIS.
One major achievement is the publication of the 2010 revisions to the McDonald criteria for 
the diagnosis of MS.[5] With these revised criteria, the diagnosis of MS can already be made 
after one attack (CIS) in a subgroup of patients with specific abnormalities on the MRI scan. 
However, this subgroup includes only a minority of CIS patients[6], leaving most patients 
still in the dark. 
For this reason, we set out to make a reliable prediction model for MS in patients with CIS, 
aiming to make it simple and clinically useful by using parameters that are readily available. 
Methods
Patients
In the Rotterdam MS Center, patients with CIS suggestive of multiple sclerosis were included 
who fulfilled the following inclusion criteria: age between 18 and 50 years, inclusion within 
6 months after symptom onset and no serious comorbidity. At baseline, clinical and demo-
graphic data were collected, an MRI scan was performed, a blood sample was taken and 
fatigue was assessed. All patients were clinically assessed at baseline and thereafter seen 
regularly for reassessment. Patients were instructed to contact the clinic in case of a sus-
pected exacerbation. Patients with alternative diagnoses were excluded from the analyses. 
The Ethics Committee of the Erasmus MC University Hospital approved the ‘PROUD’ (Pre-
dicting the OUtcome of a Demyelinating event) study protocol. 
Candidate predictors
Candidate predictors were chosen a priori based on existing literature and clinical expertise. 
Age, sex, localization of first symptoms, fatigue and presence of first or second degree rela-
tives with MS were the clinical parameters selected. For simplicity and because optic neu-
ritis appeared to be the localization with the highest discriminating ability, this localization 
was chosen in the model (optic neuritis yes/no) instead of localization (optic nerve/spinal 
cord/ brainstem/ other). Fatigue was assessed using the Krupp’s Fatigue Severity Scale (FSS)
[7]. This is a self-administered questionnaire that is widely used and has been validated for 
use in patients with MS [7-9]. It has nine items and seven possible responses per item, rang-
ing from 1 (strong disagreement) to 7 (strong agreement). The mean value of the nine items 
is the final score. Fatigue was defined as an FSS score of ≥ 5.0[10]; this variable was used in 
the model after examination of the continuous FSS variable showed that such dichotomiza-
tion did not cause much loss of the discriminative ability. 
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The following MRI parameters were considered: abnormal MRI (defined as 1 or more le-
sions), number of T2 lesions (with the following groups: 0 lesions, 1-9 lesions, >9 lesions), 
gadolinium enhancement, presence of a lesion in the corpus callosum, modified Bark-
hof criteria (defined as at least 3 of 4 criteria fulfilled[11, 12]), Swanton criteria[13], and 
DIS+DIT2010 (defined as: the baseline scan fulfills criteria for dissemination in time and 
place according to the 2010 revised McDonald criteria[5]). In the cerebrospinal fluid (CSF), 
the IgG index and the presence of oligoclonal bands were assessed. A serum sample was 
taken at baseline for the measurement of 25-OH-vitamin D. 
Outcome measure
The outcome measure in the analyses was clinically definite MS (CDMS). This was diagnosed 
in case of clinical evidence for dissemination in space and time as described by Poser and 
colleagues[14]. 
Statistical analyses
Time to CDMS was calculated from start of first symptoms. Patients without CDMS were 
considered as censored observations. The 2- and 5-year cumulative incidence of CDMS 
were estimated using Kaplan-Meier curves. Missing values were imputed using a multiple 
imputation method, which is a sophisticated method to preserve data and reduce bias in 
case of missing data[15]. Cox proportional hazard regression analysis was used to calculate 
univariate and multivariable hazard ratios. A multivariable model was created including all 
predictors with univariate p-values <0.2. This multivariable model was then further simpli-
fied using stepwise backward selection. Non-linearity of continuous variables was checked 
using restricted cubic splines. A scoring system was constructed based on the regression 
coefficients of the multivariable model. To further facilitate clinical application, a scoring 
system was developed in which predictors with similar regression coefficients were given 
equal weight. The discriminative ability of the model was quantified with the c statistic. 
The c statistic is similar to the area under the curve of a receiver-operating characteristic 
curve for logistic regression models and can range from 0.5 to 1.0 for sensible models. The 
internal validity of the model was assessed by bootstrapping techniques. To determine how 
over-optimistic the model was, the discriminative ability of the model was determined on 
the bootstrap samples and on the full model. Statistical analyses were performed using SPSS 
21.0 for Windows and R statistical software.
Results
Among 497 CIS patients consecutively included, 2 patients were found to have had previous 
symptoms (e.g., no CIS), 52 were lost to follow up and 12 patients were excluded because of 
alternative diagnoses (3 neuromyelitis optica, 2 sarcoidosis, 2 chronic relapsing inflamma-
tory optic neuropathy, 5 other). This left 431 patients for the analysis. Of these patients, 109 
patients met the criteria for CDMS within 2 years of follow up. Univariate hazard ratios and 
2- and 5-year risk of CDMS for the variables are shown in table 1. 
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Variable  n Even
ts 
2-year risk of MS 
(95% CI) 
5-year risk of MS 
(95% CI) 
Hazard ratio 
(95% CI) 
Age <30 
30-40 
>40 
164 
156 
111 
69 
63 
44 
30.7% (23.1-38.3) 
27.4% (20.0-34.8) 
26.9% (17.9-35.9) 
51.4% (40.8-62.0) 
51.1% (40.3-61.9) 
63.1% (49.4-76.8) 
1 (ref) 
1.0 (0.7-1.4) 
0.9 (0.7-1.3 
Sex Male 
Female 
117 
314 
42 
134 
25.5% (16.9-34.1) 
29.6% (24.1-35.1) 
50.0% (36.7-63.3) 
55.7% (48.1-63.3) 
1 (ref) 
1.1 (0.8-1.6) 
Optic neuritis 
 
Yes 
No 
178 
252 
62 
113 
21.2% (14.7-27.7) 
33.1% (26.8-39.4) 
43.3% (33.5-53.1) 
63.0% (54.0-72.0) 
1 (ref) 
1.6 (1.2-2.2) 
First or second 
degree relatives 
with MS 
No 
Yes 
187 
26 
75 
6 
29.2% (22.1-36.3) 
22.6 (5.2-40.0) 
61.9% (50.7-73.1) 
31.2 (8.9-53.5) 
1 (ref) 
0.5 (0.2-1.2) 
Nr of T2 lesions 0 
1-9 
>9 
54 
186 
154 
6 
63 
92 
6.1% (0.0-12.8) 
23.4% (16.7-30.1) 
39.4% (31.4-47.4) 
13.1% (1.7-24.5) 
49.5% (38.7-60.3) 
70.1% (60.7-79.5) 
1 (ref) 
4.2 (1.8-9.6) 
7.4 (3.2-16.9) 
Abnormal MRI No 
Yes 
54 
340 
5 
155 
6.1% (0.0-12.8) 
31.1% (25.8-36.4) 
13.1% (1.7-24.5) 
60.1% (52.7-67.5) 
1 (ref) 
5.6 (2.5-12.7) 
Gadolinium 
enhancement 
No  
Yes 
186 
65 
54 
42 
20.2% (13.9-26.5) 
50.4% (37.5-63.3) 
41.9% (31.1-52.7) 
84.3% (70.6-98.0) 
1 (ref) 
3.5 (2.3-5.2) 
DIS+DIT2010 No 
Yes 
352 
51 
128 
36 
23.5% (18.8-28.2) 
54.4% (39.7-69.1) 
48.6% (41.2-56.0) 
94.9% (85.5-104.3) 
1 (ref) 
3.6 (2.4-5.2) 
Corpus 
callosum lesion 
No 
Yes 
239 
167 
68 
98 
16.7% (11.6-21.8) 
42.3% (34.5-50.1) 
40.4% (31.4-49.4) 
73.4% (63.8-83.0) 
1 (ref) 
2.8 (2.0-3.8) 
3 of 4 Barkhof 
criteria 
No 
Yes 
253 
151 
73 
92 
18.9% (13.8-24.0) 
41.6% (33.2-50.0) 
39.7% (31.1-48.3) 
75.5% (66.3-84.7) 
1 (ref) 
2.5 (1.9-3.5) 
Swanton 
criteria 
No 
Yes 
167 
219 
39 
119 
15.0% (9.1-20.9) 
36.9% (30.2-43.6) 
31.6% (21.6-41.6) 
68.9% (60.3-77.5) 
1 (ref) 
3.0 (2.1-4.3) 
CSF oligoclonal 
bands  
No 
Yes 
107 
167 
33 
86 
18.2% 10.4-26.0) 
33.9% (26.3-41.5) 
38.9% (26.7-51.1) 
67.4% (57.4-77.4) 
1 (ref) 
2.4 (1.6-3.6) 
IgG index <0.7 
>0.7 
115 
146 
36 
80 
18.1% (10.7-25.5) 
34.2% (26.0-42.4) 
45.1% (32.0-58.2) 
63.8%  (54.0-73.6) 
1 (ref) 
2.0 (1.4-3.0)  
25-OH-vitamin 
D 
<50 
>50 
37 
90 
19 
35 
28.1% (13.2-43.0) 
24.0% (15.0-33.0) 
58.5% (39.9-77.1) 
54.1% (38.8-69.4) 
1.3 (0.8-2.3) 
1 (ref) 
Fatigue No 
Yes 
85 
62 
28 
36 
17.3% (9.1-25.5) 
40.6% (28.1-53.1) 
47.4% (32.3-62.5) 
79.8% (60.6-99.0) 
1 (ref) 
2.5 (1.5-4.1)  
 Table 1. Potential predictors for CDMS risk among 431 CIS patients.
The following variables had strong univariable effects: age, optic neuritis, number of T2 
lesions, abnormal MRI, gadolinium enhancement, DIS+DIT2010, corpus callosum lesion, 
Barkhof criteria, Swanton criteria, oligoclonal bands, IgG index and fatigue. We found no 
evidence for non-linearity of the continuous variable (IgG index) in this model. After further 
simplification, the multivariable model contained 5 predictors: DIS+DIT2010, corpus callo-
sum lesion, oligoclonal bands, abnormal MRI and fatigue (table 2). Using a simple scoring 
system with equal weight for all predictors in the multivariable model resulted in similar 
predictive performance compared to a  more detailed scoring system. The observed c statis-
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Risk variables Hazard ratios (95% CI) Score 
DIS+DIT2010 2.2 (1.4-3.3) 1 
Corpus callosum lesion 1.9 (1.2-2.9) 1 
Oligoclonal bands 1.7 (1.1-2.6 1 
Fatigue 2.3 (1.4-3.9) 1 
Abnormal MRI 2.3 (0.9-6.0) 1 
CDMS risk score  0-5 
 
tic for the final model was 0.72, indicating reasonable discriminative ability. After correction 
for over-optimism this was reduced to 0.71, indicating limited over-optimism. 
With this simple scoring system, 3 groups were created: a low, intermediate and high risk 
group (table 3). The 5-year risk for CDMS in the low-risk group was 19% versus 56% in the 
intermediate-risk group and 93% in the high-risk group (figure 1). The c-statistic for the sim-
ple model with 3 groups was 0.66.
Table 2. Hazard ratios and scores for the final prediction model. DIS+DIT2010= the baseline scan fulfills criteria for 
dissemination in time and place according to the 2010 revised McDonald criteria[5]
Table 3. Risk of clinically definite MS for three risk groups at 2 and 5 years after CIS.
Discussion
The uncertainty of whether or not a patient will develop MS after a first demyelinating event 
is problematic for patient wellbeing and hinders early treatment. We propose a simple clini-
cal prediction model for clinically definite MS to be used in patients with CIS, based on 5 
readily available clinical parameters: 1. abnormal MRI, 2. DIS+DIT2010 (the baseline scan 
fulfills the criteria for dissemination in space and time according to the 2010 revised Mc-
Donald criteria), 3. corpus callosum lesion, 4. CSF oligoclonal bands, and 5. fatigue. With the 
model, 3 risk groups can be distinguished, with 5-year risks for clinically definite MS ranging 
from less than 20% in the low-risk group to more than 90% in the high-risk group.
The identified variables were combined by means of a simple scoring system, giving equal 
weight to all parameters. In comparison with a scoring system based on the regression coef-
ficients, this simpler scoring performed equally well. To facilitate clinical use, we advocate 
the use of this simpler scoring system, possibly further simplified in 3 prognostic groups.
 
Number of risk factors present 
DIS+DIT2010, corpus callosum lesion, oligoclonal 
bands, fatigue or abnormal MRI 
Risk category 2-year risk of MS 5-year risk of MS 
0 or 1  Low 6.1% (1.0-11.2) 19.4% (8.0-30.8) 
2 or 3  Intermediate 27.8% (21.7-33.9) 56.0% (47.2-64.8) 
4 or 5  High 56.5% (45.7-68.5) 92.5 (82.7-100) 
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Figure 1. Cumulative incidence of CDMS for the three risk groups.
Another notable predictor is the abnormal MRI. Of course, the fact that an abnormal MRI 
was predictive for CDMS in CIS patients has been known for long [1, 17]. However, it is re-
markable that an abnormal MRI adds to the risk of MS, even in addition to a lesion in the 
corpus callosum or the fulfilling of DIS+DIT2010 criteria, where the patient has an abnormal 
MRI per definition. Apparently, this parameter contributes to separate the high and low risk 
groups even further.
A relatively new predictor is fatigue, as defined by an FSS score of ≥5. Fatigue is a well-
known feature of MS, but has not been extensively studied in patients with CIS. However, 
we recently investigated fatigue in CIS patients and found that fatigue was quite common 
and relatively severe, and that it was predictive of CDMS[18]. It was therefore decided to 
include fatigue as a parameter in this prognostic model. The fact that fatigue is a relatively 
strong and independent predictor even in a model including all well-known MS parameters 
suggests that it is related to intrinsic disease activity rather than a result of damage[18]. It 
also asks for more attention for this problem already at the very early stage of the disease. 
The FSS is a validated questionnaire that is available in many languages and can easily be 
filled out at the outpatient clinic. 
Of the MRI parameters, a lesion in the corpus callosum is less frequently mentioned in the 
MS literature than number of T2 lesions, Barkhof criteria, Swanton criteria, gadolinium en-
hancement and DIS+DIT2010 , and it is interesting that among all other parameters, this 
less-frequently used parameter was most relevant. However, as the Barkhof criteria, Swan-
ton criteria and DIS+DIT2010 criteria all consider the same lesion locations (i.e. periventricu-
lar, juxtacortical, infratentorial and spinal cord) they might be expected to cancel each other 
out, and the predictive value of the callosal lesion independent of Barkhof criteria has been 
described before[11, 16]. 
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In our model, oligoclonal bands were a significant predictor in addition to DIS+DIT2010 cri-
teria. In the 2010 revised McDonald criteria, oligoclonal bands can no longer be used to re-
duce the MRI requirements for the diagnosis of MS, because the contribution of CSF status 
to the newest MRI criteria for DIS and DIT was never evaluated. Our results suggest that 
oligoclonal bands do in fact add predictive value when used in addition to these criteria, 
and may provide a reason to perform  a lumbar puncture in CIS patients, not only to rule 
out other disease from the differential diagnosis, but also to predict the risk for CDMS[19]. 
A variable that had little predictive value was 25-OH-vitamin D. Two studies have investi-
gated the predictive value of 25-OH-D in CIS patients before[20, 21]. The first one, in 465 pa-
tients[20], found significantly increased risks for new lesions and increased lesion volumes 
on MRI for patients with low 25-OH-vitamin D levels, but only a borderline increased risk for 
CDMS. The second study found increased risk only in women with very low 25-OH-vitamin D 
levels. In our study, the contribution of 25-OH-vitamin D to the model was very modest[21]. 
This does not exclude the possibility of a predictive value for vitamin D in CIS patients, but 
its effects are moderate compared to other more powerful predictors. 
We chose not to include other known predictors for MS such as HLA and EBV antibody titers, 
because these are not easily and routinely available in all patients presenting with CIS, and 
would therefore make the prediction model less useful in clinical practice.  
There are several limitations to our study. First, data were not fully complete in all individu-
als, especially on the 25-OH-D measurements and family history. Furthermore, we did not 
have the possibility to validate our results in an external cohort of patients yet, which is a 
necessary step before introducing the model in clinical practice. Internal validation revealed 
a relatively good discriminative ability.  We started building this model with well-known pre-
dictors for MS in CIS patients, obtained after years of international investigations. Therefore 
it seems unlikely to find additional predictors amongst the currently available parameters 
that would add substantially to the discriminative ability of the currently proposed model. 
This is the first clinical prediction model for CDMS in patients with CIS, distinguishing a low, 
intermediate and high-risk group based on widely available clinical parameters. MS and its 
disease course are very heterogeneous, and this model is far from perfect in separating 
those who will and will not develop MS. Nevertheless, if further validated, this model can be 
a practical tool to inform and provide support to CIS patients and support decision-making 
regarding the early start of immunomodulatory treatment. 
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Abstract
Objective 
There is increasing evidence that vitamin D can be protective against the development of 
multiple sclerosis (MS), but it may also be beneficial for the clinical course of the disease. 
Our objective was to prospectively investigate if 25-hydroxy-vitamin D (25-OH-D) levels are 
associated with exacerbation risk in MS in a study with frequent serum measurements.
Methods
This was a prospective longitudinal study in 73 patients with relapsing-remitting MS. Blood 
samples for 25-OH-D measurements were taken every 8 weeks. Associations between 25-
OH-D levels and exacerbation rates were assessed using Poisson regression (generalized 
estimating equations) with the individual serum levels as time-dependent variable. 
Results 
During follow-up (mean 1.7 years), 58 patients experienced a total of 139 exacerbations. 
Monthly moving averages of 25-OH-D levels were categorized into low (<50 nmol/L), medi-
um (50–100 nmol/L), and high (>100 nmol/L) levels. Exacerbation risk decreased significant-
ly with higher serum vitamin D levels: respective relative exacerbation rates for the medium 
and high level category as compared to the low-level category were 0.7 and 0.5 (p value for 
trend: p=0.007). The association between 25-OH-D concentrations and exacerbation rate 
was log linear without a threshold. With each doubling of the serum 25-OH-D concentration 
the exacerbation rate decreased by 27% (95% confidence interval 8%–42%, p=0.008).
Conclusions 
Our finding that higher vitamin D levels are associated with decreased exacerbation risk in 
relapsing-remitting MS suggests a beneficial effect of vitamin D on disease course in MS. 
However, the possibility of reverse causality cannot be ruled out completely. Randomized 
intervention studies are therefore needed to investigate the effect of vitamin D supplemen-
tation in MS.
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Introduction
Multiple sclerosis (MS) is a chronic disease of the CNS that starts in most patients with a 
relapsing-remitting disease course. The etiology of MS is multifactorial. Both genetic suscep-
tibility and environmental exposure contribute to the pathogenesis[1]. One of the environ-
mental factors associated with the development of MS is vitamin D[2].
Vitamin D is a group of fat-soluble prehormones, related to steroid hormones. It can be 
absorbed from food, but in the human body the main source for vitamin D is the produc-
tion in the skin under influence of UVB light. Although the active metabolite of vitamin D is 
1,25-dihydroxy-vitamin D (1,25-diOH-D), or calcitriol [3], the metabolite best reflecting the 
vitamin D status of the patient is 25-hydroxy-vitamin D (25-OH-D), or calcidiol[4].
A protective effect of vitamin D on the onset of MS is supported by many studies in epide-
miology as well as in basic and clinical science[5–10] but recent evidence suggests that vi-
tamin D might also influence the clinical course of the disease. Several studies report lower 
serum 25-OH-D concentrations during exacerbations then during remission[11–13]. So far, 
only one prospective study was conducted to investigate the association between serum 
25-OH-D concentrations and exacerbation rate[14]. In that study, higher serum 25-OH-D 
concentrations were found to be associated with a lower hazard for exacerbation. However, 
calculations were based on only 2 measurements of serum 25-OH-D concentrations per 
person per year. Because serum 25-OH-D concentrations are known to be fluctuating with 
season, more frequent sampling would allow for a more accurate estimation of vitamin D 
levels. The aim of this study is therefore to investigate the association between serum 25-
OH-D concentrations and disease course in relapsing-remitting MS prospectively with serum 
measurements every 8 weeks.
Methods
Standard protocol approvals, registrations, and patient consents
Data and samples were collected in the Rotterdam Study on Exacerbations in Multiple Scle-
rosis, a longitudinal prospective study in patients with relapsing-remitting MS[15]. Patients 
were included sequentially during an inclusion period of 1.7 years in 1997–1999. Serum 
25-OH-D measurements were performed in 2010. At the time of recruitment and data col-
lection, written informed consent was obtained from all patients. The Medical Ethical Com-
mittee of the Erasmus MC approved the study protocol. 
Patients
Patients aged 18–55 years could be included in the study if they had clinically definite MS 
with a relapsing remitting disease course. Patients were excluded from participation if they 
suffered from other serious diseases. 
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Definitions
All patients fulfilled the McDonald criteria for the diagnosis of MS[16]. Exacerbation was 
defined as a worsening of existing symptoms or the appearance of new symptoms lasting 
for more than 24 hours, after a period of more than 30 days of improvement or stability, 
confirmed by neurologic examination[17]. A temporary neurologic deterioration associated 
with fever was not considered as an exacerbation. 
Because infection is a known risk factor for exacerbations in MS, the at-risk period around 
infection was used as a covariate in this study[15]. Infection was defined as the appearance 
of coryza, sore throat, flu-like feeling, myalgia, fever, diarrhea, or a urinary infection lasting 
>24 hours. The at-risk period for infection was defined as the period of 2 weeks before until 
5 weeks after the onset of a clinical infection, as described previously[18].
Visits, samples, and measurement of exacerbations
All patients visited the outpatient clinic of the Erasmus Medical Centre University Hospital 
regularly every 8 weeks. On every visit, samples for 25-OH-D measurements were taken 
and disability was measured using the Kurtzke Expanded Disability Status Scale (EDSS)[19]. 
Furthermore, patients were instructed to contact the study center when they experienced 
symptoms of infection or neurologic impairment. In case of a suspected infection or exac-
erbation, an additional visit to the outpatient clinic was arranged within 3 days, to confirm 
the infection or exacerbation. Serum samples were stored at -80°C until serum 25-OH-D 
measurement, performed in 2010. 
Measurement of 25-OH-vitamin D
Concentrations of 25-OH-D have been determined by a RIA method (DiaSorin, USA) using 
an extraction method. The interassay variation coefficient at a concentration of 62 and 109 
nmol/L is 11.6% and 10.3%, respectively. The intra-assay variation coefficient at the levels is 
5.7% and 6.6%, respectively. Only serum samples taken at the regular 8-weekly visits were 
used for 25-OH-D measurements; samples taken during exacerbation visits were not evalu-
ated. 
Statistical analysis 
Graphical display of individual serum 25-OH-D concentrations vs calendar time indicated a 
sinusoidal pattern. Therefore a sinusoidal model was used to describe the 25-OH-D concen-
trations along calendar time:
Log10(concentration) = a + b sin(2π[t + c].
In this formula the parameter a represents the mean logarithmically transformed concen-
tration, b represents the amplitude, c denotes the phase of the sinusoidal curve, and t rep-
resents the day of the year the blood sample was taken. Concentrations were transformed 
logarithmically in order to get approximately normal distributions.
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Nonlinear regression was used to estimate the parameters in the regression model and the 
parameters a and b were allowed to differ from patient to patient, i.e., individual’s levels 
and amplitudes were taken as random effects in the regression model. SAS software (PROC 
NLMIXED; SAS Institute Inc., Cary, NC) was used in the calculations.
To assess the association between individual serum 25-OH-D concentrations and the inci-
dence rate of exacerbations, the follow-up time for each patient, which covered a maximum 
period of 2.3 years, was split into intervals of 1 week each. For each of these intervals the 
number of exacerbations was determined. The individual exacerbation rate was assumed to 
depend on the geometric mean serum 25-OH-D concentration during the previous 4 weeks. 
To obtain the latter mean level, for each individual the 4-weekly levels between measure-
ments were determined using interpolated values. In case a planned sample was missing for 
a patient, and his last as well as the next observation occurred more than 4 weeks earlier, 
respectively later, than the date at which patients were estimated to have their maximal or 
minimal value in view of the sinusoidal pattern, this interpolation was not done and interpo-
lated values were set missing. This was done to avoid weekly estimates of the concentration 
that were likely to be either too low or too high in view of the sinusoidal pattern. During the 
period of 4 weeks following an exacerbation, the individual was not considered at risk for 
another exacerbation. A priori it was decided to categorize the geometric mean serum lev-
els of the 4 preceding weeks into a low level (<50 nmol/L), a medium level (50–100 nmol/L), 
and a high level (>100 nmol/L). The relationship between serum 25-OH-D concentrations 
and the incidence rate of exacerbations was assessed using Poisson regression models with 
the geometric mean individual serum levels as a time-dependent variable. Generalized esti-
mating equations with an exchangeable covariance matrix for the subsequent study weeks 
were used in the calculations (SAS PROC GENMOD). The effect of other factors including 
gender, age, EDSS, number of exacerbations before study entry, and use of interferon-during 
the study was also estimated using a multivariable generalized linear model with a log-link 
function. To evaluate whether the occurrence of exacerbations after entry into study af-
fected the dropout rate, Cox regression was used with the cumulative number of exacerba-
tions as a time dependent variable. P=0.05 (2-Sided) was considered the limit of significance 
in all analyses.
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Results
Patient characteristics
A total of 73 patients were included in this study. Mean follow-up time of all patients was 1.7 
years (range 0.4 –2.3). Nine patients had dropped out of the study before intended comple-
tion date (1 patient because of participation in another study; for the 8 other patients no 
reason was known). All patients were Dutch Caucasians; baseline characteristics of included 
patients are shown in table 1. In addition to the 13 patients who used interferon- β at study 
entry, 15 patients started to use interferon-β during follow-up; 28 patients used interferon- 
β at some point during on average 56 weeks. Vitamin supplements were not widely used 
among the patients: 5 patients used vitamin B complex and 2 used multivitamin pills not 
containing vitamin D. One patient took calcium supplements; it was unknown if those con-
tained vitamin D. 
 
* EDSS is a method for quantifying disability in MS, ranging from 0.0 (normal neurological exam) to 10.0 (death 
due to MS)
Table 1. Characteristics of patients at baseline.  
A total of 58 patients experienced a total of 139 exacerbations during this study. Median 
time from inclusion to first exacerbation was 20 weeks. Thirty-three patients had more than 
1 exacerbation; the average exacerbation rate was 1.2 per year (range 0–6.2 per year). Three 
patients experienced a sixth exacerbation during follow-up.
Serum 25-OH-D concentrations
Serum 25-OH-D concentrations showed a seasonal sinusoidal fluctuation (figure 1). Serum 
concentrations were high in summer and low in winter, with peak levels in mid-August and 
nadirs in mid-February. The fitted sinusoidal curve resulted in a geometric mean 25-OH-D 
concentration of 69 nmol/L. There was a considerable variation in mean levels between 
patients (coefficient of variation 41%). 
Association between serum 25-OH-D concentrations and exacerbation risk
Exacerbation rates were found to decrease with increasing levels of serum 25-OH-D con-
Variable (n=73) Mean (range)  Std. Deviation 
Age, years 39.4 (19-55) 9.1 
Disease duration, years 5.2 (0-25) 4.1 
Disability (EDSS) * 2.5 (0-6.0) 1.6 
Exacerbations in previous 2 
years 
2.2 (1-8)  
 
1.3 
Variable (n=73) Proportion (%)  
Gender, F/M  77% / 23%  
IFN use, N/Y  82% / 18%  
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centrations (figure 2A). For the low (<50 nmol/L), medium (50 –100 nmol/L), and high (>100 
nmol/L) category the monthly exacerbation rates were 0.15 (95% confidence interval [CI] 
0.12– 0.20), 0.10 (95% CI 0.08–0.14), and 0.07 (95% CI 0.05– 0.12), respectively. The risk 
of an exacerbation was significantly increased in the group with low serum 25-OH-D con-
centrations (<50 nmol/L) compared to the group with high serum concentrations (>100 
nmol/L). Rate ratios for the low and medium group were 2.0 and 1.4, respectively (p for 
trend = 0.007). 
 
Figure 1. 25-OH-D concentrations per patient versus date of blood sampling. Data of individual patients are con-
nected by straight lines. The dotted curve represents the overall fitted sinusoidal curve. Estimates (+/- standard 
error) of the parameters of the model Log10(concentration) = a + b sin(2π(t+c)) are a=1.837 +/- 0.022, b=0.125 
+/- 0.009 and c=-0.367 +/- 0.006.
In univariate analysis it was also found that infections were associated with the risk of an ex-
acerbation. The exacerbation rate within an at-risk period was 2.1-fold increased (95% CI 1.6 
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–2.8, p < 0.001, figure 2B). Simultaneous evaluation of categories of levels of serum 25-OH-
vitamin and infections showed that both factors were related to the exacerbation rate (table 
2). Also the effect of one factor did not depend on the other (interaction: p = 0.18). 
Other characteristics (gender, age, EDSS, use of interferon- β, and number of exacerbations 
in the 2-year period before entry into the study) were not significantly associated with the 
exacerbation rates. This applied in univariate (all p > 0.18) as well as multivariable analysis 
(all p > 0.17). In particular, the effect of vitamin D on exacerbations was not modified by 
interferon use (p = 0.78 for the interaction effect).
Figure 2. (A) Monthly exacerbation rates for the different groups of serum 25-OH-D concentrations, and (B) for at 
risk period for infections. Error bars denote 95% confidence intervals. Serum 25-OH-D concentrations: p (trend) = 
0.007; infections p<0.001.
No significant differences among the 4 seasons were found regarding exacerbation rates, in 
univariate, or in multivariate analysis. Analyzing logarithmically transformed serum 25-OH-D 
concentrations on a continuous scale showed that a doubling of serum 25-OH-D concentra-
tions caused a decrease of the exacerbation rate by 27% (95% CI 8%–42%, p = 0.008) (ad-
justed for the effect of infections). Adding quadratic and cubic terms of the linear predictor, 
i.e., log(serum concentration), did not significantly improve the fit of the model, indicating 
A B
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the linearity of the association and the absence of a threshold.
Analyzing the 9 dropouts it was found that the dropout rate did not significantly correlate 
with the cumulative number of exacerbations during the study (Cox regression: p =0.29), 
  Relative 
exacerbation rate 
95% Confidence 
Interval 
P-value 
ARP infection Yes 2.3 1.7 – 3.1 <0.001 
 No 1 (reference) -  
Vit D level Low 
<50nmol/l  
1.9 1.1 – 3.2 0.013 # 
 Medium  
50-100 nmol/l 
1.4  0.8 – 2.2 0.235 # 
 High  
>100 nmol/l 
1 (reference) -  
 
nor with any baseline characteristic. 
# p-value for trend: 0.012
Table 2. Association between exacerbation rate and serum 25-OH-D concentrations and infection according to 
multivariable analysis.
Discussion
In the present study we show that lower 25-OH-D levels are significantly associated with 
a higher exacerbation risk in patients with relapsing-remitting MS. In the category of low 
25-OH-D levels, the risk for an exacerbation was 2 times higher than in the category of high 
levels. This association was log linear without a threshold effect; a doubling of serum 25-OH-
D concentrations lowered the exacerbation risk by 27%. Adjustment for potential confound-
ers, including infection, gender, disability (EDSS), and use of immunomodulatory therapy, 
did not alter this association. In particular, although in experimental autoimmune encepha-
lomyelitis the effect of vitamin D is found to be stronger in female mice[10], we did not find 
an influence of gender on the association between 25-OH-D and exacerbations in this study.
The key strength of this study is the frequent measurement of serum 25-OH-D concentra-
tions. So far, only one prospective study has been performed to investigate the association 
between serum 25-OH-D concentrations and disease course in patients with relapsing-re-
mitting MS with more than 1 serum measurement[14]. In that study, a significant associa-
tion between 25-OH-D levels and exacerbation risk was found, but this was based on only 
2 serum measurements per patient per year. It is well known that vitamin D levels fluctuate 
with season. Also, there is great interindividual variation of the mean vitamin D level and 
the amplitude of the seasonal fluctuation (also shown in our data). This makes extrapolating 
data from only 1 or 2 measurements per year using sinusoidal models very imprecise. With 
the present study, the suggested association between 25-OH-D levels and exacerbation risk 
can now be confirmed with much more accurate data on vitamin D levels. Furthermore, we 
included infection as a confounder and provide more frequently measured information on 
disability. 
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An additional strength of this study is the infrequent use of interferon-β among the patients. 
This allowed us to study the sole effect of vitamin D. Although some studies suggest an 
additional beneficial effect of vitamin D in interferon-β users[20,21], we did not find an ad-
ditional effect of interferon-β treatment in this study. The fact that the association between 
vitamin D and exacerbation risk held in patients who used interferon-β might suggest that 
the effect of vitamin D is additive to the effect of interferon-β. However, this study was not 
set up to measure such an additive effect. 
Our study was limited by the lack of information on the amount of sunshine the patients had 
during this study. We do not expect sun exposure and subsequent cutaneous vitamin D pro-
duction to differ much among patients, as all patients were Caucasians from the Rotterdam 
region, but sun exposure is a potential confounder that we could not adjust for. 
Although we found a strong seasonal fluctuation of vitamin D levels, the association be-
tween clinical disease activity and season was not significant in this study. Several other 
studies describe seasonality of MS disease activity, mostly with higher activity in spring. 
What we show here is an association between vitamin D and exacerbation risk that per-
sists through all seasons. In this respect it should be noted that vitamin D and some other 
UV-mediated immune processes can act separately on the immune system, as recently de-
scribed[22,23].
In studies on vitamin D and disease course in MS, there is often the issue of reverse causal-
ity: the possibility that the higher relapse rate is not caused by lower vitamin D levels, but 
that the low vitamin D levels are caused by increased disability that prevents patients from 
spending time outdoors. In this study, 2 facts argue against such a phenomenon. First, for 
every week the influence of the vitamin D levels during the preceding 4 weeks on exacer-
bations was calculated. Secondly, adjustment for disability (EDSS) did not alter the inverse 
association between 25-OH-D levels and exacerbation risk. Furthermore, only the serum 
samples taken at the regular 8-weekly visits were used in the sinusoidal model, and samples 
taken during exacerbation visits were not evaluated. 
The biological plausibility for a protective role of vitamin D on the disease course of MS has 
been given in many experimental settings. Different cells of the immune system, including 
macrophages and activated T lymphocytes[24] and B lymphocytes[25], contain vitamin D re-
ceptors. 1,25-(OH)2 D has been shown to inhibit the production of inflammatory cytokines 
in vitro[26] and to promote the development of regulatory T lymphocytes[27,28]. Further-
more, a correlation between serum 25-OH-D concentrations and a more anti-inflammatory 
Th1/Th2 ratio has been found[20]. Also in other autoimmune diseases, such as rheumatoid 
arthritis, type 1 diabetes, and systemic lupus erythematosus, evidence for a protective role 
of vitamin D is growing[29]. However, in these ailments prospective studies are scarce.
To evaluate if the association between vitamin D levels and exacerbations in MS could be 
causal, Hill’s criteria of causation can be used[30]. Hill’s criteria are as follows: 1) strength 
of the association, 2) consistency of the association, 3) temporality, i.e., does the exposure 
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precede the disease (this is the issue of reverse causality), 4) biological gradient, or dose-
response curve, 5) plausibility of the causation, and 6) experiment: have there been experi-
ments to investigate if a change in exposure alters disease frequency. In the present study, 
we found a moderately strong association (criterion 1), which was linear (criterion 4). Our 
findings are consistent with previous research and are biologically plausible (criteria 2 and 
5). Despite arguments provided above, the theoretic possibility of reverse causality (crite-
rion 3) cannot be ruled out completely. Therefore clinical intervention trials are needed to 
further investigate the relationship between vitamin D supplementation and disease course 
in MS.
In this prospective cohort study we have demonstrated that lower serum vitamin D levels 
are associated with increased exacerbation risk in patients with relapsing-remitting MS; for 
each doubling of the serum 25-OH-D concentration the relapse risk in MS decreases by 27%. 
Vitamin D has the advantages of being cheap, safe, and easy to administer, and could there-
fore be a valuable addition to the existing treatment opportunities in MS. 
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Abstract
Background
In relapsing-remitting MS patients, lower serum vitamin-D concentrations are associated 
with higher relapse risk. In a number of conditions, low vitamin D has been associated with 
fatigue. Pregnant women are at particular risk for vitamin-D insufficiency. 
Objective
To investigate whether vitamin-D status is associated with postpartum relapse and quality 
of life during pregnancy. 
Methods
43 pregnant RRMS patients and 21 pregnant controls were seen at regular times before, 
during and after pregnancy. At every visit clinical assessment, samples for 25-OH-D meas-
urements, and QOL questionnaires were taken. 
Results
Lower 25-OH-D concentrations were not associated with postpartum relapse risk. Pregnan-
cy-25-OH-D levels of patients and controls were not significantly different. In controls, but 
not patients, higher 25-OH-D concentrations were correlated with better general health, 
social functioning and mental health, but not with vitality. 
Conclusion
Low vitamin-D levels are not associated with postpartum relapse. In pregnant MS patients, 
vitamin-D levels are similar to levels in healthy women and are not associated with quality 
of life. Therefore, with regard to QOL and postpartum relapse, we found no arguments for 
advising pregnant MS patients to take more vitamin-D supplements than healthy women.
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Introduction
Vitamin D insufficiency is not only thought to be involved in the development of multi-
ple sclerosis (MS)[1], but also in its disease course: in patients with relapsing-remitting MS 
(RRMS), lower serum vitamin D concentrations are associated with a higher relapse risk[2]. 
In a number of conditions, low serum vitamin D concentrations have also been associated 
with worse scores on quality-of- life items[3, 4] such as fatigue[5, 6]. 
It is known that vitamin D deficiency is very common in pregnant and lactating women 
throughout the world [7, 8]. In MS, although the relapse rate generally decreases during 
pregnancy, there is an increased risk of relapse in the first 3 months after delivery[9]. It is 
not fully known what causes this increased postpartum relapse risk, but it could be hypoth-
esized that low serum vitamin D levels during or after pregnancy play a role. Vitamin D might 
also be associated with quality of life during and after pregnancy. 
In this study we aimed to investigate whether vitamin D is associated with the postpartum 
relapse risk, and whether it is associated with quality of life. The Rotterdam Study on Preg-
nancy in MS is a longitudinal study in pregnant MS patients, with serum sampling before 
conception, in the first and third trimester of pregnancy and after delivery. Because it is not 
known if vitamin D status of MS patients during pregnancy and lactation differs from the 
vitamin D status of healthy pregnant women, we also included a control group. 
 
Patients and Methods
Participants and study design
Study design and recruitment of patients and healthy controls in the Rotterdam Study on 
Pregnancy in MS was described previously[10-12]. In brief, ambulant relapsing-remitting 
MS patients were recruited before conception and healthy controls were included in the 
first trimester of pregnancy. Visits were planned at the end of the first trimester (at 10-12 
weeks of pregnancy), at the beginning of the third trimester (at 28-30 weeks of pregnancy) 
and at 4-8 weeks after delivery. MS patients also had a visit at least 9 months after delivery, 
at a time point where there was no infection or recent disease activity. At every visits blood 
samples were taken and disability was measured using Kurtzke Expanded Disability Status 
Scale (EDSS)[13]. Patients were included between October 2002 and February 2009.
The study was approved by the ethics committee of the Erasmus MC and all participants 
provided written informed consent. 
Definitions
All patients fulfilled the McDonald criteria for the diagnosis of multiple sclerosis[14]. Re-
lapse was defined as a worsening of existing symptoms or the appearance of new symptoms 
lasting for more than 24 hours, after a period of more than 30 days of improvement or 
stability, confirmed by neurologic examination[15]. A temporary neurological deterioration 
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associated with fever was not considered as a relapse. Postpartum relapse was defined as 
a relapse occurring in the first 3 months after delivery. Duration of disease was measured 
from time of diagnosis. 
Measurement of 25-OH-vitamine D
Concentrations of 25-OH-vitamin D were determined by a RIA method (DiaSorin, USA) using 
an extraction method. The inter-assay variation coefficient at a concentration of 62 nmol/L 
was 11.6% and at 109 nmol/L it was 10.3%. The respective intra-assay variation coefficients 
at these levels were 5.7% and 6.6%, respectively. All samples were analyzed at the same 
time, and samples of MS patients and controls were run in the same batch. 
Measurement of quality of life
To measure quality of life, the MOS 36 item short form health survey questionnaire (SF-36)
[16] was used. The SF-36 consists of four physical health domains and four mental health 
domains and has been used before in MS patients[17, 18]. The physical health domains are 
physical functioning, role physical functioning, bodily pain, and general health. The men-
tal health domains are social functioning, vitality, role emotional functioning, and mental 
health. For each domain a score is generated ranging from 0 (poor health) to 100 (optimal 
health). The vitality domain has implications for a patients’ fatigue. 
Statistical analysis
Comparisons of patient characteristics were performed using Student’s t test for continuous 
variables or chi-square test for categorical variables. Relapse rate and  serum 25-OH-D levels 
at different time points of pregnancy were compared using mixed linear model analysis, 
with season as covariable; seasons were defined as spring (March-May), summer (June-
August), autumn (September-November) and winter (December-February). For the analysis 
of the quality-of-life scores, correlation analysis was used (Pearson or Spearman depending 
on the distribution). The differences of 25-OH-D levels of patients and healthy women and 
patients with and without postpartum relapses were calculated with Student’s t test and 
with regression analysis to correct for season.
All calculations were performed using SPSS 20 for Windows.
 
Results
Participants
43 patients and 21 healthy controls were included in the study. 26 patients were included 
before pregnancy, 16 during the first trimester and 1 during the third trimester. All controls 
were included in the study during the first trimester of pregnancy. As described previous-
ly[11], healthy controls were recruited from the outpatient clinic of the obstetrics depart-
ment in our hospital, reasons for referral being: previous cesarean section (six), history of 
cardiac problems (three, of which one also had twin pregnancy), medically assisted preg-
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nancy (two), prematurity in previous pregnancy (two), previous post-natal depression (one), 
uterus duplex (one), epilepsy (one), twin pregnancy (one), metabolic disorder (one). Two 
women had no specific medical indication. Data on pregnancy and birth outcome are shown 
in table 1. 
 Patients (n=43) Controls (n=21) 
Maternal age (±SD)(years) 31.5 (±3.8) 31.2 (±4.5) 
Nulliparous  28 (65%) 7 (33%) 
Ceasarian section  6 (14%) 5 (24%) 
Assisted vaginal delivery (forceps/vacuum) 5 (12%) 1 (5%) 
Twin pregnancy  0 (0%) 2 (10%) 
Birth weight (±SD)(grams) 3,347 (±385) 3,223 (±860) 
Gestational age at delivery (±SD)(weeks) 39.3 (±1.5) 38.2 (±2.7) 
Prematurity1 1 (2%) 3 (14%) 
Small for gestational age2 1 (2%) 3 (14%) 
Breastfeeding >2 months  25 (58%) 9 (43%) 
(Pre)eclampsia  0 (0%) 0 (0%) 
Use of vitamin supplements containing vitamin D  20 (46.5%) 7 (33.3%) 
Duration of disease (±SD)(years) 5.5 (±6.0)  
Median EDSS first trimester (IQR) 1.5 (1.0-2.0)  
 
1 Defined as birth <37 weeks of gestation, not including twin pregnancies 
2 Defined as birth weight under -2SD, using standardized intrauterine growth charts
Table 1. Data on pregnancy and birth outcome of patients and controls. SD = standard deviation, IQR = interquartile 
range.
In the MS patients, disease activity decreased during pregnancy: mean annualized relapse 
rate (ARR) was 0.47 in the year before pregnancy and lowered to 0.09 in the third trimes-
ter. After delivery, there was a significant increase in relapse rate ( the ARR in the first 3 
months after delivery was 1.02; 11 women experienced a postpartum relapse). During the 
study (mean follow-up time 19.8 months), a total of 31 relapses were observed.  None of 
the patients received medication during the study except for three patients who received 
intravenous immunoglobulin directly after delivery, with the aim to protect for possible 
exacerbations[19]. Eighteen MS patients did not use any vitamin supplements during the 
study. Twenty patients and 7 controls used vitamin supplements containing vitamin D at 
some point during follow-up. Of 5 patients and 3 controls, use of vitamin supplements was 
not known. There was no association between supplements use and disease activity before 
pregnancy (nor with EDSS nor with relapse in the year before pregnancy).
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Serum 25-OH-D concentrations
Serum 25-OH-D concentrations of patients and controls showed a strong seasonal fluctua-
tion, with the peak level in August and nadir for patients in February. Mean 25-OH-D con-
centrations per month are shown in supplemental figure 1. 
We found a rise in 25-OH-D levels in the third trimester of pregnancy, and a decrease after 
delivery. This fluctuation was stronger in patients than in controls, but in both groups it was 
significant (p<0.001 for patients and p<0.05 for controls, corrected for seasonal influences). 
The differences in serum 25-OH-D concentrations between patients and healthy controls 
were not statistically significant (all p>0.7). In figure 1, serum 25-OH-D concentrations dur-
ing pregnancy are depicted for patients and controls. Because parity has been associated 
with vitamin D status during pregnancy[20] we investigated this but we found no difference 
in 25-OH-D concentrations between nulliparous and multiparous women. 
 
Figure 1. Mean serum 25-OH-D levels (nmol/l) of patients and controls before, during and after pregnancy. De-
picted serum 25-OH-D values are corrected for season. 
* p<0.05 only for patients
**p<0.001 for patients and p<0.05 for controls
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Association between serum 25-OH-D concentrations and postpartum relapse and breast-
feeding
The serum 25-OH-D concentrations during pregnancy were not associated with the occur-
rence of a postpartum relapse, also not when corrected for season. 25-OH-D concentrations 
of patients with and without a postpartum relapse are shown in figure 2. The proportion of 
patients that used vitamin supplements was the same among patients with and without a 
postpartum relapse. Also, the percentage of women who breastfed was not different among 
the women who did and did not experience a postpartum relapse (63.6%  vs 65.6%). When 
looking at the relation of breastfeeding and vitamin D levels, we found that 25-OH-D levels 
were not significantly different between breastfeeding and non-breastfeeding women. We 
found that 25-OH-D levels were not associated with annualized relapse rate. 
 
Figure 2. Mean serum 25-OH-D levels (nmol/l) before, during and after pregnancy for patients who did and did not 
experience a postpartum relapse.
Association between serum 25-OH-D concentrations and quality-of-life scores
In controls, but not in MS patients, a higher vitamin D concentration was positively cor-
related with better scores on several quality-of-life measures: these were general health 
(r=0.442), social functioning (r=0.365) and mental health (r=0.386). Vitamin D concentra-
tions were not associated with vitality (r=-0. 04), not in healthy women nor in MS patients. 
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Discussion
The main finding of this study is that low vitamin D levels are not associated with postpar-
tum relapse. It is hypothesized that in MS, but also in other autoimmune diseases like rheu-
matoid arthritis[21-23], during pregnancy there is a shift from a predominantly Th1 cell pro-
inflammatory immunologic state to a more anti-inflammatory Th2 profile, reducing disease 
activity. After delivery, the immunologic state shifts back into the more pro-inflammatory 
profile  resulting in the higher postpartum relapse risk. The changes in immune tolerance 
and reactivity during pregnancy are highly complex and not yet fully known. A major fac-
tor is thought to be the change in hormone levels during pregnancy, especially a strong 
increase in the levels of estrogens and cortisol. Other possible contributing factors include 
the increased secretion of anti-inflammatory cytokines, peptides, proteins and hormones by 
the fetal-placental unit [24], the downregulation during pregnancy of inflammation-related 
genes that are abnormally upregulated in MS [25], or microchimerism [26]. Because higher 
vitamin D is also associated with a more anti-inflammatory immunological profile[27], and 
has been associated with lower relapse risk in MS[2], we hypothesized that low vitamin D 
levels during pregnancy might also play a role in the postpartum relapse risk. However, we 
did not find any evidence for this. 
One previous study,  by Langer-Gould et al.[28], found no evidence for an association of low 
vitamin D levels and postpartum relapses; this study even found that postpartum levels of 
25-OH-D were significantly higher in patients with a postpartum relapse than in patients 
without a relapse. The authors explained this by the fact that more women who relapsed 
did not breastfeed: in their study, breastfeeding was associated with lower vitamin D levels, 
although this was not significant when corrected for season. However, in our study, breast-
feeding did not seem to influence 25-OH-D levels, nor did women with and without post-
partum relapse differ significantly in their breastfeeding behavior. Because it is known that 
severity of the disease before pregnancy is a predictor of postpartum relapse[29], women 
with more severe disease might be expected to take more vitamin supplements; however, 
we found no evidence for difference in supplements use in our cohort. Vitamin D has immu-
nological properties, and very likely plays a role in MS[1]. A possible explanation for the fact 
that we did not find any association with postpartum relapse is that  vitamin D has a rela-
tively small effect that is overridden by the much stronger hormonal effects on immunity. 
A second finding of our study is that serum 25-OH-D concentrations changed under the in-
fluence of pregnancy, and did so equally in patients and controls; we did not find any signifi-
cant difference between 25-OH-D levels of patients and controls. Higher 25-OH-D levels in 
the third trimester have been described before[30]. It is known that vitamin D metabolism 
changes during pregnancy. This might be related to altered calcium needs in the pregnant 
woman, but this does not seem completely true: during pregnancy, there is an uncoupling 
of vitamin D metabolism from calcium so that 1,25-diOH-D levels can increase without a 
concurrent rise in calcium concentrations, driven solely by 25-OH-D availability[7, 30, 31]. 
This uncoupling is only observed during pregnancy and at no other point in normal human 
physiology. Reasons for this possibility of vitamin D levels to rise independently of calcium 
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might include the altered immune function with increased innate immunity and decreased 
adaptive immunity, but also the possibility to provide the baby with sufficient levels of vi-
tamin D; at term, for cord blood to attain a 25-OH-D level of 50 nmol/l, the maternal level 
would need to be at least 80 nmol/l[31, 32]. 
Finally, we found that vitamin D was associated with better general health, social function-
ing and mental health in healthy pregnant women. To our knowledge, this has not been 
studied before. No association was found with vitality. The fact that we did not find an as-
sociation of vitamin D and improved quality of life in MS patients could be explained by the 
fact that pregnancy generally ameliorates MS. Therefore, MS patients already feel better 
during pregnancy than before[11], and may not notice a relatively small beneficial effect of 
vitamin D. 
This study has some limitations, including small sample sizes at some time points and lack 
of dose information on vitamin D supplementation in some patients. Furthermore, we de-
fined breastfeeding as a yes/no question and did not distinguish between exclusive and 
non-exclusive breastfeeding. 
In conclusion, we found that although low vitamin D has been associated with MS relapse 
risk, and vitamin D levels are generally lower after delivery, there was no association with 
postpartum relapse. The exact mechanism behind the postpartum relapse in MS and the 
role of vitamin D in immunity during pregnancy remain to be further elucidated. In pregnant 
MS patients, vitamin D levels are similar to levels in healthy women and are not associated 
with quality of life. Therefore, with regard to QOL and postpartum relapse, we conclude that 
there is  no evidence for a need to advise MS patients to take more vitamin D supplements 
during pregnancy than healthy pregnant women.
However, the following should be kept in mind when advising pregnant MS patients: the 
possibility that maternal vitamin D may influence the risk of the fetus to develop MS, and 
the impact of low vitamin D levels on bone health and other systems in any pregnant wom-
an. For these reasons, it is important to make sure that 25-OH-D levels during pregnancy are 
sufficient, for all women, with or without MS.   
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Abstract
Background 
Vitamin A is a multifunctional vitamin that can inhibit the formation of Th17 cells, which 
are probably involved in the development of relapses in MS. Furthermore, it promotes Treg 
formation. Therefore, vitamin A can be hypothesized to be lower in patients than in healthy 
controls, and to decrease relapse risk in relapsing–remitting MS(RRMS) patients.
Objectives 
To compare vitamin A levels in MS patients and controls, and to investigate whether vitamin 
A levels are associated with relapse risk.
Methods
In a case-control study all-trans-retinol levels were compared between 31 RRMS patients 
and 29 matched controls. 
In a prospective longitudinal study in 73 RRMS patients, serum samples for all-trans-retinol 
measurements were taken every eight weeks. Associations between all-trans-retinol con-
centrations and relapse rates were calculated using Poisson regression with the individual 
serum levels as time-dependent variable. Associations between vitamin A and vitamin D 
were calculated. 
Results
Mean vitamin A levels were lower in patients (2.16 μmol/l) than in controls (2.44μmol/l) but 
with borderline significance (p=0.05). In the longitudinal study, during follow-up (mean 1.7 
years), 58 patients experienced a total of 139 relapses. Monthly moving averages of all-trans 
retinol levels were categorized into tertiles: a low (<2.9 μmol/l), medium (2.9-3.7 μmol/l) 
and high level (>3.7 μmol/l). Relapse rates were not associated with serum all-trans retinol 
levels (p>0.2), in univariate nor in multivariate analysis. 
Serum concentrations of all-trans-retinol and 25-OH-vitamin D were positively correlated, 
although this correlation was weak (r=0.15). 
Conclusions
We did not find evidence for a role for vitamin A in the disease course of RRMS. We did find 
an association between vitamin A and D levels in the RRMS patients, possibly explained by 
dietary products that contain both fat-soluble vitamins.
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Introduction
Vitamin A or retinol is a fat-soluble vitamin with multiple functions, such as those in vision, 
growth and the normal differentiation of epithelia[1,2]. Over the last 2 decades, it has be-
come clear that vitamin A also has important roles in immune functioning, both in immuno-
logical tolerance and in adaptive immune responses [2].
After absorption from food, most vitamin A is stored in the liver, from where it is added to 
the circulation bound to retinol-binding protein (RBP)[3,4]. Inside the target cells, retinol is 
oxidized by alcohol dehydrogenase (ADH) into retinal, which can then be oxidized into the 
active form retinoic acid (RA) by the more selectively expressed retinaldehyde dehydroge-
nase (RALDH)[2]. 
RA is a signaling molecule that can control gene expression, mainly through the activation 
of nuclear retinoid receptors. There are three subgroups of retinoid receptors: retinoic 
acid receptors (RARα-γ), retinoid X receptors (RXRα-γ), and retinoic acid orphan receptors 
(RORα-γ)[5]. RXR can form heterodimers with other nuclear receptors, such as vitamin D 
receptor (VDR)[4]. 
RA has been shown to inhibit the formation of Th17 cells, which are probably involved in the 
development of relapses in MS[6], in vitro[7] via binding to RARα[8,9]. It can do so synergis-
tically with 1,25-diOH-vitamin D[10]. In EAE, a synthetic retinoid could also inhibit Th17 cell 
differentiation and ameliorate EAE[11]. Furthermore, RA can promote the formation of anti-
inflammatory Treg cells expressing Foxp3[7,8,12].  Recently, it was also found that vitamin A 
is possibly associated with MS risk[13] and MRI outcomes in MS[14]. 
Because of the roles described for vitamin A on Th17 and Treg cells, we hypothesized that 1) 
vitamin A would be lower in MS patients than in healthy controls, and 2) MS patients with 
higher vitamin A levels would have a lower relapse risk. To investigate this, we performed 
two studies: a case-control study of vitamin A levels, and a prospective longitudinal study 
of vitamin A levels in relapsing-remitting MS (RRMS) patients to investigate the association 
between vitamin A and relapse risk. Because of possible synergistic effects, we also looked 
at the associations of vitamin A and vitamin D in the longitudinal study.  
Patients and methods
1. Case control study on vitamin A and MS
Patients and controls
We randomly selected 31 patients with RRMS from our pool of MS patients, subsequently 
selecting 29 controls matched for age and sex. All controls had signed for informed consent, 
and all patients were aware that serum would be stored for later use. The Medical Ethical 
Committee of the Erasmus Medical Center University Hospital approved the use of these 
materials. 
110
ch
ap
te
r 8
Chapter 8
Measurement of vitamin A
All-trans retinol was measured because this is the main form of retinol in the circula-
tion[4,15,16], and also the best measure of vitamin A status. For analysis of retinol levels, 
the samples were extracted with hexane and, after evaporation, dissolved in methanol. 
Retinol levels were measured through reverse-phase high-performance liquid chromatogra-
phy (HPLC) (column: 150 × 4.8 mm, Polaris C18A, Waters Alliance HT2795; detector: Waters 
2475 [Waters, Milford, MA]), with excitation at 328 nm and detection of emission at 468 nm. 
The intra-assay variability of retinol measurements was 3.9% and the inter-assay variability 
was 5.1%.
Statistical analysis
Student’s T-test was used to compare mean all-trans retinol levels between RRMS patients 
and healthy controls. ANOVA was used to adjust for age. P=0.05 (two-sided) was considered 
the limit of significance in all analyses. All calculations were done using SPSS 20.0 for Win-
dows.
2. Longitudinal study on vitamin A and exacerbations
Patients 
For the longitudinal study, data and samples were collected in the Rotterdam Study on Ex-
acerbations in MS, a prospective study in patients with relapsing-remitting MS[17]. Patients 
aged 18-55 years could be included in the study if they had clinically definite MS with a 
relapsing-remitting disease course and at least two exacerbations in the previous 2 years. 
Patients were excluded from participation if they suffered from another serious disease. All 
patients signed for informed consent. The study protocol was approved by the Medical Ethi-
cal Committee of the Erasmus Medical Center University Hospital. 
Definitions
Exacerbation was defined as a worsening of existing symptoms or the appearance of new 
symptoms lasting for more than 24 hours after a period of more than 30 days of improve-
ment or stability, if confirmed by neurologic examination[18]. A temporary neurological de-
terioration associated with fever was not considered to be an exacerbation. 
Because infection is a known risk factor for exacerbations in multiple sclerosis, the ‘at risk 
period’ around infection was used as a covariate in this study, as described previously[17]. 
Visits, samples and measurement of exacerbations
All patients visited the outpatient clinic of the Erasmus Medical Centre University Hospi-
tal regularly every 8 weeks. At every visit, blood samples were taken and disability was 
measured using the Kurtzke Expanded Disability Status Scale (EDSS)[19]. In the event of a 
suspected exacerbation or infection, additional visits were arranged within 3 days. Serum 
samples were stored at -80ºC until serum vitamin A measurement.
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Measurement of vitamin A and vitamin D
Measurements of all-trans retinol were as described above.  To investigate the association 
between vitamin A and D, we used a RIA method (DiaSorin, USA) using an extraction meth-
od, to measure 25-OH-vitamin D levels. The inter-assay variation coefficient at a concentra-
tion of 62 nmol/L was 11.6%; at 109 nmol/L it was 10.3%. The respective intra-assay varia-
tion coefficients at these levels were 5.7 and 6.6%. Only serum samples taken at the regular 
eight-weekly visits were used for the measurement of all-trans retinol and 25-OH-vitamin D; 
samples taken during exacerbation visits were not evaluated.
Statistical analysis
To assess the association between individual serum all-trans retinol concentrations and 
the incidence rate of exacerbations, we split the follow-up time for each patient, which 
covered a maximum period of 2.3 years, into intervals of one week each. The number of 
exacerbations was determined for each of these intervals. The individual exacerbation rate 
was assumed to depend on the mean serum all-trans retinol concentration over the previ-
ous 4 weeks. To obtain this mean level, the weekly levels between measurements were 
determined per individual using interpolated values. These interpolated values were sub-
sequently averaged. During the period of 4 weeks that followed an exacerbation, an indi-
vidual was not considered to be at risk for another exacerbation. It was decided a priori to 
categorize the mean serum levels of the 4 preceding weeks into tertiles: low (<2.9 μmol/l), 
medium (2.9-3.7 μmol/l) and high (>3.7 μmol/l). The relationship between serum all-trans 
retinol concentrations and the incidence rate of exacerbations was assessed using Poisson 
regression models with the mean individual serum levels as a time-dependent variable. In 
the calculations we used generalized estimating equations with an exchangeable covariance 
matrix for the subsequent study weeks. The effect of other factors, including gender, age, 
EDSS, number of exacerbations before study entry and use of interferon-β during the study, 
was also estimated using a multivariable generalized linear model with a log-link function. 
Associations between measured vitamin A and vitamin D concentrations, the latter log-
transformed to get an approximate normal distribution, were calculated using  mixed model 
regression analysis for repeated measurements.  P=0.05 (two-sided) was considered the 
limit of significance in all analyses. All calculations were done using SPSS 20.0 for Windows.
 
Results
1. Case control study on vitamin A concentrations and MS
Patient characteristics
The baseline characteristics of the 31 patients and 29 controls included are shown in table 
1. We had no information on the use of vitamin supplements of patients and controls. None 
of the patients were using interferon β at the time of blood sampling, because sampling was 
done during a clinical workup for therapy advice within our MS center. 
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Table 1. Characteristics of patients and controls of the case-control study
Characteristic Patients SD Controls SD 
Sex (f/m) 22/7  24/7  
Age mean (range) 35.4 (19-56) 10.3 35.9 (19-56) 10.4 
Ethnicity (%) 
White caucasion 
Meditterranean 
Black 
 
77.4 
16.1 
6.5 
  
89.7 
10.3 
 
Disease duration (years) mean (range) 4.5 (0-29)  5.4   
 
Serum vitamin A concentrations
For most patients and controls, serum all-trans retinol concentrations fell within the normal 
range. None of the patients and none of the controls were vitamin-A deficient. As figure 1 
shows, all-trans retinol concentrations where somewhat lower in patients than in controls 
(mean 2.16 ± 0.55 μmol/l vs. 2.44 ± 0.52 μmol/l), but this difference was only borderline 
significant (p= 0.050). Vitamin A depended on age in the case-control study, but not in the 
longitudinal study. It did not depend on sex. When adjusting for age, there was no significant 
difference between patients and controls (p=0.070).
Figure 1. Serum all-trans retinol concentrations of relapsing-remitting MS patients and healthy controls.
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2. Longitudinal study on vitamin A and exacerbations
Patient characteristics
73 patients were included in this study. The mean follow-up time of all patients was 1.7 
years (range 0.4-2.3). Nine patients had dropped out of the study before the intended com-
pletion date, one due to participation in another study, the other eight for unknown rea-
sons. All patients were Dutch Caucasians; their baseline characteristics are shown in table 
2. In addition to the 13 patients who used interferon-β at study entry, 15 started to use 
interferon-β during follow-up; these 28 patients used interferon-β at some point during an 
average of 56 weeks. Vitamin supplements were not widely used among the patients: five 
used vitamin B complex (without vitamin A) and two used multivitamin pills, one of which 
contained 6 mg of beta-carotene. 
Variable (n=73) Mean (range)  Std. Deviation 
Age, years 39.4 (19-55) 9.1 
Disease duration, years 5.2 (0-25) 4.1 
Disability (EDSS) * 2.5 (0-6.0) 1.6 
Exacerbations in previous 2 years 2.2 (1-8) 1.3 
Variable (n=73) Proportion (%)  
Gender, F/M  77% / 23%  
IFN use, N/Y  82% / 18%  
 * EDSS is a method for quantifying disability in MS, ranging from 0.0 (normal neurological exam) to 10.0 (death 
due to MS)
Table 2. Characteristics of patients of the longitudinal study at baseline.  
58 patients experienced a total of 139 exacerbations during this study. Median time from 
inclusion to first exacerbation was 20 weeks. Thirty-three patients had more than one ex-
acerbation; the average exacerbation rate was 1.2 per year (range 0-6.2 per year). Three 
patients experienced a sixth exacerbation during follow-up.
Serum vitamin A concentrations
Serum all-trans retinol concentrations fluctuated considerably, without a seasonal pattern 
or other clear pattern. Mean serum all-trans retinol concentration was 3.31 ± 1.14 μmol/l. 
Mean levels varied substantially between patients (Anova: P<0.001). Within patients there 
was also a considerable variation between measurement occasions. Of the total variation 
in levels 40% was due to differences between patients while 60% was due to differences 
within patients.
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Association between serum vitamin A concentrations and exacerbation risk
Univariate analysis did not show exacerbation rates to be associated with serum all-trans 
retinol levels (p>0.2). 
As shown previously[20], infections were associated with the risk of an exacerbation, the ex-
acerbation rate within an “at risk period” being 2.1-fold higher (95% CI 1.6 to 2.8, p<0.001). 
Also, vitamin D (25-OH-D) serum levels were found to be associated with exacerbation risk. 
In the multivariate model including 25-OH-D and infections, infections and 25-OH-D were 
both still related to the exacerbation rate, whereas all-trans retinol was not (table 3). Adding 
gender or the use of interferon-β to the model did not alter these results. Also age, EDSS 
and the number of exacerbations in the 2 year period before entry into the study were not 
significantly associated with the exacerbation rates (all p>0.18).  
  Relative 
exacerbation rate 
95% CI P-value 
All-trans retinol concentrations Low 
<2.9 μmol/l 
1.2 0.8-1.8 0.329# 
 Medium  
2.9-3.7 μmol/l 
1.3 0.8-1.9 0.254# 
 High  
>3.7 μmol/l 
1 (reference) - - 
ARP infection Yes 1 (reference) - - 
 No 0.4 0.3-0.6 <0.001 
25-OH-D concentrations Low 
<50 nmol/l 
2.0 1.2-3.4 0.012* 
 Medium 
50-100 nmol/l 
1.3 0.8-2.2 0.281* 
 High 
>100 nmol/l 
1 (reference) - - 
 
# overall p-value: 0.489
* p-value for trend: 0.010
Table 3. Association between exacerbation rate and categorized serum all-trans retinol concentrations according 
to the multivariable analysis including infection and 25-OH-vitamin D concentrations. ARP infection = at risk period 
for infection.
Association between vitamin A and vitamin D 
Serum concentrations of all-trans retinol and 25-OH-D had a significant linear correlation. 
Mixed model regression analysis showed that for every doubling of serum 25-OH-D concen-
tration the mean all-trans retinol level  increased by 0.59 μmol/l (p<0.001). The correlation 
however was weak (r=0.15).  
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Discussion
This case-control study shows that vitamin A concentrations are not significantly lower in 
MS patients than in healthy controls. Our longitudinal study also shows that vitamin A is not 
associated with relapse risk in MS patients. We also found that vitamin A and vitamin D were 
associated in a linear manner.  
There are several reasons to hypothesize that vitamin A is involved in MS. In the past, it 
has been hypothesized that the susceptibility period in multiple sclerosis lies in early child-
hood[21] and that the element responsible was (a deficiency in) vitamin A[22]. This hypoth-
esis was based mainly on epidemiological evidence, and the mechanisms through which 
vitamin A deficiency was thought to cause MS were effects on normal CNS myelination and 
effects on skull and bone growth affecting normal CNS growth. Since knowledge of the func-
tions of vitamin A in immunity has grown in the last decades[2] (inhibiting Th17 cell for-
mation[7] and promoting Treg formation[7,8,12]), the hypothesis that vitamin A might be 
involved in the development and disease course of MS has become stronger. Recently, it 
was also found that RXR agonists can stimulate remyelination[23]. Vitamin A has even been 
suggested as a (supplementary) treatment option in MS[11,15]. However, in the present 
case-control and longitudinal studies we cannot provide any evidence that vitamin A is re-
ally involved in MS.
In the case-control study, we found somewhat lower retinol concentrations in patients than 
in controls, but this was not significant. Other studies that addressed this topic had conflict-
ing results. One study also did not find lower levels than in controls[24]. Another study 
found lower levels in MS patients than in controls[25]. Differences with our study were that 
all patients had a secondary progressive disease course, and that  a different technique was 
used for the measurements (Neeld-Pearson with trifluoroacetic acid instead of HPLC). A 
third study compared retinol levels in patients and controls, finding significant differences 
only between subgroups[15]. It should be noted that in that study retinol levels were slightly 
higher in interferon-β treated patients. 
The borderline significance in our results suggests that our groups might have been too 
small. On the other hand, as figure 1 shows, the mean levels of vitamin A in patients and 
controls are not far apart, and confidence intervals are wide, suggesting substantial varia-
tion within the patient and control group. In our longitudinal study, we also found substan-
tial within-patient variation of retinol levels. We found that vitamin A was also dependent 
on age, which has been described before by Looker et al. [26] but was not found by Hall-
frisch et al.[27]. Because our control group was age- and sex matched, this has not influ-
enced our conclusions.
In the longitudinal study we found no association between vitamin A and exacerbation rate. 
One recent study using the same technique for retinol assessment, found an inverse as-
sociation between new lesion formation on MRI and vitamin A levels[14]. We could not 
confirm an association between vitamin A and clinical disease activity in MS in our study. But 
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although our longitudinal study with its frequent serum sampling provides a robust way of 
studying this topic, the fact that we found no association does not totally exclude a role for 
vitamin A in MS relapses. There might be local function or production of RA in the CNS as-
sociated with relapses, that cannot be measured systemically, for example by tissue-specific 
expression of retinoid receptors or retinaldehyde dehydrogenase (RALDH)[2]. 
A limitation of our study is that none of the patients in the case-control study used 
interferon-β. In the longitudinal study, the use of interferon-β did not influence our results. 
In studies by others on this topic conflicting results have been found: some found a syner-
gistic effect of RA with interferon-β on T suppressor cell augmentation[28], others found the 
association between vitamin A and MRI outcomes to be non-significant during interferon-β 
use[14]. We were unable to confirm any of this here. 
We found an association between serum levels of vitamin A and D. Vitamin A can be ab-
sorbed from food, but its levels can also be increased via a rise in hepatic production as a 
result of exposure to light[29,30]. Because vitamin D is also a fat-soluble vitamin that can be 
absorbed from food and can also be synthesized under the influence of sun light, it is not 
surprising that the concentrations of both vitamins increase and decrease simultaneously. 
However, we did not find synergistic action in this study: whereas a higher vitamin D level 
was associated with a lower relapse risk, vitamin A was not. 
For our analyses of retinol levels, we used random serum samples and not fasting samples. 
This is justified because  retinol is derived from hepatic and other body stores and is a good 
measure of vitamin-A status, unlike retinyl-esters, which are absorbed after a vitamin-A rich 
meal[15].  
In recent years, several studies on the relation between vitamin A and MS have been 
performed, using different techniques and markers, sometimes with conflicting re-
sults[13,14,15,24,25,31]. Routine measurement of vitamin A and carotenoids is now gener-
ally done using high performance liquid chromatography (HPLC). Lately, the use of plasma 
RBP as a surrogate marker for retinol is increasing. It should be realized that this is only valid 
in the absence of infection or when adjusted for CRP levels[13,32]. 
In conclusion, there are several reasons to hypothesize that vitamin A has a role in the de-
velopment and disease course of MS. Here we did not observe differences in retinol levels 
between patients and controls. In addition, in the prospective study on exacerbations, we 
found no association with disease activity. These results do not feed the perception that 
vitamin A could be a useful treatment for MS patients [11,15].
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We read with interest the article by Kivisäkk et al[1]. in which they evaluated the plasma 
levels of osteopontin in a cohort of patients with multiple sclerosis (MS). Kivisäkk and col-
leagues measured higher plasma osteopontin levels in MS patients than in controls, but 
they could not demonstrate any significant association of osteopontin with disease activity.
Osteopontin is a multifunctional molecule that has been proposed as a biomarker for dis-
ease activity in MS. It has been hypothesized to be involved in relapses in MS for several 
reasons: osteopontin has been found to be one of the genes with the most common tran-
scripts in MS lesions. In experimental autoimmune encephalomyelitis (EAE) models, admin-
istration of osteopontin induced relapse and inhibited spontaneous recovery. In patients 
with relapsing–remitting MS, levels of osteopontin were higher during relapses than during 
remission[2]. One study showed that osteopontin levels were increased 1 month before the 
appearance of a new lesion on brain magnetic resonance imaging (MRI)[3], and although 
this study had some methodological shortcomings, its results added to the suggestion of 
osteopontin as a possible biomarker for MS disease activity.
We have conducted a prospective longitudinal study in which we measured osteopontin 
plasma levels every 8 weeks in 58 relapsing–remitting MS patients. Patients were followed 
for a mean of 1.6 years. Osteopontin levels were measured using a commercially available 
enzyme-linked immunosorbent assay (ELISA; IBL International, Hamburg, Germany). The as-
sociation between osteopontin levels and the relapse risk in the first, second, third and 
fourth week after sampling were calculated using generalized linear mixed-effects models.
In this prospective study, we found no association between osteopontin levels and relapse 
risk. We also found no difference in osteopontin levels between patients with active and sta-
ble disease and no association of osteopontin with EDSS score. There was also no difference 
between interferon treated and non-treated patients, and no association with infections.
With this, we confirm the results of the cross-sectional study by Kivisäkk et al. that no as-
sociation was found between osteopontin and clinical disease activity, even in a prospective 
study with frequent plasma measurements.
Although these results do not rule out a role for osteopontin in MS pathophysiology, we 
conclude that as a biomarker for MS disease activity, osteopontin does not seem useful.
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Chapter 10
General discussion
Multiple sclerosis is a devastating disease that strikes young people in the prime of their 
lives. The fact that MS is also characterized by a large heterogeneity in clinical disease course 
brings along substantial uncertainty for the patients and their treating physicians. The main 
aim of this thesis was to find predictors for diagnosis and disease course of MS. In this 
chapter the main findings are discussed, along with their clinical implications and future 
perspectives. 
Part 1: CIS to MS
Main findings and clinical implications
After a clinically isolated syndrome, not all patients will develop MS; after 20 years, 37% still 
has monophasic disease according to a study by Fisniku et al.[1]. In our own cohort of CIS 
patients, with a mean follow-up of almost 4 years, 40-45% has reached clinically definite 
MS. Because there is no single gold-standard laboratory test to diagnose MS, the diagnosis 
is primarily clinical, and based on the exclusion of other diagnoses and the demonstration 
of symptoms and signs attributable to CNS lesions that are disseminated in space (“DIS”) 
and time (“DIT”). International committees of experts have published diagnostic criteria for 
MS[2], which, over the years, have been revised several times with the aims to allow for a 
faster and simpler diagnosis[3-6]. The most recent (McDonald 2010) revisions were pub-
lished in 2011, with as most important change the simplification of the MRI requirements. 
In chapter 2, we applied these criteria to a cohort of 178 CIS patients to validate them, and 
we found that test characteristics of 2010 criteria were similar to 2005 criteria, but the di-
agnosis of MS could be made significantly faster with the newest criteria, in some patients 
even already at baseline, which is a great advantage. Also other groups have tested and 
validated the newest diagnostic criteria [7-9] showing that they function well in CIS patient 
populations from around the world. However, it should be noted that although the 2010 
criteria are advantageous compared to previous diagnostic criteria, the diagnosis of MS can 
be made at baseline only in a minority of patients, still leaving the future uncertain for most 
CIS patients. 
In the search for new prognostic markers in CIS patients, we took both a clinical and a pro-
teomics approach. 
Because MS patients very often suffer from fatigue, we investigated if this was already a 
common symptom at the stage of CIS. In chapter 3, we show that indeed fatigue is a fre-
quent symptom in CIS patients, with the prevalence and severity of fatigue in our cohort 
similar to that in MS patients: 46.5% of CIS patients suffered from fatigue. This fatigue was 
not related to the type or severity of the attack, nor with lesion load on brain MRI. Impor-
tantly, we found that fatigue was associated with an increased risk for CDMS, even inde-
pendent of MRI measures. The pathophysiology of MS-related fatigue is not exactly known; 
inflammatory cytokines combined with CNS dysfunction, sleep disorders and depression are 
likely to play a role[10, 11]. We investigated if vitamin D was associated with fatigue in CIS 
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patients, but it was not. Although one previous study[12] has shown that fatigue sometimes 
precedes other symptoms in MS and another study[13] described fatigue in early MS, this is 
the first time that fatigue has been studied separately in CIS patients and that its predictive 
value for CDMS has been shown. Because MS-related fatigue can be very disabling, we feel 
that the evaluation of fatigue deserves more attention in the routine work-up of patients 
with CIS. In clinical practice, it is easy to measure using the FSS questionnaire[14].
In chapter 4, we describe a proteomics approach to find biomarkers in the CSF of CIS pa-
tients. We studied the CSF of 47 CIS patients and 45 controls, and found peptides relating to 
36 proteins to be differentially abundant in CIS patients and controls. Contrary to what we 
expected, only 1 protein was more abundant in patients than controls (unsurprisingly immu-
noglobulin-related; Ig kappa chain C region), but 35 proteins were lower in CIS patients than 
controls. Most of these 35 proteins were related to gray matter integrity or cell-cell signal-
ing in the nervous system. There are two possible explanations for the lower abundance of 
these proteins in the CSF of patients: the lower abundance of proteins involved in the in-
tegrity of the CNS may either precede or even predispose for a first demyelinating attack, or 
alternatively be the result of the attack and subsequent smoldering chronic disease process. 
The first explanation is in line with others who describe the phenomenon that gray-matter 
related proteins are less abundant in the CSF of patients than in controls, in CIS[17-19] but 
also in more neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease 
and Huntington[15, 16]. In a study in Alzheimer’s patients at disease onset [20], a depletion 
of several proteins was found in the serum of patients in the very early stage of the disease; 
this was hypothesized to reflect the breakdown of neural cell membranes in those individu-
als destined to phenoconvert from cognitive intactness to Alzheimer’s disease. In a similar 
manner, in early MS it can be hypothesized that a dysfunction in CNS gray matter physiology 
can be observed as a depletion of proteins essential for normal development and function 
in the CSF in those destined to undergo a first demyelinating event. The fact that recently 
discovered new MS-related genes also included several gray-matter related genes might add 
to the credibility of this hypothesis [21]. The alternative explanation for lower protein abun-
dance in CSF of patients compared to controls, is that the disease process leads to lower 
levels, for example by means of decreased production as a result of the disease process, or 
of increased elimination by macrophages because of increased immune activation. An argu-
ment in favor of the latter explanation is the fact that most identified proteins were even 
lower in patients with the highest MRI lesion load, which can be regarded as a measure for 
inflammation. It is remarkable that we did not find any marker to distinguish the patients 
who remained monophasic and those who developed clinically definite MS during follow-
up, not even when only the fast converters were taken into account. Which factors deter-
mine if a patient remains monophasic or goes on to develop MS remain to be elucidated.
In chapter 5, we put many of the known predictors together to create a prediction model for 
CDMS in CIS patients. Based on a Cox regression model with stepwise backward selection, 
the final model consisted of 5 predictors: DIS+DIT2010 (the baseline scan fulfills criteria for 
dissemination in time and place according to the 2010 revised McDonald criteria), a le-
sion in the corpus callosum, cerebrospinal fluid oligoclonal bands, fatigue and an abnormal 
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MRI. With this model, 3 risk groups were created (low, intermediate and high risk) with 
respective 5-year risks for CDMS of 19.4%, 56.0% and 92.5%. Of note, in this model CSF 
oligoclonal bands added significant predictive ability to the model, even in addition to the 
DIS+DIT2010 MRI parameters. In the McDonald 2010 criteria, OCB have lost importance 
and can no longer be used for the criterion of dissemination in space. But importantly, OCB 
can add biological information to the mere images of the MRI by indicating central nervous 
system inflammation, and are also important to exclude other diagnoses[24]. Furthermore, 
our results indicate that OCB have predictive value, even when used in addition to the 2010 
MRI criteria. This argues for the performance of a lumbar puncture in CIS patients, not only 
to rule out other diseases from the differential diagnosis, but also to predict the risk subse-
quent for CDMS. 
Although some studies have shown that vitamin D was a predictor for CDMS in CIS patients, 
its predictive value was not strong enough to make it into the final prediction model de-
scribed in chapter 5. Also, in the study on fatigue described in chapter 3, we did not find 
an association between vitamin D levels and a diagnosis of CDMS. Vitamin D is regarded 
as one of the most important environmental risk factors for MS, with evidence for a role 
for vitamin D in MS from research in epidemiology[25, 26], genetics[27] and experimental 
autoimmune encephalitis[28-30]: it is well known that the latitudinal gradient of MS preva-
lence may be attributed to vitamin D, and that people with lower intake of fatty fish, less 
childhood sunlight or lower vitamin D levels have a higher risk to develop MS [26, 31, 32]. 
Furthermore, it is known that vitamin D has immunological properties, being able to shift 
the immune response to a more regulatory, anti-inflammatory state[33]. Two studies have 
investigated the predictive value of 25-OH-D in CIS patients before. The first one, in 465 pa-
tients[34], found significantly increased risks for new lesions and increased lesion volumes 
on MRI for patients with low 25-OH-vitamin D levels, but only a borderline increased risk 
for CDMS. The second study[35] found increased risk only in women with very low 25-OH-
vitamin D levels. In our study described in chapter 3, we found no association of vitamin D 
with CDMS (HR 0.9, 95% CI 0.3-2.1), not even when looking only at female patients (data not 
shown). We don’t exactly know when in life low levels of vitamin D affect MS risk (assuming 
that vitamin D does affect MS risk, and not the other way around). There are indications 
that this is already in utero or in early childhood[25, 36], but also later in life, affecting the 
disease course of MS, as several studies, including one described in this thesis (chapter 6) 
have shown. Although the latter are all observational studies, it seems as if vitamin D can 
affect MS risk and severity continuously through life. If this would be true, one would expect 
it to also be associated with progression from CIS to MS. Then, our study might have been 
underpowered to find the association, but as the hazard ratio we found was very close to 1, 
the influence of vitamin D, if it is real, will probably be only moderate.  
In summary, the findings of the first part of this thesis bring us to the hypothesis that pos-
sibly, some dysfunction of neuro-axonal physiology predisposes for a first demyelinating 
event. Patients with monophasic CIS and (future) RRMS can be distinguished at the time 
of CIS by means of the latest diagnostic criteria, the presence of fatigue, the presence of 
lesions in the corpus callosum and CSF oligoclonal bands. Maybe with the exception of fa-
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tigue, all of these markers can be regarded as (surrogate) markers of increased inflammation 
in the patients who go on to develop RRMS. 
Main findings part 1: 
-  The 2010 revised criteria are valid and accurate and allow for a faster diagnosis of  
 MS; in a subgroup of patients already after one attack 
- Fatigue is common and relatively severy among CIS patients  
- Fatigue is an independent predictor for CDMS in CIS patients
-   Multiple gray matter proteins are lower abundant in the CSF of CIS patients than  
 in the CSF of controls
-   No CSF proteins differentiate between CIS patients who do and do not develop   
 MS
- Vitamin D does not seem to be a strong predictor for CDMS in CIS patients
-  With a clinical prediction model based on 5 widely available clinical parameters, 3  
 risk groups for CDMS can be distinguished
Clinical implications part 1: 
-  The McDonald 2010 criteria are validated 
-  Fatigue in CIS patients deserves more attention 
-  Although the clinical prediction model described in this thesis needs validation,   
 CSF OCB, corpus callosum lesion and fatigue can be measured in addition to the  
 McDonald 2010 criteria to give additional information regarding the risk for CDMS  
 in CIS patients. 
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Part 2: RRMS to next attack
Main findings and clinical implications 
In about 80% of patients with MS, the disease starts with a relapsing-remitting course. In 
addition to the short-term disability associated with the relapses, they are known to be the 
cause of residual disability in 50% of cases[37]. Therefore, it is important to find factors as-
sociated with relapses. 
Because vitamin D is one of the main environmental factors implicated in MS, as described 
before, we investigated the association of serum 25-OH-vitamin D levels and relapse risk 
in relapsing-remitting MS patients, described in chapter 6. Serum samples of 73 patients 
were collected frequently (every 8 weeks), which is advantageous because of the known 
seasonal fluctuation of 25-OH-D levels. 25-OH-D levels were divided into three categories: 
low (<50 nmol/L), medium (50–100 nmol/L), and high (>100 nmol/L) levels. It was shown 
that lower 25-OH-D levels were significantly associated with a higher exacerbation risk in 
RRMS patients. In the low 25-OH-D category, the risk for an exacerbation was 2 times higher 
than in the high 25-OH-D category. This association was log linear without a threshold ef-
fect. A doubling of serum 25-OH-D concentrations lowered the exacerbation risk by 27%. 
Other prospective studies have confirmed these findings[38, 39], although the latter found 
significantly less T2 lesions with increasing 25-OH-D levels, but only a trend in relapse risk 
decrease[39]. 
There are many reasons to assume that there is in fact a beneficial effect of sufficient vita-
min D levels on MS disease course: the association we found was significant, with a linear 
dose-response effect, it has biological plausibility, and is consistent with results from other 
studies. However, the possibility that an association between vitamin D levels and MS dis-
ease course is caused by reverse causality (the possibility that the higher relapse rate is not 
caused by lower vitamin D levels, but that the low vitamin D levels are caused by increased 
disability that prevents patients from spending time outdoors) cannot be ruled out com-
pletely. In the study described in chapter 6, several facts argue against such a phenomenon. 
First, for every week the influence of the vitamin D levels during the preceding 4 weeks on 
exacerbations was calculated. Secondly, adjustment for disability (EDSS) did not alter the 
inverse association between 25-OH-D levels and exacerbation risk. Furthermore, only the 
serum samples taken at the regular 8-weekly visits were used in the sinusoidal model, and 
samples taken during exacerbation visits were not evaluated. Still, clinical intervention stud-
ies are needed to further investigate the relationship between vitamin D supplementation 
and disease course in MS. So far, only few intervention studies on vitamin D in MS patients 
have been performed. A recent meta-analysis including 5 randomized controlled trials eval-
uating any form or dose of vitamin D on relapse risk, with a total of 129 treated patients and 
125 controls, showed no significant association of treatment with vitamin D and relapse risk 
(OR 0,98, 95%CI 0,45-2,16) [40]. However, the included studies were limited by small sample 
sizes and included different formulations and durations of vitamin D treatment. Larger and 
more prolonged high-quality randomized controlled trials are needed to address this issue. 
In chapter 7, we investigated if vitamin D was also associated with the postpartum relapse 
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in pregnant MS patients. As is known, the relapse rate of patients decreases during preg-
nancy, but the risk for a relapse increases again after delivery. It is not known exactly known 
what causes this postpartum relapse, but it is hypothesized that there is a shift from a pre-
dominantly Th1 cell pro-inflammatory immunologic state to a more anti-inflammatory Th2 
profile during pregnancy, reducing disease activity. After delivery, the immunologic state 
shifts back into the more pro-inflammatory profile  resulting in the higher postpartum re-
lapse risk[41-43]. A major factor in these changes in immune tolerance is thought to be 
the change in hormone levels during pregnancy, especially a strong increase in the levels 
of estrogens and cortisol. Other possible contributing factors include the increased secre-
tion of anti-inflammatory cytokines, peptides, proteins and hormones by the fetal-placental 
unit[44], the downregulation during pregnancy of inflammation-related genes that are ab-
normally upregulated in MS[45], or microchimerism[46]. We hypothesized that vitamin D 
might also play a role here, but we could not find any association of vitamin D with postpar-
tum relapse risk. Possibly, an effect of vitamin D is small, and is overridden by much stronger 
hormonal influences. Importantly, we found that serum 25-OH-D concentrations changed 
under the influence of pregnancy, and did so equally in patients and controls; we did not 
find any significant difference between 25-OH-D levels of patients and controls. Further-
more, we found that 25-OH-D levels were associated with better general health, social func-
tioning and mental health in healthy pregnant women, but not in MS patients. This might 
be explained by the fact that pregnancy generally ameliorates MS. Therefore, MS patients 
already feel better during pregnancy than before[12], and may not notice a relatively small 
beneficial effect of vitamin D. 
Although the study has some limitations (including small sample sizes at some time points 
and lack of dose information on vitamin D supplementation in some patients), we conclude 
that there was no association of 25-OH-D with postpartum relapse nor with quality of life in 
MS patients, and that vitamin D levels did not differ between healthy pregnant women and 
pregnant MS patients. Therefore, with regard to QOL and postpartum relapse, we feel that 
there is  no evidence for a need to advise MS patients to take more vitamin D supplements 
during pregnancy than healthy pregnant women. However, in all pregnant women, vitamin 
D sufficiency should be maintained, for reasons of bone health, general health and the pos-
sibility that maternal vitamin D may influence the risk of the fetus to develop MS.
Another fat-soluble vitamin that has been hypothesized to play a role in MS is vitamin A. Vi-
tamin A has been shown to inhibit Th17 cell formation and promote Treg formation[47-49]. 
Furthermore, it was recently found that agonists for RXR receptors (a vitamin A receptor) 
can stimulate remyelination[50]. Vitamin A has even been suggested as a (supplementary) 
treatment option in MS[51, 52]. In chapter 8 we describe a case-control study on vitamin 
A levels and a longitudinal study with frequent serum sampling where we investigated the 
association of vitamin A with MS relapses. We did not find significant differences between 
vitamin A levels in patients and controls, nor did we find associations of vitamin A and re-
lapse risk in RRMS patients. Vitamin A and vitamin D were correlated in a linear manner. One 
recent study using the same technique for retinol assessment, found an inverse association 
between vitamin A levels and new lesion formation on MRI, but not with clinical disease 
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activity[53]. Although our longitudinal study with its frequent serum sampling provides a 
robust way of studying this topic, the fact that we found no association does not totally 
exclude a role for vitamin A in MS relapses. There might be local function or production of 
RA in the CNS associated with relapses, that cannot be measured systemically, for example 
by tissue-specific expression of retinoid receptors or retinaldehyde dehydrogenase (RALDH)
[54]. Limitations of our study include a small sample size for the case-control study and the 
lack of interferon-β using patients in the longitudinal study; others have described conflict-
ing findings: one study found synergistic effects of retinoic acid with interferon-β on T sup-
pressor cell augmentation[55], another found the association between vitamin A and MRI 
outcomes to be non-significant during interferon-β use[53]. This was something we could 
not address. Although vitamin A has immunological properties and although conflicting re-
sults have been published on this topic in recent years, the results of our study do not feed 
the perception that vitamin A could be a useful treatment for MS patients. 
In chapter 9, we describe a study that investigated the association of osteopontin levels 
and MS relapses. In 2001 it was discovered that the osteopontin gene was one of the most 
common transcripts in MS lesions[56]. Later studies showed that administration of osteo-
pontin inhibited remission and induced relapse in EAE models, and in MS patients levels of 
osteopontin were higher during relapses than during remission[57, 58]. One study showed 
that osteopontin levels were increased 1 month before the appearance of a new lesion on 
brain magnetic resonance imaging (MRI)[59]. However, we and others could nog confirm 
these findings[60]. We also found no difference in osteopontin levels between patients with 
Main findings part 2: 
- Low vitamin D levels are associated with higher relapse risk 
- There is no evidence for an association of vitamin D with postpartum relapse risk
- Vitamin A is not associated with relapse risk
-  Vitamin A levels of MS patients and controls do not differ significantly
- Osteopontin is not associated with relapse risk
Clinical implications part 2: 
- In patients with relapsing-remitting MS, vitamin D deficiency should be preven-  
 ted, but there is not enough evidence to start vitamin D treatment in MS patients
- Pregnant MS patients do not need to take more vitamin D supplements than   
 healthy controls
131
ch
ap
te
r 1
0
General discussion
active and stable disease and no association of osteopontin with EDSS score, treatment, or 
infections. Although these results do not rule out a role for osteopontin in MS pathophysiol-
ogy, we concluded that as a biomarker for MS disease activity, osteopontin does not seem 
useful. 
Future perspectives
MS is a complex disease resulting from an interplay of genetic and environmental factors. Its 
etiology and pathophysiology are still not completely clear. 
In order to better understand such a complex disease and to identify prognostic factors and 
biomarkers that could ultimately lead to the discovery of new treatments, natural history 
studies are of great importance. From the Rotterdam MS center ErasMS, the PROUD study 
(Predicting the OUtcome of a Demyelinating event) is coordinated. This study, performed 
at ErasMS and several regional hospitals, includes all patients with a clinically isolated syn-
drome within 6 months of symptom onset, if they sign for informed consent. Clinical as-
sessment, blood and CSF samples and MRI scans are taken at baseline, and patients are 
followed prospectively. Because the identification of reliable prognostic factors or biomark-
ers might need large numbers of patients and many years of follow up, (international) col-
laboration is indispensable. Recently, guidelines have been published for the collection of 
samples[61], control groups[62] and the reporting of biomarker study results[63] to simplify 
and accelerate such collaboration and the publication of findings. Focus of international 
collaboration is now also on the influence of genetics on clinical outcome; both the associa-
tion of known MS-related genes with outcome, and new GWAS analyses related to pooled 
outcome parameters. Not only for biomarker research, but also to study MS genetics and 
gene-environment interactions, the collection of data and samples from large groups of 
patients in a transparent and uniform way in order to simplify the integration of data from 
multiple centers is key. 
One of the topics presented in this thesis, and one of the most studied environmental fac-
tors associated with MS is vitamin D. As vitamin D is cheap and relatively safe, it would make 
an attractive addition to the current treatment options in MS. However, data from high-
quality randomized controlled trials are lacking. As mentioned before, only few intervention 
studies have been performed so far, including only a small number of patients[40]. Because 
of the increasing observational evidence that higher vitamin D levels are beneficial for MS 
disease course, and because vitamin D is cheap and widely available, some argue for the 
treatment of MS patients with vitamin D in spite of the absence of evidence from treatment 
trials, and some patients and treating physicians even already use and prescribe it. Although 
one study in 25 patients that were followed for 1 year using up to 40.000 IU vitamin D per 
day showed no serious side effects[64], there is no information about the long-term effect, 
and vitamin D can certainly cause side effects when used in high dosages, most importantly 
hypercalcemia[65]. For these reasons, there is a strong call for intervention studies on vi-
tamin D in MS patients. At ErasMS, the VIDEO study (VItamin D treatment Effect on retinal 
nerve fiber loss after Optic neuritis) is being performed. This is randomized, placebo-con-
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trolled an intervention study on the effect of cholecalciferol in patients with optic neuritis. 
The main outcome measure is the thickness of the retinal nerve fiber layer as measured by 
OCT, which is known to decrease after optic neuritis. Difficulties in studying vitamin D treat-
ment in MS/CIS patients include the fact that it is not known what the optimum dose or 
serum concentration is, and difficulties to obtain distinct treatment- and placebo groups: it 
is inevitable that 25-OH-D levels vary between patients, due to the fact that sunlight and fish 
intake are major sources. Furthermore, it is not ethical to keep people at very low vitamin D 
levels, so some patients in the placebo groups will have to be treated with low dose vitamin 
D as well. Finally, as we also notice in the VIDEO-study, people hesitate to take part in such a 
study, because from the many publications in the media it seems as if the beneficial effect of 
vitamin D on MS has already been proven and patients do not want to risk ending up in the 
placebo group. However, in spite of these difficulties, it is important that this kind of stud-
ies are being performed. Until evidence from treatment trials becomes available, vitamin D 
insufficiency should be treated but high dose vitamin D treatment should be discouraged.
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Summary
Multiple sclerosis (MS) is a complex disease that is characterized by a large heterogeneity 
in radiological and pathological findings but also in clinical disease course and treatment 
response. For reasons of diagnosis, treatment, patient counselling as well as insight into the 
pathology of MS, prognostic factors are needed. 
This thesis aimed to identify predictive factors for ‘the next attack’, both in patients with a 
first demyelinating event, for whom a second attack means getting the diagnosis of clinically 
definite MS, and in patients with relapsing-remitting MS. 
In chapter 1, an overview of the known prognostic factors or risk factors for MS and for MS 
relapses is given.  
Part 1 of the thesis focuses on the prediction of the next, disease defining attack in patients 
with a clinically isolated syndrome suggestive of MS (CIS). First, in chapter 2, the latest re-
vised McDonald criteria for the diagnosis of MS are applied to a cohort of CIS patients to test 
their accuracy. We show that the newest diagnostic criteria have similar test characteristics 
as the older criteria, but the diagnosis can be made significantly faster, which is a great ad-
vantage. 
In the search for new predictive markers in CIS patients, we took both a clinical and a bio-
marker approach. First, we were interested in fatigue. Fatigue is one of the most common 
and disabling features of MS, but little is known about its prevalence and severity in patients 
with CIS. Therefore, we investigated the prevalence and severity of fatigue in a cohort of CIS 
patients, and we also investigated its predictive value for a subsequent diagnosis of CDMS. 
Fatigue was measured using the Fatigue Severity Scale (FSS, see appendix). We observed 
that, already at the stage of CIS, fatigue was common (a prevalence of 46.5%) and relatively 
severe (mean FSS 4.3). Furthermore, the presence of fatigue at time of CIS was found to be 
an independent predictor for CDMS, in a model correcting for sex, age, neuroanatomical 
localization of CIS, 25-OH-vitamin D, anxiety, depression, MRI dissemination in space and 
gadolinium enhancement; the hazard ratio for patients suffering from fatigue was 4.5 (95% 
CI 1.9 to 10.6). This is described in chapter 3. 
Next, in chapter 4, we investigated the cerebrospinal fluid of CIS patients using high-resolu-
tion proteomics techniques, with the aims to find markers that could distinguish between 
patients and controls, and markers that could distinguish between monophasic CIS patients 
and patients who would go on to develop MS. We performed a proteomics analysis in CSF of 
47 CIS patients and 45 controls, and identified a total of 3159 peptides, relating to 485 pro-
teins. Only 1 protein was significantly more abundant in CSF of CIS patients than in controls: 
Ig kappa chain C region. Thirty-five proteins were lower in CIS patients than controls, most 
of them with functions in nervous system development and function. This lower abundance 
in CIS patients may either precede or even predispose for a first demyelinating attack (e.g. 
by some disturbed neuro-axonal physiology that shows as a lower abundance of proteins in 
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the CSF, which predisposes for a first demyelinating event), or be the result of it (for example 
due to an increased immune activation in patients, which might cause a higher rate of elimi-
nation of proteins from the CSF by macrophages). We observed no significant differences in 
specific peptide abundance levels between patients who did and did not reach a diagnosis 
of clinically definite MS. 
In chapter 5, multiple predictors for CDMS in CIS patients are integrated into a predictive 
model. A multivariate Cox regression model was created after univariate screening of candi-
date predictors, based on baseline demographic, clinical, MRI, serum and CSF parameters of 
431 CIS patients. The model was then further simplified using stepwise backward selection. 
A simple scoring system was then constructed giving equal weight to all predictors. The final 
model consisted of the following 5 variables: DIS+DIT2010 (the baseline scan fulfills crite-
ria for dissemination in time and place according to the 2010 revised McDonald criteria), 
corpus callosum lesion, cerebrospinal fluid oligoclonal bands, fatigue and abnormal MRI. 
Three risk groups were created: low risk (0-1 risk factor present), intermediate risk (2-3 risk 
factors) and high risk (4-5 risk factors). The 5-year risk for CDMS in the low-risk group was 
19.4% versus 56.0% in the intermediate-risk group and 92.5% in the high-risk group.
In the second part of this thesis, factors associated with relapse risk in patients with relaps-
ing-remitting MS are discussed. 
Because there was growing evidence for a role of vitamin D in MS, but little was known 
about its association with clinical disease course in MS patients, this was investigated in 
chapter 6. In a prospective longitudinal study in 73 patients with relapsing-remitting MS, 
blood samples for 25-OH-D measurements were taken every 8 weeks. Associations between 
25-OH-D levels and exacerbation rates were assessed using Poisson regression (generalized 
estimating equations) with the individual serum levels as time-dependent variable. During a 
mean follow-up of 1.7 years, 58 patients experienced a total of 139 exacerbations. Monthly 
moving averages of 25-OH-D levels were categorized into low (<50 nmol/L), medium (50–
100 nmol/L), and high (>100 nmol/L) levels. It was found that exacerbation risk decreased 
significantly with higher serum vitamin D levels: respective relative exacerbation rates for 
the medium and high level category as compared to the low-level category were 0.7 and 
0.5 (p value for trend: p=0.007). With each doubling of the serum 25-OH-D concentration 
the exacerbation rate decreased by 27% (95% confidence interval 8%–42%, p=0.008). These 
results suggest a beneficial effect of vitamin D on disease course in MS, although the pos-
sibility of reverse causality cannot be ruled out completely. 
After finding that vitamin D levels were associated with relapse risk, we also set out to inves-
tigate if vitamin D was associated with the postpartum relapse risk. In the study described in 
chapter 7,  vitamin D levels were measured during pregnancy in 43 pregnant RRMS patients 
and 21 pregnant healthy women, and the association of pregnancy vitamin D levels and 
the risk for a postpartum relapse and with pregnancy quality of life was investigated. It was 
found pregnancy-25-OH-D levels of patients and controls were not significantly different, 
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and lower 25-OH-D concentrations were not associated with postpartum relapse risk. In 
controls, but not patients, higher 25-OH-D concentrations were correlated with better gen-
eral health, social functioning and mental health, but not with vitality. We concluded that, 
with regard to QOL and postpartum relapse, we found no arguments for advising pregnant 
MS patients to take more vitamin-D supplements than healthy women.
In chapter 8, a possible association of vitamin A levels and relapse rate was investigated. 
Vitamin A is a multifunctional vitamin that can inhibit the formation of Th17 cells, which 
are probably involved in the development of relapses in MS. Furthermore, it promotes Treg 
formation. Therefore, vitamin A can be hypothesized to be lower in patients than in healthy 
controls, and to decrease relapse risk in RRMS patients. We measured all-trans-retinol lev-
els in a case-control study in 31 RRMS patients and 29 matched controls. Furthermore, in 
a prospective longitudinal study in 73 RRMS patients, serum samples for all-trans-retinol 
measurements were taken every eight weeks. Associations between all-trans-retinol con-
centrations and relapse rates were calculated using Poisson regression. Mean vitamin A 
levels were lower in patients (2.16 μmol/l) than in controls (2.44μmol/l) but with borderline 
significance (p=0.05). In the longitudinal study, all-trans retinol levels were categorized into 
tertiles: a low (<2.9 μmol/l), medium (2.9-3.7 μmol/l) and high level (>3.7 μmol/l). We found 
that relapse rates were not associated with serum all-trans retinol levels (p>0.2), in univari-
ate nor in multivariate analysis. Serum concentrations of all-trans-retinol and 25-OH-vitamin 
D were positively correlated, although this correlation was weak (r=0.15). It was concluded 
that we did not find evidence for a role for vitamin A in the disease course of RRMS. 
In chapter 9, the association of osteopontin levels and relapse risk was investigated. Os-
teopontin is a multifunctional molecule that has been proposed as a biomarker for disease 
activity in MS, based on results from pathology studies, animal experiments and studies 
on osteopontin levels in RRMS patients. In a prospective longitudinal study, samples for 
osteopontin measurement were taken every 8 weeks in 58 relapsing–remitting MS patients. 
Osteopontin levels were measured using a commercially available enzyme-linked immuno-
sorbent assay (ELISA). The association between osteopontin levels and the relapse risk in 
the first, second, third and fourth week after sampling were calculated using generalized lin-
ear mixed-effects models. We found no association between osteopontin levels and relapse 
risk. We also found no difference in osteopontin levels between patients with active and sta-
ble disease and no association of osteopontin with EDSS score. There was also no difference 
between interferon treated and non-treated patients, and no association with infections. 
Although these results do not rule out a role for osteopontin in MS pathophysiology, we 
concluded that as a biomarker for MS disease activity, osteopontin does not seem useful.
In summary, patients with monophasic CIS and (future) RRMS can be distinguished at the 
time of CIS by means of the latest diagnostic criteria, the presence of fatigue, the presence 
of lesions in the corpus callosum and CSF oligoclonal bands. In patients with RRMS, vitamin 
D levels are associated with relapse risk. In order to better understand a complex disease 
such as MS, and to identify prognostic factors and biomarkers that could ultimately lead to 
the discovery of new treatments, natural history studies are of great importance. Not only 
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for biomarker research, but also to study MS genetics and gene-environment interactions, 
the collection of data and samples from large groups of patients in a transparent and uni-
form way in order to simplify the integration of data from multiple centers is key.
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Samenvatting
Multiple sclerose (MS) is een complexe ziekte die wordt gekenmerkt door een grote hetero-
geniteit, zowel in radiologische en pathologische bevindingen als in klinisch ziektebeloop en 
respons op therapie. Voor de diagnose, behandeling, patiëntenvoorlichting en inzicht in de 
pathologie van MS zijn voorspellende factoren van groot belang. 
Dit proefschrift had tot doel om voorspellende factoren voor ‘de volgende aanval’ te iden-
tificeren, zowel in patiënten met een eerste aanval van demyelinisatie, voor wie een tweede 
aanval het krijgen van de diagnose klinisch definitief MS betekent, als in patiënten met re-
lapsing-remitting MS. 
In hoofdstuk 1 wordt een overzicht gegeven van de bestaande voorspellende factoren of 
risicofactoren voor MS en MS-aanvallen.
Deel 1 van dit proefschrift gaat over het voorspellen van de volgende, ziekte-definiërende 
aanval in patiënten met een zogenaamd klinisch geïsoleerd syndroom verdacht voor MS 
(CIS). Eerst, in hoofdstuk 2, zijn de nieuwste herziene McDonald-criteria voor de diagnose 
MS toegepast op een cohort van CIS-patiënten om hun testeigenschappen te onderzoeken. 
We tonen aan dat de nieuwste diagnostische criteria ongeveer gelijke testeigenschappen 
hebben als de oude criteria, maar dat de diagnose significant eerder gesteld kan worden, 
wat een groot voordeel is. 
Op zoek naar nieuwe voorspellende markers in CIS-patiënten hebben we zowel naar klinis-
che kenmerken als naar biomarkers gekeken. Eerst hebben we vermoeidheid onderzocht; 
dit wordt beschreven in hoofdstuk 3. Vermoeidheid is een van de meest voorkomende en 
meest invaliderende kenmerken van MS, maar er is niet veel bekend over het voorkomen 
en de ernst ervan in patiënten met CIS. Daarom hebben we de prevalentie en ernst van 
vermoeidheid in een cohort van CIS-patiënten getest, en ook de voorspellende waarde van 
vermoeidheid voor het krijgen van de diagnose klinisch definitief MS onderzocht. Vermoei-
dheid werd gemeten met de Fatigue Severity Scale (FSS: deze loopt van 1 tot 7, zie bijlage). 
We vonden dat vermoeidheid veel voorkwam, zelfs al op moment van CIS, met een prev-
alentie van 46.5%, en dat het relatief ernstig was (gemiddelde FSS 4.3). Bovendien was de 
aanwezigheid van vermoeidheid op het moment van CIS voorspellend voor de diagnose kli-
nisch definitief MS, in een model dat corrigeerde voor leeftijd, geslacht, neuro-anatomische 
lokalisatie van de klachten, vitamine D, angst, depressie en MRI-afwijkingen. De hazard ratio 
voor vermoeide patiënten om later MS te krijgen was 4.5 (95% CI 1.9 tot 10.6). 
In hoofdstuk 4 onderzochten we vervolgens de hersenvloeistof van CIS-patiënten met be-
hulp van hoogwaardige proteomics-technieken, op zoek naar markers die patiënten en 
controles zouden kunnen onderscheiden, en markers die een onderscheid zouden kunnen 
maken tussen patiënten met monofasisch CIS en patiënten die later MS krijgen. Er werd een 
proteomics-analyse gedaan van de liquor van 47 CIS-patiënten en 45 controles, en daarbij 
werden 3.159 peptides geïdentificeerd, die gerelateerd waren aan 485 eiwitten. Slechts 1 
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van deze eiwitten was significant verhoogd in de liquor van patiënten ten opzicht van con-
troles: Ig kappa chain C region. Vijfendertig eiwitten waren lager in de liquor van patiënten 
dan controles, en dit waren voor het grootste gedeelte eiwitten met functies in de ontwikke-
ling en functie van het centraal zenuwstelsel. Deze lagere aanwezigheid van eiwitten in CIS-
patiënten zou ofwel 1. vooraf kunnen gaan aan de eerste aanval van demyelinisatie, ofwel 
2. er het gevolg van zijn. Een mogelijke verklaring voor de eerste optie zou kunnen zijn dat 
een verstoorde neuro-axonale fysiologie, zichtbaar als een lagere aanwezigheid van eiwit-
ten, predisponeert voor een CIS. Voor de tweede optie zou een mogelijkheid zijn dat door 
een verhoogde immuunactivatie in patiënten een verhoogde eliminatie van eiwitten uit de 
liquor, bijvoorbeeld door macrofagen, wordt veroorzaakt. We vonden geen significante ver-
schillen in eiwitten tussen patiënten die wel en niet definitief MS kregen. 
In hoofdstuk 5 worden meerdere voorspellers voor MS in CIS-patiënten samengevoegd in 
een voorspellend model. Er werd een multivariaat Cox-regressiemodel gecreëerd na univar-
iate screening van kandidaatvoorspellers, gebaseerd op baseline demografische, klinische, 
MRI-, serum- en liquorparameters van 431 CIS-patiënten. Het model werd verder vereen-
voudigd met behulp van stepwise backward selection. Er werd een eenvoudig scoringssys-
teem gemaakt dat gelijk gewicht gaf aan alle variabelen. Het uiteindelijke model bestond 
uit de volgende 5 variabelen: DIS+DIT2010 (de baseline scan voldoet aan de criteria voor 
spreiding in plaats en tijd volgens de 2010 McDonald criteria), corpus callosum laesie, oli-
goclonale banden in de liquor, vermoeidheid en een abnormale MRI-scan. Op basis hiervan 
werden drie risicogroepen onderscheiden: laag risico (0-1 risicofactor), middelmatig risico 
(2-3 risicofactoren) en hoog risico (4-5 risicofactoren). De 5-jaarsrisico’s  op klinisch definitief 
MS in de verschillende groepen liepen uiteen van 19% in de laag-risicogroep ten opzichte 
van 56% in de middelmatige groep en 93% in de hoog-risicogroep. Na verdere validatie 
kan dit een praktisch hulpmiddel zijn bij het voorlichten van patiënten en het besluiten tot 
starten met immuunmodulerende therapie. 
In het tweede deel van dit proefschrift worden factoren beschreven die geassocieerd zijn 
met het risico op een aanval in patiënten met relapsing-remitting  MS. 
Er was groeiend bewijs voor een rol voor vitamine D in MS, maar er was maar weinig bekend 
over de associatie van vitamine D met het beloop van de ziekte. Dit hebben we daarom 
onderzocht in hoofdstuk 6. In een prospectieve longitudinale studie in 73 patiënten met 
relapsing-remitting MS werden bloedmonsters voor 25-OH-D-bepaling elke 8 weken af-
genomen. De associatie tussen 25-OH-D-concentraties en aanvalsrisico werd berekend met 
behulp van Poisson-regressie met de individuele serumconcentraties als tijdsafhankelijke 
variabele. Tijdens een gemiddelde follow-up van 1.7 jaar kregen 58 patiënten in totaal 139 
MS-aanvallen. Gemiddelde 25-OH-D-concentraties werden in drie categorieën ingedeeld: 
laag (<50nmol/l), gemiddeld (50-100 nmol/l) en hoog (>100 nmol/l).  We vonden dat het 
risico op een aanval significant afnam met hogere serumconcentraties van vitamine D: de 
respectievelijke aanvalsfrequenties voor de gemiddelde en hoge categorie ten opzichte van 
de lage vitamine D-categorie waren 0.7 en 0.5 (p-waarde voor trend: p=0.007). Met elke 
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verdubbeling van de serum 25-OH-D-concentratie nam de aanvalsfrequentie af met 27%. 
(95% betrouwbaarheidsinterval 8-42%, p=0.008). Deze resultaten suggereren een gunstig 
effect van vitamine D op het ziektebeloop van MS, maar reverse causality kan niet helemaal 
worden uitgesloten. 
Na de bevinding dat vitamine D-levels geassocieerd waren met ziektebeloop, hebben we 
onderzocht of vitamine D ook geassocieerd was met het postpartum-aanvalsrisico. In de 
studie beschreven in hoofdstuk 7 werden vitamine D-concentraties gemeten tijdens de 
zwangerschap in 43 zwangere RRMS-patiënten en 21 gezonde zwangere vrouwen, en werd 
de associatie van zwangerschaps-vitamine D-concentraties met het risico op een aanval na 
de bevalling en met kwaliteit van leven tijdens de zwangerschap onderzocht. Zwangersc-
haps-vitamine D-concentraties bleken niet te verschillen tussen zwangere patiënten en con-
troles, en lagere vitamine D-waarden waren niet geassocieerd met het postpartumrisico op 
een aanval van MS. In controles, maar niet in patiënten, waren hogere vitamine D-waarden 
geassocieerd met betere algemene gezondheid, sociaal functioneren en mentale gezond-
heid, maar niet met vitaliteit. We concludeerden dat er, met betrekking tot postpartum 
aanval en kwaliteit van leven, geen argumenten zijn gevonden om zwangere MS-patiënten 
meer vitamine D-supplementen te adviseren dan gezonde zwangeren. 
In hoofdstuk 8 werd een mogelijke associatie van vitamine A met aanvalsrisico onderzocht. 
Vitamine A is een multifunctionele vitamine die de aanmaak van Th17-cellen kan onderdruk-
ken; deze zijn mogelijk betrokken bij het ontstaan van MS-aanvallen. Bovendien stimuleert 
vitamine A de vorming van regulatoire T-cellen (Treg). Daarom kan worden verondersteld 
dat vitamine A lager is in patiënten dan in controles, en dat vitamine A het aanvalsrisico 
in RRMS-patiënten kan verlagen. We hebben all-trans-retinolconcentraties gemeten in een 
case-controlstudie in 31 RRMS-patiënten en 29 gematchte controles. Verder hebben we in 
een prospectieve longitudinale studie in 73 RRMS-patiënten vitamine A gemeten in mon-
sters die elke 8 weken zijn afgenomen. Gemiddelde vitamine A-concentraties waren lager in 
patiënten (2.16 μmol/l) dan in controles (2.44μmol/l) maar dit verschil was net niet signifi-
cant (p=0.05). In de longitudinale studie werden all-trans-retinolconcentraties in tertielen 
ingedeeld: laag (<2.9 μmol/l), gemiddeld (2.9-3.7 μmol/l) en hoog (>3.7 μmol/l). We vonden 
dat de aanvalsfrequentie niet was geassocieerd met serum all-trans-retinolconcentraties 
(p>0.2), in univariate noch in multivariate analyse. Serumconcentraties van vitamine A en 
D waren gecorreleerd, maar met een zwakke correlatie (r=0.15). We concludeerden dat er 
evidentie is voor een rol van vitamine A in het ziektebeloop van MS. 
In hoofdstuk 9 beschrijven we een onderzoek naar het verband tussen osteopontincon-
centraties en aanvalsrisico. Osteopontin is een multifunctioneel molecuul, dat gesugger-
eerd werd als biomarker voor ziekteactiviteit in MS, gebaseerd op pathologiestudies, di-
erexperimenteel onderzoek en studies naar osteopontinlevels in RRMS-patiënten. In een 
prospectieve longitudinale studie werden bloedmonsters voor osteopontinonderzoek elke 
8 weken afgenomen bij 58 RRMS-patiënten. Osteopontinconcentraties werden bepaald met 
een commercieel verkrijgbare enzyme-linked immunosorbent assay (ELISA). De associatie 
tussen osteopontinlevels en aanvalsrisico in de eerste, tweede, derde en vierde week na 
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bloedafname werd berekend met behulp van generalized linear mixed-effects models. We 
vonden geen associatie tussen osteopontin en het risico op een aanval. We vonden ook 
geen verschil in osteopontin tussen patiënten met actieve en stabiele ziekte, en geen ver-
band met EDSS-score. Ook was er geen verschil tussen patiënten behandeld met interferon 
en onbehandelde patiënten, en geen verband met infecties. Hoewel deze resultaten een rol 
voor osteopontin in de pathofysiologie van MS niet uitsluiten, concludeerden we dat osteo-
pontin als marker voor ziekteactiviteit in MS-patiënten niet nuttig lijkt. 
Samenvattend kunnen patiënten met monofasisch CIS en patiënten met (toekomstig) MS 
onderscheiden worden op het moment van CIS met behulp van de nieuwste diagnostische 
criteria, de aanwezigheid van vermoeidheid, de aanwezigheid van corpus-callosumlaesies 
en oligoclonale banden in de liquor. In patiënten met RRMS zijn vitamine D-concentraties 
geassocieerd met het risico op een aanval. Om een complexe ziekte als MS beter te kunnen 
begrijpen, en om voorspellende factoren te identificeren die uiteindelijk zouden kunnen lei-
den tot de ontdekking van nieuwe behandelingen zijn studies van het natuurlijk beloop van 
de ziekte van groot belang. Om samenwerken tussen meerdere centra te vereenvoudigen is 
het noodzakelijk dat data en samples van grote groepen patiënten op een transparante en 
eenduidige manier worden verzameld, niet alleen voor biomarkeronderzoek maar ook voor 
het onderzoek naar genetica en gen-omgevingsinteracties.
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Appendix 1 - Fatigue Severity Scale
Vermoeidheid 
Lees de volgende uitspraken één voor één aandachtig door en omcirkel per uitspraak een 
cijfer tussen 1 en 7, afhankelijk van hoe goed de uitspraak volgens u aansluit bij hoe u zich 
de afgelopen week gevoeld heeft. 
Gedurende de afgelopen week:  
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1. was ik minder gemotiveerd om dingen te doen als 
ik vermoeid was.  
1  2  3  4  5  6  7  
2. leidde lichamelijke inspanning tot vermoeidheid.  1  2  3  4  5  6  7  
3. was ik snel moe/vermoeid.  1  2  3  4  5  6  7  
4. beïnvloedde moeheid/vermoeidheid mijn 
lichamelijk functioneren.  
1  2  3  4  5  6  7  
5. leidde moeheid/vermoeidheid voor mij vaak tot 
problemen.  
1  2  3  4  5  6  7  
6. verhinderde moeheid/vermoeidheid langdurige 
lichamelijke inspanning.  
1  2  3  4  5  6  7  
7. beïnvloedde moeheid/vermoeidheid de uitvoering 
van bepaalde taken en verplichtingen.  
1  2  3  4  5  6  7  
8. behoorde moeheid/vermoeidheid tot mijn 3 
voornaamste belemmerende klachten.  
1  2  3  4  5  6  7  
9. beïnvloedde moeheid/vermoeidheid mijn werk, 
gezinsleven of sociale activiteiten.  
1  2  3  4  5  6  7  
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List of abbreviations
CDMS clinically definite multiple sclerosis
CIS clinically isolated syndrome
CNS central nervous system
CSF cerebrospinal fluid
DIS dissemination in space
DIT  dissemination in time
EBV Epstein-Barr virus
EDSS expanded disability status scale
FSS fatigue severity scale
MRI magnetic resonance imaging
MS multiple sclerosis
OCB oligoclonal bands
PPMS  primary progressive multiple sclerosis
RRMS relapsing-remitting multiple sclerosis
SPMS secondary progressive multiple sclerosis
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Dankwoord
Voor het onderzoek leidend tot dit proefschrift zijn we van Amsterdam naar Rotterdam ver-
huisd. Een grote stap, die door veel Amsterdammers met argwaan werd aanschouwd. Maar 
Rotterdam heeft ons met open armen ontvangen. We hebben ontzettend veel fijne, leuke 
mensen om ons heen gekregen. Vooral in de vervelende periode na de geboorte van Jippe 
heb ik me erg gesteund gevoeld. Er zijn dan ook een heleboel mensen die ik wil bedanken.
 
Allereerst mijn promotor Prof.dr. R.Q. Hintzen. Beste Rogier, ik ben erg blij dat ik de stap naar 
Rotterdam heb gemaakt. Tijdens ons eerste gesprek wist je mij meteen enthousiast te mak-
en voor een baan in het MS-onderzoek, en dat is zo gebleven. Ik ben er trots op onderdeel te 
zijn van het Rotterdamse MS-centrum. Je bent soms een beetje chaotisch maar ik bewonder 
je scherpe en kritische blik, en je moed om tegen de stroom in te gaan. Ook waardeer ik zeer 
je gevoel voor humor en gezelligheid. Veel dank voor je begeleiding de afgelopen jaren, en 
vooral ook voor de ruimte die je me vorig jaar hebt gegeven toen het nodig was.
 
Mijn co-promotor die geen co-promotor is: drs. T.A.M. Siepman. Lieve Dorine, wat een voor-
recht was het om elke week poli met jou te mogen doen. Van jou heb ik geleerd om een MS-
dokter te zijn. Dank dat je altijd alles zo goed voorbereidt, grondig leest en duidelijk uitlegt, 
en dank dat je altijd de tijd voor me neemt, ook als je het zelf erg druk hebt. Heel erg leuk 
dat je mijn paranimf wilt zijn zodat we toch nog een beetje samen promoveren! Heel veel 
dank voor alles.
 
Prof.dr. J.D. Laman. Beste Jon, dank je wel voor je enthousiasme, oprechte interesse, voor 
het vele leuke en goede onderwijs dat je ons hebt gegeven en voor het kritisch lezen van het 
manuscript. Je bent naar Groningen vertrokken inmiddels, maar ik neem aan dat we elkaar 
nog regelmatig zullen treffen. Dr. B.C. Jacobs en Prof. Dr. J.M.W. Hazes, hartelijk dank voor de 
beoordeling van het manuscript. Samen met Prof. E.W. Steyerberg, Prof. Dr. T. Luider en Prof.
dr. J.P.T.M. van Leeuwen wil ik u allen ook bedanken voor het plaatsnemen in de oppositie.
De patiënten van de PROUD-studie en de VIDEO-studie wil ik bedanken voor hun vertrou-
wen. De dokters en verpleegkundigen van de deelnemende ziekenhuizen aan de PROUD-
studie, en alle andere neurologen die patiënten naar ons doorstuurden dank ik hartelijk 
voor hun inzet, en hierbij wil ik vooral dr. J. Samijn noemen: dank voor de vele inclusies. De 
co-auteurs van de artikelen wil ik natuurlijk bedanken voor de samenwerking. De dames van 
de poli wil ik bedanken voor het organiseren van de poli en het verwerken van de samples. 
Collega’s van de genetica, dank voor het opslaan van de PROUD-samples. 
Mijn collega’s van de MS-groep. Lieve collega’s, ik heb het erg fijn gevonden om in zo’n 
hechte groep terecht te komen, waar iedereen oog voor elkaar heeft, en waar enthousiast 
wordt meegedaan met allerhande activiteiten, ook (of juist) als die buiten werktijd zijn. De 
collega’s van de immunologie horen hier ook eigenlijk bij. Ik heb goede herinneringen aan 
alle etentjes, spinning-evenementen, kinder-MS-dagen en hoop dat we dat soort dingen 
nog lang blijven doen! Hasrat, dank voor alle hulp bij de PROUD-administratie. 
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Alle (voormalige en huidige) onderzoekers van de 22ste: dank voor de vele koffiemomenten 
en de mooie kantooravonturen. Fijn om niet steeds zelf het wiel uit te hoeven vinden. Juna 
en Krista, dank voor jullie gezelschap tijdens alle soorten verlof.
 
Alle vrienden, vriendinnen, familieleden en buren die ik de laatste maanden ernstig heb 
verwaarloosd: ik hoop dat jullie het nog een half jaar vol kunnen houden! Dank vooral aan 
Joke dat je zo vaak naar Rotterdam kwam gereden. Jammer en raar dat je er niet bij bent 
vandaag! In augustus gaan we alle dingen vieren! Hein, je hebt zo je eigenaardigheden maar 
je bent waarschijnlijk de enige van mijn vrienden die min of meer weet waar mijn onderzoek 
over gaat. Wat leuk dat je mijn paranimf wilt zijn! Ook speciale dank aan Jetteke en Hugo 
voor laatste-moment oppassen, BBQ-en of koffiedrinken, en aan Stephan en Rewana voor 
het zijn van de ‘goede buur’. 
Lieve Rinske en Jeroen, bedankt dat jullie altijd klaarstaan voor mij maar vooral ook voor 
Noor en Jippe. Vooral de afgelopen maanden hebben jullie regelmatig extra bijgesprongen, 
waardoor ik weer eens kon gaan typen. Veel dank daarvoor!
Lieve Wieke en Lex, dank voor alle dingen! Ik bewonder het dat jullie altijd zo hard werken 
maar ook niet vergeten om genoeg leuke dingen te doen. Ik vind het erg leuk om te zien hoe 
jullie genieten van het project Bavel (en als ge...) en ik hoop dat ik op een gegeven moment 
toch wat meer tijd heb om vaker langs te komen. Ik ben er trots op dat jullie mijn ouders 
zijn! 
Mijn kleine stoere lieve Noor, en mijn lieve vrolijke ventje Jippe. Wat ben ik trots op jullie, en 
wat geniet ik van elke dag dat jullie er zijn! 
Lieve Hans, je zegt zelf natuurlijk altijd al dat je mijn steun & toeverlaat, rots in de bran-
ding, etc. etc. bent, maar je bent het ook echt! Dank je wel dat je met me mee bent gegaan 
naar Rotterdam, dank je wel dat je altijd positief blijft, en dank je wel voor het creëren van 
de randvoorwaarden. Ik heb superveel zin om samen naar de US of A te gaan de komende 
maanden! Dank voor alles. 
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1. PhD training   
Courses Year Workload (ECTS) 
Writing successful grant proposals  2009 0.8 
Basiscursus Regelgeving Klinisch Onderzoek (BROK)  2010 0.9 
Infections and inflammations of the central nervous system;     
Imaging and clinical symptoms 
 
2010 
 
0.6 
Biostatistics for clinicians 2010  1.0 
Biostatistical methods I: basic principles  2011 5.7 
Biostatistical methods II: popular regression models 2011 4.3 
Biomedical English writing and communication 2011 4.0 
Introduction to clinical and public health genomics  2011  2.0 
SNP course VIII   2011 1.5 
EDSS course 2012 0.2 
Neuro-immunology course 2010, 2012 1.0 
Seminars and workshops   
Basiscursus MS  2009  0.4 
MSMS symposium 2012 0.2 
Oral presentations   
Meeting of the Dutch MS Research Foundation  2012  1.4 
Wetenschappelijke vergadering NVN 2014 1.0 
ErasMS symposium; Environmental factors in MS 2012  1.4 
Poster presentations   
ECTRIMS (8 posters) 2010 - 2014 8.0 
Wetenschappelijke vergadering NVN (2 posters) 2011 1.5 
Meeting of the Dutch MS Research Foundation 2011  1.0 
(Inter)national conferences   
Congress of the European Committee for Treatment and  
Research in Multiple Sclerosis (ECTRIMS) 
2011, 2012, 
2014 
 
3.0 
Meeting of the Dutch MS Research Foundation  2009 - 2013 1.4 
Wetenschappelijke vergadering NVN  2011, 2014 0.8 
2. Teaching   
Lecture ‘Optic neuritis, MS and NMO’, Rotterdam Eye Hospital 2012 0.4 
Lecture ‘Pregnancy and MS’, Research Master Programme 
Infection & Immunity (MolMed), Rotterdam 
 
2013  
 
1.0 
Total ECTS  43.5 
 
PhD portfolio
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